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Abstract 
Exosomes are small secreted vesicles of endocytic origin with a size range of 50-150 
nm. They are secreted by many cell types and display multiple biological functions 
including immune-activation, immune-suppression, antigen presentation, and the 
shuttling of mRNA and miRNA, as well as other cargo. We have characterised the 
exosomes secreted from two breast cancer cell lines, MDA-MB-231 and MCF7. 
Exosomes secreted from both cell lines display typical markers including ALIX, 
Tsg101, CD9 and CD63, and were capable of inducing apoptosis of the Jurkat T cell 
line, indicating the potential immune-suppressive function of such tumour-derived 
exosomes. To further investigate the biological potential of exosomes, we loaded 
purified exosomes with gene specific siRNAs using electroporation, and observed the 
targeted inhibition of both a known component of the exosome pathway, Rab27a, and 
also the arthritis associated gene ERAP1, demonstrating the potential novel use of 
exosomes as therapeutic gene delivery vectors. We have also shown that exosomes 
derived from MDA-MB-231 cells and the parental cells have different lipid 
composition, as analysed by lipidomics study.  
 
Nanoparticle tracking analysis (NTA), which allows the rapid detection of size and 
concentration of nanoparticles within the size range 10 nm-1000 nm was tested for its 
ability to accurately measure size and concentration of exosomes and microvesicles 
under different conditions. NTA was capable of detecting apoptotic vesicles induced by 
Taxol and Curcumin treatment. Immunodepletion was used to determine the percentage 
of CD9 and CD63 positive vesicles. Our data suggest that NTA is a useful technique for 
measuring size and concentration of exosomes and microvesicles. We hypothesized that 
V 
 
NTA could assist in the screening of agents that interfere or promote exosome release. 
NTA was therefore used to detect increases in exosomes secretion induced by 
Tamoxifen and Thimerosal treatment, and to monitor the inhibition of exosome 
secretion from MDA-MB-231 breast cancer cells expressing inhibitory RNA targeted 
for Rab27a, a component of the exosome pathway. Increases in exosome release 
induced by Tamoxifen and Thimerosal was detected by NTA and a significant reduction 
in the release of exosomes by inhibition of Rab27a expression was also observed. 
Treatment with the known exosomal pathway inhibitor DMA also reduced exosome 
release, establishing the principle of NTA as a screening technique. We further 
compared the siRNA targeted cells for their ability to migrate, invade and form 
anchorage-independent colonies, which were all significantly reduced. Supplementation 
with MDA-MB-231 derived exosomes restored the ability to form colonies, suggesting 
exosomes may contribute to metastatic lesion formation. These data suggest that the 
exosomal pathway is a valid target to disrupt the behaviour of tumour cells and NTA 
can be used to monitor its activity.  
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Chapter I. Introduction 
 
One basic way of cell communication is by releasing extracellular molecules such as 
nucleotides, lipids and proteins into the environment, where these molecules will then 
bind to receptors on surrounding cells, leading to intracellular signalling and 
modification of the recipient cell (Bobrie et al., 2011).  However, cells also contain and 
secrete more complicated structures in the form of membrane vesicles, with the cell type 
and compartment they are derived from determining their biological functions.  These 
vesicles can contain numerous proteins, lipids and nucleic acids, and the way they 
interact and affect the recipient cell is complex. Exosomes, among the several different 
types of secreted vesicles, are probably the most studied.  Exosomes are formed by 
inward budding of endosomal compartments called multivesicular bodies (MVBs). 
Although they have been known for decades, they were initially characterised as cell 
debris and signs of cell death.  They were first described by the  two research groups of 
Stahl and Johnstone, who reported that instead of fusing with lysosomes and being 
degraded, multivesicular endosomes in reticulocytes could fuse with the plasma 
membrane and release the contents in vitro (Harding et al., 1983; Pan et al., 1985). 
Johnstones’s group used electron microscopy to demonstrate that multivesicular bodies 
fused with the plasma membrane and released their contents including ‘50 nm bodies’ 
(Pan et al., 1985). The term ‘Exosome’ was proposed in 1987 by the same group to 
describe these vesicles (Johnstone et al., 1987). Nevertheless, this area did not receive 
much attention for the next 10 years until Raposo et al. reported that exosomes secreted 
from Epstein-Barr virus (EBV)-transformed B lymphocytes bear functional MHC 
molecules and could present MHC-antigenic peptide complexes to specific T cells 
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(Raposo et al., 1996).  Two years later, it was discovered that dendritic cells also secrete 
exosomes bearing functional MHC-peptide complexes, which could induce antitumour 
immune responses in mice in vivo (Zitvogel et al., 1998). 
 
Studies then started to show that exosomes secreted from one cell could be captured by 
another cell to allow information to be transferred to the recipient. Such information 
could include antigens to increase the number of antigen-presenting cells and improve 
immune responses (Thery et al., 2002). The discovery that exosomes can deliver mRNA 
and microRNA has sparked interest even more (Valadi et al., 2007), with evidence 
being presented that mRNA contained in exosomes can be translated into functional 
protein, indicating that exosomes can directly transfer genetic information that may 
modify recipient cell behaviour.  Studies have also now shown that exosomes can act as 
delivery vectors for siRNA. Specially engineered exosomes successfully carried siRNA 
into the brain and knocked down a therapeutic target gene for Alzheimer’s disease 
(Alvarez-Erviti et al., 2011), and plasma exosomes have been shown to be able to 
transfer siRNA into monocytes and lymphocytes (Wahlgren et al., 2012).  
 
Types of membrane vesicles 
 
Microvesicles including exosomes. 
 
Microvesicle terminology often includes exosomes and shedding vesicles (cell surface 
membrane-derived particles). Exosomes are characterised as membrane vesicles with a 
size range of 50-150 nm. They are from endosomal origin and are secreted by most cell 
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types, such as haematopoietic, lymphocytes, dendritic cells, epithelial (van Niel et al., 
2001), reticulocytes (Johnstone et al., 1987) and many tumour cells.  Exosomes are 
limited by a lipid bilayer and are formed through inward budding of endosomal 
membranes, giving rise to intracellular multivesicular bodies (MVB) or multivesicular 
endosomes (MVE) that either fuse with the plasma membrane, releasing the exosomes 
to the extracellular environment, or are degraded by fusion with lysosomes.  After 
exosomes reach their destinations, they can enter a target cell either by entering the 
cell’s endocytic pathway, through ligand-receptor binding, or by fusing with the target 
cell’s plasma membrane and releasing the contents into the cytoplasm of the target cell 
directly.  
  
Figure 1.1 shows how exosomes are formed, possible molecules that are associated with 
the formation and secretion of exosomes, and how viruses hijack the pathway.  It has 
been reported that ESCRT (endosomal sorting complex required for transport) 
machinery is required for the formation of internal vesicles of multivesicular bodies 
(MVB)/late endosomes. In 2001, two members of the ESCRT family, Alix and Tsg101, 
were shown to be involved in exosomes secretion in dendritic cells (Thery et al., 2001). 
It has been suggested that ESCRT-I and ESCRT-II together contribute to the budding 
processes and that ESCRT-III could be responsible for cleaving the buds to form 
intraluminal vesicles (Wollert and Hurley, 2010).  A very recent study showed that 
syndecans (single transmembrane domain proteins, also known as SDC1-4) have a short, 
evolutionarily conserved cytoplasmic domain, which binds cytosolic factors such as the 
small PDZ scaffolding protein syntenin (also known as SDCBP) (Grootjans et al., 1997). 
The interaction of the syndecans with syntenin, and through syntenin with ALIX has 
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been suggested to support the biogenesis of intraluminal vesicles and exosomes, and the 
sorting of signalling cargo to these vesicles (Baietti et al., 2012). 
 
It has been hypothesized that there are two distinct pathways for lysosome degradation 
and exosome secretion. The first pathway was found to be active in immature dendritic 
cells and sorted MHC II to intraluminal vesicles for degradation by lysosomes. The 
second pathway sorted MHC II together with a tetraspanin CD9 to intraluminal vesicles 
which were then secreted as exosomes (Buschow et al., 2009).  An alternative pathway 
for sorting cargo into MVEs has been reported in oligodendroglial cells, suggesting that 
secretion of the myelin proteolipid protein (PLP) in association with exosomes was 
independent of the ESCRT machinery, but required the sphingolipid ceramide. Purified 
exosomes were enriched in ceramide, and inhibition of neutral sphingomyelinases 
(which help synthesise ceramide), reduced the release of exosomes (Trajkovic et al., 
2008). Another lipid, lysobisphosphatidic acid (LBPA), has been shown to allow 
formation of intraluminal vesicles of MVBs for degradation by lysosomes, but it is 
unknown whether it also plays a role in exosome formation (Matsuo et al., 2004). In 
conclusion, these findings suggest that by using different intracellular machinery, 
subpopulations of MVBs can be formed which may also lead to different types of 
exosomes (Bobrie et al., 2011).  
 
MVBs need to fuse with the plasma membrane to release exosomes. Small GTPases of 
the Rab family are classical proteins responsible for intracellular trafficking. Different 
Rab proteins have been reported to be responsible for exosome secretion in different 
cell types. Rab11 promotes docking and fusion of MVBs with the plasma membrane in 
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a calcium-dependent manner in human erythroleukemic K562 cells (Savina et al., 2005).  
In oligodendroglial cells, Rab35 is involved in secretion of exosomes that are enriched 
with PLP (Hsu et al., 2010). Rab27a and Rab27b play important roles in spontaneous 
secretion of MHC class II-containing exosomes secreted by HeLa cells (Ostrowski et al., 
2010). Furthermore, fusion of MVB with plasma membrane may involve some specific 
SNARE proteins, although it has not been confirmed which SNARE proteins are 
responsible for this process.  
 
Studies have shown monensin (a Na+/H+ exchanger) treatment results in the 
accumulation of intracellular Ca
2+
 as well as increased exosome release, indicating that 
exosomes secretion can be affected by changes in intracellular Ca
2+
 levels (Savina et al., 
2003). Merendino et al supported the importance of intracellular Ca
2+
 levels by 
demonstrating that treatment with dimethyl amiloride (DMA, a blocker of Na+/H+ 
exchange) inhibited exosome secretion (Merendino et al., 2010). In addition, nutrient 
starvation, stress, rapamycin and hormone treatment induce autophagy, which then 
inhibit exosome release by redirecting the MVBs towards autophagic pathway and 
lysosome degradation.  In this condition, fusion of MVBs with autophagosomes forms 
hybrid organelle-amphisomes and makes MVBs appear enlarged (Fader and Colombo, 
2009; Fader et al., 2008).  
 
In addition, intracellular and intercellular pH has also been shown to affect exosome 
release. When the microenvironment pH is low, exosome secretion and uptake 
increases. Of particular note the core mass of many tumours usually has low pH, caused 
by limited vascularization, nutrient and oxygen supplies. It has also been demonstrated 
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that p53 regulates the production of exosomes by regulating tumour suppressor-
activated pathway 6 (TSAP6) under stressed conditions (Yu et al., 2006). This supports 
the importance of both exosomes and tumour pH as future anti-cancer strategies 
(Parolini et al., 2009). 
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Figure 1.1:  Exosome biogenesis and secretion and molecules involved, and the 
‘Trojan horse hypothesis’. Exosomes are formed by inward budding from the limiting 
membrane of the endosomes to form multivesicular endosomes/bodies (ESCRTs, 
tetraspaninins, LBPA, ceramide and Syndecan/syntenin might be involved in this 
process). These multivesicular endosomes/bodies can either be degraded by lysosomes 
or fuse with the plasma membrane and release the exosomes into the extracellular 
environment. The targeting of the MVE towards the plasma membrane may be 
regulated by some Rab family proteins such as Rab27, Rab11 and Rab35. Finally, the 
fusion of the MVEs with the plasma membrane may require SNARE proteins.  
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Shedding vesicles/membrane vesicles  
 
Shedding vesicles bud directly from the plasma membrane and are then secreted directly 
into the extracellular environment. They can be of similar sizes to exosomes (50-150 
nm) or can be larger than exosomes (over 150 nm and could be up to 1 μm) (Figure 
1.1).  Since they bud from the plasma membrane, it was expected that their composition 
would be comparable with the membrane composition of the originating cells. 
However, the targeting of proteins into shedding vesicles is selective and specific 
proteins are included or excluded. Increasing intracellular Ca
2+
 has been shown to 
increase the release of membrane vesicles (Salzer et al., 2002). It is unknown how the 
targeting is regulated and their function on distant tissue is not clear. Ectosomes are 
shedding vesicles of neutrophils and monocytes (Stein and Luzio, 1991). Microparticles 
are referred to as shedding vesicles from platelets and monocytes (Cocucci et al., 2009). 
To add to the confusion, sometimes these names are used interchangeably by different 
groups, and the literature on all such vesicles must be read with care. 
 
Vesicles released from apoptotic cells 
 
Dying and/or apoptotic cells will also release membrane vesicles that are different from 
vesicles released from healthy cells. They vary in size between 50-500 nm and are 
relatively heterogeneous. They contain very abundant histones (Thery et al., 2001), float 
at a higher sucrose density (1.24-1.28 g/ml) compared to exosomes and do not have the 
characteristic cup shape that exosomes have, when visualised by electron microscopy.  
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Apoptotic vesicles have been reported to have immune-activating functions. One study 
suggested that apoptotic vesicles from mycobacteria-infected macrophages contained 
TB-derived antigens, and uptake of these apoptotic vesicles by dendritic cells and the 
subsequent migration of these cells to the lymph nodes stimulated CD8
+
 T cells in 
lymphatic tissues, indicating a possible role of apoptotic vesicles derived from dying 
infected cells in immunological regulation (Winau et al., 2006).  
 
Exosome-like vesicles 
 
There might be other types of microvesicles, some of which are exosome-like.  Some of 
the differences between exosomes and these exosomes-like vesicles include their lipid 
composition, with lipid rafts present on exosomes but not on exosome-like vesicles; and 
their main protein markers (tetraspanins, Alix and Tsg101 for exosomes and TNFR1 for 
exosome-like vesicles (Thery et al., 2006). 
 
Overall, the classification of the multiple vesicles secreted by cells has not been 
officially identified and a standard terminology on secreted vesicles should ideally be 
achieved. Most of the studies published have focused on exosomes, so not much is 
known about the function and composition of other types of vesicles. With more and 
more groups starting to study other types of vesicles, their function should become more 
clearly defined in the near future.  
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Composition of exosomes 
 
The composition of exosomes is variable depending on what cells they were secreted 
from. Different techniques including immunoblotting, fluorescence activated cell 
sorting, mass spectrometry, electron microscopy and atomic force microscopy have 
been used to study the contents of exosomes.  
 
The first “proteomic” analyses of the protein composition of exosomes were performed 
in late 1990s using mass spectrometry and the exosomes used were secreted from 
dendritic cells (Thery et al., 2001). More recently, an academic website that gathers all 
the analysis of exosomal protein, RNA and lipid content has been established to 
encourage participation of the scientific community (http://exocarta.ludwig.edu.au).  
 
Protein composition 
 
Some proteins are common to exosomes from almost any cell type, but also some 
proteins are cell type specific. One class of cytosolic proteins commonly seen in 
exosomes include the Rabs, the largest family of small GTPases, which regulate 
exosome docking and membrane fusion. A search for Rab proteins in Exocarta revealed 
more than 40 Rab proteins identified in different exosome studies. Exosomes are also 
rich in annexin, which play a role in membrane trafficking and fusion. Exosomes 
contain abundant transmembrane tetraspanins  (CD9, CD63, CD81 and CD82) and heat 
shock proteins (HSP60, HSP70 and HSP90) which can facilitate peptide loading onto 
major histocompatibility complex (MHC) I and II (Gastpar et al., 2005; Graner et al., 
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2009). Other transmembrane molecules include MHC class I and II molecules, integrins 
(various alpha and beta chains), surface peptidases (CD13 and CD26, and GPI-anchored 
molecules (CD55 and CD59), etc. 
 
 In their lumen, exosomes contain molecules associated with the internal side of 
membranes (clathrin, annexins, GTPases of the Rab family proteins), and also various 
cytosolic proteins: ESCRT proteins (Tsg 101, Alix) cytoskeleton proteins 
(moesin,tubulin, actin and actin-binding molecules), signal transduction molecules 
(protein kinases, heterodimeric G proteins, 14-3-3 proteins and syntenin), chaperone 
molecules (Hsc70 and Hsp90 and cyclophilin A), metabolic enzymes (GAPDH, enolase, 
pyruvate and phosphoglycerate kinases and aldolase), and translation initiation or 
elongation factors (EIF4 and EEF1) (Chaput and Thery, 2011).  
 
Some proteins are cell type specific, including  MHC class II, co-stimulatory proteins 
(CD80 and CD86) on antigen presenting cell-derived exosomes, integrin CD41a and 
Von Willebrand factor on platelet-derived exosomes, perforin and granzyme on 
cytotoxic T-lymphocyte derived exosomes, MFGE8/ lactadherin on immature dendritic 
cells derived exosomes (Veron et al., 2005), B cell receptor on B cell derived exosomes 
and CD11c (a specific marker for DCs) on DC-derived exosomes, etc (Janiszewski et al., 
2004; Muntasell et al., 2007; Wolfers et al., 2001).  
 
Lipid Composition 
 
In addition to proteins, exosomes also obviously contain lipids as part of their 
membrane structure. Erythrocyte-secreted exosomes display similar lipid composition 
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to the plasma membrane of the erythrocytes (Vidal et al., 1989), whereas exosomes 
secreted from other cells such as dendritic cells, B cells and mast cells are enriched in 
sphingomyelin in comparison with the cells they were secreted from (Laulagnier et al., 
2004; Subra et al., 2007; Wubbolts et al., 2003). B cells secreted exosomes are also 
enriched in cholesterol.  LBPA, which has been identified for its involvement in the 
formation of internal vesicles in multivesicular endosomes, was unexpectedly found to 
be very low or undetectable in B cell and mastocyte exosomes (Buschow et al., 2009; 
Subra et al., 2007). Ceramide, a lipid which has been proposed to also be involved in 
the formation of the internal vesicles in MVEs that are finally released as exosomes, 
was found to be enriched in oligodendroglial exosomes (Trajkovic et al., 2008) 
 
RNA composition 
 
Exosomes have been reported to contain very abundant mRNA, miRNA and also non-
coding RNA. Some studies have reported that certain RNAs are present at significantly 
different levels compare to the RNA content of the originating cell (Mittelbrunn et al., 
2011; Skog et al., 2008; Zomer et al., 2010). There are also contradictory results which 
suggest that exosomal RNA contents were similar to their parental cells and exosomes 
could be potentially used as diagnostic markers (Rabinowits et al., 2009; Taylor and 
Gercel-Taylor, 2008). Thus, it still need to be determined if any RNA molecules can 
serve as reliable generic exosomal markers. 
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Interaction of exosomes with recipient cells. 
 
How individual exosomes interact with recipient cell is still relatively unknown. It is 
possible exosomes bind to specific receptors at the cell surface, or enters the cell via 
endocytosis or fuse with plasma membrane (Figure 1.3). 
 
1. Entry through Endocytosis 
 
The most effective way of exosome uptake is phagocytosis. Tian et al. showed that after 
exosomes from PC12 cells (a rat pheochromocytoma) were internalised through 
endocytosis they were actively transported by the cytoskeleton to the perinuclear region 
(Tian et al., 2010) 
Escrevente et al. showed that SKOV3, an ovarian carcinoma cell line, used an energy 
dependent mechanism to internalize exosomes secreted from the same cell line. In their 
study, internalization of exosomes was inhibited when they treated the cells or 
exosomes with proteinase K indicating the requirement of proteins on exosomes and on 
cells. They suggested clathrin-dependent endocytosis to be implicated in the uptake of 
exosomes by SKOV3 cells but also that other endocytic pathways may be involved 
(Escrevente et al., 2011). Feng et al. have reported that phagocytic cells have a greater 
uptake of exosomes than nonphagocytic cells (Feng et al., 2010) 
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2. Entry through ligand-receptor binding 
 
Second, exosomes could enter the recipient cell through ligand-receptor binding. The 
exosomal membrane contains phospholipids (e.g. phosphatidylserine) and proteins on 
their surface that can be captured by phosphatidylserine receptors such as the T cell 
immunoglobulin domain and mucin domain protein (TIM).  Miyanishi et al. showed 
that TIM1 and TIM4 are phosphatidylserine-binding molecules and are expressed on the 
surface of activated lymphocytes or phagocytes, respectively. TIM1 and TIM4 also 
been shown to mediate exosomes uptake (Miyanishi et al., 2007).  
 
It has been demonstrated that intercellular adhesion molecule 1 (ICAM1) is present on 
exosomes secreted from mature dendritic cells and can bind to leukocyte function 
associated antigen-1 (LFA-1, a ligand for ICAM1) expressed on the surface of dendritic 
cells (Segura et al., 2007) and activated T cells (Nolte-'t Hoen et al., 2009). Retroviruses 
such as HIV can hijack this mechanism to favour spreading. HIV-1 viruses budded from 
infected T cells bear host-derived ICAM1 and can interact with other T cells that 
express IFA1, thus helping with the spreading of the viruses (Fortin et al., 1998).  
 
Furthermore, milk fat globule epidermal growth factor 8 protein (MFGE8) could play a 
role in the intake of exosomes into a neighbouring cell. MFGE8 has two domains: one 
binds to αvβ3 and αvβ5 integrins (expressed by human DCs and macrophages) and the 
other domain binds to phosphatidylserine-containing membranes (including exosomes). 
It has been shown to act as a bridge between apoptotic cells that express 
aminophospholipids and phagocytes that express integrins (Hanayama et al., 2002). 
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MFGE8 could bind to phosphatidylserine exposed on the surface of apoptotic cells 
through one domain, and the other domain of MFGE8 that is exposed on the surface of 
MFGE8-bearing apoptotic cells could bind to αvβ3 and αvβ5 integrins expressed on 
macrophages and promote the phagocytosis of these apoptotic cells by macrophages. It 
is possible that MFGE8 can also play a role in the capture of membrane vesicles by 
phagocytes that express αvβ3 or αvβ5 integrins (Andersen et al., 1997; Veron et al., 
2005). 
 
3. Entry through direct fusion 
 
Exosomes can directly fuse with the plasma membrane and release the exosomal 
content into the cell cytoplasm. Parolini et al provided evidence that exosomes could 
fuse with the plasma membrane by showing that exosomes go across a lipid-dependent 
fusion process with plasma membrane, and this fusion is more efficient in an acidic 
microenvironment. (Parolini et al., 2009), suggesting that fusion of exosomes to cells is 
more frequent in the acidic environment found in a tumour compared to that in the 
surrounding normal tissue. 
15 
 
Nucleus
Phosphatidylserine (PS)
Exosome
ICAM1
MFGE8
TIM1 
Or TIM4
Exosome
1. Enter through 
endocytosis
2. Enter through ligand-
receptor binding
LFA1
ICAM1PS
αvβ3 or αvβ5 
integrins
MFGE8
Exosome
Exosome
PS
Exosome
3. Direct fusion
 
 
Figure 1.2:  Three possible pathways exosomes utilise for communication with 
recipient cells. Exosomes may interact with neighbour cells via three different ways: 1. 
Exosomes may enter cell via endocytosis. 2. Certain phospholipids or proteins may bind 
to receptors on neighbour cells. 3. Direct fusion of exosomes with the plasma membrane 
of the target cell.  
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Function of exosomes 
 
Exosomes can cause immune-activating responses in vitro 
 
Exosomes secreted from antigen-presenting cells contain a range of immunostimulatory 
molecules that activate T cells, which suggest that they may have an important role in 
propagation of immune responses.  
 
Dendritic cells-derived exosomes express high levels of functional MHC class- and 
class-II peptide complexes together with CD86 molecules and it has been suggested that 
these exosomes may substitute for DCs to elicit MHC-class- and class-II restricted T-
cell responses and tumour rejection.  
 
Mycobacteria-infected macrophages release exosomes containing glycopeptidolipids 
(GPLs) leading to the transfer of GPLs from infected to uninfected macrophages and 
can stimulate a proinflammatory response in resting macrophages (Bhatnagar and 
Schorey, 2007). Platelet-derived microparticles (PMPs) that are present at high 
concentration in the inflammatory areas could chemoattract immune cells such as NK 
cells, T and B lymphocytes as well as proliferation, survival and chemotaxis of 
haematopoietic cells (Baj-Krzyworzeka et al., 2002). Consistent with these results, it 
has also been reported that platelet-derived membrane vesicles may play an important 
role in inducing immune responses by acting as a vector for the CD154/CD40L (a 
ligand for CD40) which plays the role of a co-stimulatory molecule and is critical to the 
initiation and propagation of the adaptive immune response. It is mainly expressed on 
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activated T cells and also platelets. The delivery of CD154 by these microvesicles 
makes it possible for it to encounter the cells necessary to produce the antigen-specific 
response (Sprague et al., 2008). Fibroblasts obtained from the synovial fluid of patients 
with rheumatoid arthritis secrete exosomes that contain an active membrane-bound form 
of TNF, which binds to T cells and makes them resistant to activation induced cell death, 
thus potentially contributing to the development of this disease (Zhang et al., 2006)  
 
Ligands that can bind to NK cell activating receptors have been shown to be present on 
exosomes and can activate NK cells in vitro. For example, HLA-B-associated transcript 
3 (BAT3) has been identified as a ligand for natural cytotoxicity receptor 3 
(NCR3)/NKp30 and has been shown to be present on exosomes secreted from heat-
shocked dendritic cells and promote NK cell activation in vitro (Simhadri et al., 2008). 
Dendritic cell-derived exosomes from melanoma patients express NKG2D ligands 
(activatory signals for Natural Killer cells) MHC class  polypeptide-related sequence A 
(MICA) and MICB on their surface, that bind to NKG2D that are present on NK cells 
and lead to NK cell activation. IL-2 and trans-presentation of IL-15 and IL-15 receptor 
 chain (IL-15R) is required for NK cell survival, homeostasis and proliferation. The 
ability of exosomes derived from dendritic cells to promote NK cell proliferation was 
due to the simultaneous presence of IL-15R on these exosomes, which could bind to 
exogenous IL-15 and allow IFN secretion by NK cells thus induce NK cell 
proliferation. On the other hand, another ligand for NKG2D, ul16 binding protein 1 
(ULBP1), was shown to be present on exosomes secreted from dendritic cells of normal 
volunteers (Viaud et al., 2009)  
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Tumour-derived exosomes can also have immune-activating properties. This mainly 
happens when the tumour cells are under stress conditions. The stress-inducible HSP 70 
family is considered to function as an endogenous danger signal that can increase the 
immunogenicity of tumours and induce cytotoxic T lymphocytes (CTL) responses. 
They are a key part of the cell's mechanism for protein folding, and they help to protect 
cells from stress. 
 
Under stress conditions, NKG2D ligands are up-regulated on tumour exosomes. Hsp70 
also activates mouse NK cells that recognize stress-inducible NKG2D ligands on 
tumour cells. In the severe combined immunodeficiency (SCID) mice with Hsp70-
overexpressing tumours, NK cells were activated so that they killed ex vivo tumour cells 
that expressed NKG2D ligands (Elsner et al., 2007). Tumour-derived microvesicles can 
activate monocytes to produce pro-inflammatory cytokines and Reactive oxygen 
intermediates (ROI) and result in enhanced cytotoxic/cytostatic potential of these 
monocytes both in vitro and in vivo (Baj-Krzyworzeka et al., 2007). Pancreatic tumour 
cells-derived exosomes have been shown to decrease tumour cell proliferation and 
induce apoptosis (Ristorcelli et al., 2008). However, most studies believe tumour-
derived exosomes can prevent anti-tumour immune responses and promote tumour cell 
metastasize. This will be discussed in more details in the next section.  
 
Antigen presentation by Exosomes 
 
A study in 1996 showed that Epstein-Barr virus-transformed B lymphocytes, were able 
to secrete exosomes which exhibit abundant MHC class II molecules at their surface, 
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and can present antigenic peptides to T cells, suggesting their possible role in adaptive 
immune responses (Raposo et al., 1996). Two years later, it was reported that dendritic 
cells secrete exosomes that express functional MHC class Ι and class II, and T-cell 
costimulatory molecules,  which eradicated or suppressed  growth of established murine 
tumours  in a T-lymphocyte-dependent manner in mice in vivo (Zitvogel et al., 1998). 
 
Exosomes can present antigens directly or indirectly. Secreted membrane vesicles 
secreted by virtually any cell type bear MHC class I molecules that could potentially 
induce direct CD8
+
 T cell activation. APC-derived exosomes also bear abundant MHC 
class II molecules, which are functional and can be recognised by CD4
+
 T cells as 
allogeneic antigens (Peche et al., 2003). It has been reported that exosomes derived 
from dendritic cells induced activation of CD8
+
 cytotoxic T lymphocytes clones, either 
alone (Admyre et al., 2006; Luketic et al., 2007), or with dendritic cells that express 
allogeneic MHC class I. These studies indicate that these exosomes bear functional 
preformed MHC-peptide complexes. Mature dendritic cells secrete exosomes that can 
induce T-cell activation more efficiently in vitro than exosomes secreted from immature 
dendritic cells (Admyre et al., 2006; Segura et al., 2007). In addition, Segura et al also 
reported only mature exosomes trigger effector T-cell responses in vivo, suggesting that 
exosomes derived from mature dendritic cells possess co-stimulating molecules that can 
help co-stimulate the T-cells (Admyre et al., 2006).  
 
Exosomes secreted by peptide-pulsed DCs can transfer MHC II-peptide complexes to 
DCs that lack MHC class II to enable antigen-specific CD4 T cell activation (Segura et 
al., 2005; Thery et al., 2002). Exosomes bearing specific MHC II-peptide complexes 
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can activate primed CD4 T cells by themselves (Muntasell et al., 2007), but need to be 
captured by recipient DC to activate naive CD4 T cells (Muntasell et al., 2007; Segura 
et al., 2005; Thery et al., 2002). It was suggested that his difference may be due to the 
activated conformation of lymphocyte function-associated antigen (LFA-1) integrins 
that are only present at the surface of primed T lymphocytes, but not on naïve T 
lymphocytes, which allows efficient binding of exosomes that express intercellular 
adhesion Molecule-1 (ICAM1) to these primed T lymphocytes (Segura et al., 2007). 
Similar to CD8
+
 T cells, exosomes derived from mature dentritic cells induce more 
effective CD4
+
 T cell activation in vitro than exosomes derived from immature dendritic 
cells. Recipient DCs may also internalise and process MHC molecules from exosomes 
of allogeneic DCs as a source of peptides to load on their own MHC molecules 
(Montecalvo et al., 2008). Moreover, Mallegol et al reported that in intestinal epithelial 
cells that express MHC class  II, peptides instead of MHC-peptide complexes, seem to 
be the major antigenic material transferred from exosomes to recipient DCs, and the 
transfer of antigenic peptides through exosomes to DCs is expressively more efficient 
than delivery of free peptide to DCs (Mallegol et al., 2007). Exosomes derived from 
endothelial cells infected with cytomegalovirus can transfer virus-derived antigen to 
DCs and thus indirectly activated CD4
+ 
T cells. Moreover, exosomes derived from 
macrophages infected with Mycobacterium tuberculosis or Mycobacterium bovis, which 
reside in endosomal compartments, contain pathogen-derived antigens and stimulate 
CD4
+
 and CD8
+
 T cells in vitro as well as induce naive T cell activation in vivo (Giri 
and Schorey, 2008).  
 
Exosomes purified from cultured tumour cell lines (Wolfers et al., 2001) or from ascites 
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of patients (Caby et al., 2005) with tumours contain tumour antigens and can induce the 
activation of antigen-specific T cells in vitro only in the presence of recipient dendritic 
cells. It is possible this could be due to lack of co-stimulating molecules on tumours and 
tumour-derived exosomes (Thery et al., 2009). Antigens that are commonly present in 
tumour-derived exosomes are either cell surface transmembrane proteins such as human 
epidermal growth factor receptor 2 (EGFR2) and carcinoembryonic antigen (CEA), 
which are found in different types of carcinomas, or endosomal proteins from the 
endosome compartments of the donor cell (such as melanoma antigen recognized by T-
cells 1 (MART 1) and glycoprotein 100 (gp100)).  
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A. Immune-activating function by professional-APC cells-derived exosomes 
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B. Immune-activating function of exosomes secreted from other cells. 
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Figure 1.3: Immune-activating function of exosomes. A. Exosomes secreted from 
professional APC cells bear functional MHC complexes and can activate pre-activated 
CD8
+
 and CD4
+
 T cells, but will have to be transfer the antigen to dendritic cells to 
activate naive T cells. APC-derived exosomes also bear NKG2D ligands and can bind 
to NKG2D on NK cells leading to activation. Exosomes derived from heat-shocked 
dendritic cells bear BAT3, which will bind to NCR3 on NK cells leading to activation. 
B. Tumour derived exosomes can transfer antigens to specific T cells leading to 
activation; bear HSP70 under stress conditions and can activate macrophages and NK 
cells; activate monocytes to produce cytokines and ROI.  Fibroblast-derived exosomes 
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can activate primed CD4
+
 T cells and load to resistance to AICD. Platelets-derived 
exosomes can activate B cells.  
 
 
Protumourigenic roles 
 
Tumour-derived exosomes can have immunosuppressive properties  
 
Immune evasion by tumour cells is a well-established mechanism wherein tumours 
avoid detection and elimination by the host immune system. Early reports indicate that 
tumour-derived membrane vesicles have immunosuppressive functions (Poutsiaka et al., 
1985). Fas ligand (also known as CD95 ligand) is a type II transmembrane protein of 
the Tumour Necrosis factor (TNF) family. Exosomes derived from tumour cell lines 
bear Fas ligand that can induce T cell apoptosis leading to suppression of T-cell 
responses in vitro (Abusamra et al., 2005; Andreola et al., 2002). Addition of anti-FasL 
antibody blocked exosome-induced apoptosis (Abusamra et al., 2005).  
 
In cancer patients, the loss of NKG2D, an activating receptor for NK cells, CD8
+  
T cell 
and NKT cells, is a critical mechanism of cancer immune evasion. NKG2D down-
modulation is due to direct exosomal delivery of membrane-bound transmembrane 
growth factor 1 (TGF1) to CD8+ T cell or NK cell subsets (Clayton et al., 2008). 
Down-regulation of NKG2D is partly due to the presence of the expressed NKG2D 
ligand MICA. Clayton and colleagues demonstrated that other potential NKG2D ligands 
such as MICB may be present on the surface of tumour-derived exosomes, and may 
contribute to the down-regulation of NKG2D. On the other hand, some experiments 
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added combinations of other NKG2D-ligand specific antibodies and did not achieve a 
convincingly enhanced inhibitory effect, but this may be result of the poor blocking 
characteristics of the antibodies. In comparison, adding a TGF1-blocking antibody 
almost completely abrogated the reduction in surface NKG2D. These data suggest that 
down-regulation of NKG2D is mainly due to the presence of TGF1 and partly due to 
the presence of NKG2D ligands, but how precisely TGF1 and NKG2D ligands 
cooperate requires clarification.  
 
Tumour-derived exosomes can also support the function of regulatory T cells (Treg). 
Interleukin 2 (IL-2) is an important cytokine which not only supports expansion and 
differentiation of cytotoxic T cells and Natural Killer (NK) cells, but also supports Treg 
cells and their suppressive functions (Clayton et al., 2007). Tumour exosomes inhibit 
IL-2 induced T cell proliferation by promoting the function of Treg cells. Similarly, 
murine mammary carcinoma exosomes were shown to promote tumour growth, 
suppress the cytotoxic activity of NK cell function and inhibit IL-2-stimulated NK cell 
growth signalling (Liu et al., 2006). Tumour-derived exosomes were also reported to 
up-regulate the suppressive functions of human Treg cells and make them more resistant 
to apoptosis through a TGF-β and IL-10 dependent pathway (Szajnik et al., 2010). 
Similarly, exosomes derived from the malignant effusion of cancer patients helped 
maintain the number and suppressive function of Treg cells (Wada et al., 2010). 
 
It was reported that galectin-9 containing exosomes were selectively detected in 
Epstein-Barr Virus (EBV) infected nasopharyngeal carcinoma and induced apoptosis of 
mature type 1 helper T cells when interacting with the membrane receptor  Tim-3 (Klibi 
26 
 
et al., 2009). Nef (Negative factor), the HIV accessory protein, is one the most 
abundantly expressed viral proteins. It changes the host’s cellular machinery and allows 
survival and replication of the virus. It was reported that HIV-infected cells export Nef 
in microvesicles, which caused activation-induced cell death of CD4
+
 T cells, which is a 
hallmark of AIDS (Lenassi et al., 2010). 
 
The expansion of Myeloid-derived suppressor cells (MDSCs) in a tumour bearing host 
leading to immune suppression has been recognized as an important mechanism tumour 
cells use to escape from the immune system. Tumour-derived exosomes are thought to 
be involved in this process. Tumour-derived exosomes can also target myeloid cells to 
modulate their differentiation and function. It has been reported that tumour exosomes 
mediated induction of IL-6 which plays a role in blocking bone marrow DC 
differentiation. The levels of IL-6 and phosphorylated Stat3 were elevated 12 hours 
after the tumour exosomes stimulation of murine myeloid precursors, and tumour 
exosomes were less efficient in inhibiting differentiation of bone marrow cells isolated 
from IL-6 knockout mice. It was suggested that bone marrow DC precursors capture 
tumour exosomes and subsequently induce the production of IL-6 and other cytokines, 
leading to the activation of Stat3. As a result, differentiation of bone marrow precursors 
into immature DC is blocked (Yu et al., 2007). Further work by the same group 
discovered that these myeloid cells were found to switch their differentiation pathway of 
these myeloid cells to the MDSC pathway and promote tumour growth, and the MDSC 
mediated promotion of tumour progression is dependent on prostaglandin E2 (PGE2) 
and TGF- β molecules present on tumour-derived exosomes (Xiang et al., 2009). Mice 
pre-treated with tumour-derived exosomes have an increase in recruitment of more 
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MDSCs in the lung which correlate significantly with tumour metastasis, and myD88 
play an important role in this process (Liu et al., 2010). Similarly, Hsp72 present on 
tumour-derived exosomes was reported to trigger STAT3 activation in MDSCs through 
a Toll-like receptor 2(TLR2) /MyD88-dependent pathway (Chalmin et al., 2010). 
 
Facilitation of Tumour Invasion and Metastasis 
 
As described before, tumour-derived exosomes could potentially have immune-
activating properties. As a contrast, most studies indicated that tumour derived 
exosomes facilitate tumour cell invasion and metastasis by promoting angiogenesis, 
modulating stromal cells and remodelling extracellular matrix, etc. 
 
Mesothelioma cell-derived exosomes have strong angiogenic factors which increased 
vascular development in the neighbourhood of a tumour (Hegmans et al., 2004). 
Melanoma-derived exosomes were also capable of stimulating endothelial signalling 
that is important for endothelial angiogenesis. (Hood et al., 2009) It was also recently 
reported that melanoma exosomes injected locally preferentially travelled to sentinel 
lymph nodes and that this homing caused molecular signals that provoked melanoma 
cell recruitment, extracellular matrix deposition, and vascular proliferation in the lymph 
nodes (Hood et al., 2011). Tetraspanins, which are enriched in exosomes, have been 
reported to contribute to exosome-mediated angiogenesis. It was reported that exosomes 
secreted from a pancreatic tumour line that overexpress D6.1A (Human homologue CO-
029, a tetraspanin associated with poor prognosis in patients with gastrointestinal 
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cancer), strongly encouraged tumour growth by its capacity to induce systematic 
angiogenesis in a rat model (Gesierich et al., 2006).  
 
Tumour-derived exosomes can modulate the function of stromal cells such as 
fibroblasts. It was reported that exosomes derived from some cancer cells contain TGF-
β, the delivery of which can drive the differentiation of fibroblasts towards the 
myofibroblasts phenotype, the enrichment of which in tumours indicate a different 
stroma which supports tumour growth, vascularization and metastasis (Webber et al., 
2010).  
 
Furthermore, exosomes shed by ovarian cancer and breast cancer cells were found to 
contain metalloproteinases with proteolytic activity. These exosomes can increase 
extracellular matrix degradation and increase the tumour’s ability to invade into the 
stroma (Nieuwland et al., 2010; Runz et al., 2007; Stoeck et al., 2006) 
 
Gastric cancer exosomes have been shown to promote cancer cell proliferation through 
activation of PI3K/Akt and MAPK/ERK pathway (Qu et al., 2009a).  Exosomes can 
also be utilised by cancer cells to export anticancer drugs in order to develop drug 
resistance (Safaei et al., 2005). Moreover, transport of mRNAs and microRNAs, from 
tumour cells to neighbouring cells could have significant effects on tumorigenesis. This 
will be discussed in a later chapter. And a recent study has shown that exosomes 
derived from melanoma cells promoted metastatic niche formation and increased the 
metastatic behaviour of primary tumours by ‘educating’ bone marrow-derived cells 
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(BMDCs) toward a pro-metastatic and pro-vasculogenic phenotype through the receptor 
tyrosine kinase MET oncoprotein (Peinado et al., 2012)                 
 
Immune cells-derived exosomes can also be immune-suppressive 
 
Immune cell-derived vesicles can also have immunosuppressive properties. PHA-
activated T cells secrete exosomes bearing FasL and TNF-related apoptosis-inducing 
ligand (TRAIL). Activation with anti-CD59 antibody mainly triggered specific release 
of TRAIL-containing microvesicles/exosomes. FasL and TRAIL participate in 
activation-induced cell death (AICD) and eliminate over-activated T cells after a 
cellular immune response to prevent potential autoimmune damage (Monleon et al., 
2001).  Ectosomes derived from polymorphonuclear neutrophils inhibited the 
maturation of immature monocyte-derived dendritic cells by LPS (ligand for TLR4) and 
reduced capacity to activate T cells. After incubation with ectosomes, immature 
dendritic cells secreted TGF-β, which may be responsible for down-regulating of TLR4-
mediated maturation of immature dendritic cells (Eken et al., 2008).   
 
Stimulation of Fas receptor usually induces an apoptotic death signal, surprisingly the 
interaction between Fas and FASL in tumour cells does not necessarily always induce 
death, but could also promote proliferation and survival of tumour cells (Mitsiades et 
al., 2006). A very recent study reported that in the tumour environment, activated CD8
+
 
T cells were educated by tumour cells and secrete exosomes with FASL, which can not 
only induce dendritic cell apoptosis and inhibit their ability to stimulate CD8
+
 CTL 
responses, but also promote melanoma and lung cancer cell invasion by increasing 
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upregulation of MMP9 expression via Fas signalling, providing a novel mechanism of 
tumour immune escape. Thus, CD8
+
 CTL cells in the tumour environment were 
converted from a guard  to an accessory of tumour progression by releasing FASL 
bearing exosomes  (Cai et al., 2012). 
 
Exosomes from body fluids could be immunosuppressive. 
 
Vesicles purified from some body fluids can also have immunosuppressive activities.  
Exosomes from human breast milk in vitro inhibit T cell activation and increase the 
number of Treg cells (Admyre et al., 2007). It was suggested that exosomes present in 
breast milk may have a role in the immune tolerance of the infant and may also protect 
the infant from allergy development. 
 
It was recently reported that exosomes isolated from the plasma of mice bearing 
Ovalbumin (OVA)-expressing tumours were capable of suppressing OVA-specific 
immune responses. Depletion of vesicles positive for MHC class II from plasma-
derived exosomes or using exosomes isolated from MHC class II deficient mice 
abolished the suppressive effect, indicating that host-derived circulating exosomes that 
bear MHC class II may be able to suppress tumour antigen specific immune responses 
(Yang et al., 2012).  
 
MIC molecules are reported to be constitutively transcribed in human placenta 
throughout normal pregnancy and soluble MIC molecules are released from in vitro 
cultured placenta explants. Elevated levels of soluble MIC molecules are present in 
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pregnancy sera and are able to down-regulate the NKG2D receptor and impair the 
cytotoxic function of peripheral blood mononuclear cells from healthy donors. Taken 
together, these results suggest a novel mechanism for immune evasion of the fetal 
allograft through fetal MIC and maternal NKG2D interactions (Mincheva-Nilsson et al., 
2006). A more recent study by the same group showed that the second family of human 
NKG2D ligands, ULBP, is also expressed by placenta. Isolated placenta exosomes 
carried ULBP1-5 and MIC on their surface and induced down-regulation of the NKG2D 
receptor on NK, CD8
+
, and  T cells, leading to reduction of their in vitro cytotoxicity 
without affecting the perforin-mediated lytic pathway (Hedlund et al., 2009)  
 
Shuttle for genetic and protein materials between cells 
 
Exosomes have been shown to transfer protein material between cells. A study in 2008 
has shown that glioblastomas cell-derived microvesicles expressed oncogenic EGF 
receptor EGFRvIII and can transfer it to cells that were EGFRvIII negative and induced 
EGFRvIII-dependent signalling pathway (Al-Nedawi et al., 2008).  Larger particles 
have also been shown to mediate receptors transfer. Microparticles secreted by 
monocytes bear CCR-5, a chemokine receptor that is central to the transmission and 
propagation of HIV-1, and is the principal co-receptor for macrophage-tropic (M-tropic) 
HIV-1 strains. These microparticles could transfer this receptor to blood mononuclear 
cells that do not express CCR5. These cells thus became sensitive to infection by a 
macrophage-tropic HIV-1 (Mack et al., 2000). 
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A more recent advance in the field of exosome study has been the discovery that these 
vesicles can also contain, and deliver, species of RNA molecules that can be active in 
cells that take up the exosomes. In 2007, Valadi et al published in Nature Cell Biology 
demonstrating the presence of mRNA and microRNA in exosomes secreted by mast 
cells. They have also shown that some selected mRNA present in exosomes can be 
translated into proteins in target cells (Valadi et al., 2007). A study by Skog et al. also 
showed that exosomes derived from Glioblastoma cells are enriched in mRNA and 
miRNA. They showed that mRNA could be delivered into recipient normal cells and 
generate a functional protein, proving that the mRNA present was active and functional. 
These exosomes stimulated glioma cell proliferation and promoted tumour cell growth 
(Skog et al., 2008).  The identification of RNA being present in exosomes supports the 
hypothesis that exosomes may be a delivery vehicle by which one cell communicates 
with another, actually delivering RNA and, in turn, modulating recipient-cell protein 
production. Not all mRNAs in a cell end up in exosomes.  To understand the 
mechanism of mRNA targeting to these vesicles will provide us with a better 
understanding of the function of RNA delivery to secreted vesicles. Some groups are 
comparing RNA sequences in vesicles from normal and cancer cells, and also from 
biological fluids. Encapsulation into membrane vesicles protects extracellular RNAs 
from degradation, allowing efficient recovery from biological fluids such as plasma and 
urine (Thery, 2011). It should become clear whether exosomes can be used as 
biomarkers in the next few years.  
 
Some miRNAs have a higher expression in exosomes compared to cells showing that 
microRNAs were uniquely packed into exosomes. In 2010, it was shown that EBV-
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infected B cells release exosomes that bear EBV-encoded miRNAs, which can be 
transferred to non-infected cells and cause repression of target genes of these miRNAs 
(Pegtel et al., 2010). Moreover, Let-7 miRNAs, which play a tumour-suppressive role 
because they target oncogenes such as RAS and HMGA2, were released by AZ-P7a 
cells (gastric carcinoma cell line) via exosomes to the extracellular environment in order 
to maintain their tumourigenic and metastatic properties (Ohshima et al., 2010).  
 
Use of exosomes as vehicles for delivery of drugs 
 
Three main classes of delivery vehicles have been the centre of research on therapeutic 
RNAi: Viruses, polyethylenimine (PEI)-based nanoparticles and liposomes. Delivery of 
genetic material using all three types of methods have achieved some success, 
nevertheless, It is still extremely difficult to achieve clinically significant gene knock 
down in the target tissue without immune activation and toxicity.  
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Figure 1.4: Advantages and disadvantages of siRNA delivery by different classes of 
vehicles. Major advantages are indicated in green and disadvantages are indicated in 
red. Figure adapted from Van den Boorn et al. (van den Boorn et al., 2011).  
 
Delivery with virus poses unique problems. Viruses are very prone to clearance by 
complement, opsonins and coagulation factors. Insertional mutagenesis could also lead 
to gene dysregulation and oncogene activation (van den Boorn et al., 2011). Thus, 
important safety considerations for viral vectors including inflammatory reactions, 
immunogenicity, and oncogenic transformation need to be addressed.  
 
Does not induce 
immune responses 
May trigger 
inflammatory 
reactions, cell stress 
and apoptosis 
Liposomes 
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Delivery with lipid nanoparticles also has limitations. They absorb opsonins that 
activate complement and coagulations factors and could be cleared by phagocytosis.  
Also if they do not escape from the endosome, they could lead to activation of TLR7/8, 
which play a fundamental role in the activation of innate immunity.  
 
PEI nanoparticles may interact with serum protein, resulting in clearance. Release of the 
siRNA into cytosol depends on the rupture of the endosomal membrane and this could 
lead to inflammatory reactions, cell stress and apoptosis.  
 
Another system has also been proposed by Guo et, al. They have utilised the packaging 
RNA of the DNA-packaging motor of bacteriophage phi29 and manipulated it by RNA 
nanotechnology to make chimeric RNAs that form dimers via interlocking right- and 
left-hand loops. Incubation of cells with dimer, one subunit of which carried siRNA and 
the other a RNA aptamer to CD4, resulted in successful binding, entry, and silencing of 
apoptotic genes (Guo et al., 2005).  
 
The ability of exosomes to transfer nucleic acid to cells makes it possible to engineer 
specific DNA or RNA to be delivered to cells, making exosomes a potentially ideal 
candidate as vectors for gene therapy (Valadi et al., 2007). Sun et al was the first group 
that applied these naturally occurring exosomes for drug delivery (Sun et al., 2010). 
They have reported that exosomes can deliver anti-inflammatory agents, such as 
curcumin, to immune cells. A year later, the same group reported that exosomes 
encapsulating curcumin or the Stat3 inhibitor JSI124 have been delivered noninvasively 
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to microglia cells via an intranasal route in mice, and had significantly delayed brain 
tumour growth in their tumour model (Zhuang et al., 2011a, b). 
 
The first proof-of-concept demonstration that exosomes are potential delivery vehicles 
for macromolecular drugs came from Alvarez-Erviti et al (Alvarez-Erviti et al., 2011). 
They have engineered exosomes derived from immature dendritic cells to express 
Lamp2, fused with a peptide derived from the rabies virus glycoprotein (RVG), which 
specifically binds to the nicotinic acetylcholine receptor (AchR) present on neurons and 
the vascular endothelium of the blood brain barrier. Modified exosomes have carried 
siRNA into brain tissue in mice, resulting in specific knock down of the gene BACE1, a 
therapeutic target in Alzheimer’s disease.  
 
A very recent study has used plasma exosomes as gene delivery vehicles to deliver 
siRNA to human mononuclear blood cells including monocytes and lymphocytes, 
leading to gene silencing of MAPK1 (Wahlgren et al., 2012). 
 
These studies demonstrate the potential of exosomes in novel therapeutic treatments. 
Exosomes have distinct advantages over other existing siRNA delivery vehicles. They 
do not induce immune responses because they can be derived from a patient’s own cells, 
and consequently avoid clearance by antibodies because of their self-derived nature. 
Exosomes could also avoid clearance by opsonins, coagulation factors and complement. 
The exosomes used in their study express the tetraspanin CD9 on their surface, which 
facilitate direct membrane fusion and release of the exosomal content directly to the 
target cell’s cytosol. This entry method avoids the endosome-lysosome pathway, where 
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TLR7 and TLR8 could recognise the nucleic acids and activate innate immunity. The 
small size of exosomes is also an advantage, allowing the exosomes to escape from 
phagocytosis by the mononuclear phagocyte system that clears particles bigger than 100 
nm in size (van den Boorn et al., 2011). 
  
The role of exosomes in vivo and in disease 
 
The role of exosomes secreted in vivo is still in debate and needs to be fully determined. 
Study of exosomes secreted from serum has been reported. A study by Taylor et al 
indicated that exosomes with T-cell inhibiting activity are increased in pregnant women 
who deliver at full term compare to women who deliver pre-term (Taylor et al., 2006).  
 
Ultracentrifugation is the most used method to purify exosomes. It is likely that 
ultracentrifugation does not allow 100% recovery of the vesicles secreted at a given 
point of time because some of the vesicles are re-captured by cells rather than release in 
the culture medium or body fluid. It is difficult to predict whether the amount of 
vesicles used in vitro corresponds to amounts of vesicles secreted in vivo (Thery, 2011). 
It has been reported that functional differences exist when comparing exosomes 
secreted from tumour cells re-isolated from syngeneic mice to exosomes from tumour 
cells that have undergone numerous in vitro passages (Xiang et al., 2010), thus 
exosomes secreted in vivo may have different properties.  
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There are also studies that describe exosomes from biological fluids including sperm 
(Ronquist and Brody, 1985), urine (Pisitkun et al., 2004), milk (Admyre et al., 2006). 
All these studies suggest that exosomes should be secreted in vivo.  
 
HIV particles utilize multivesicular compartments that are enriched in MHC II and 
CD63 as the major site for accumulation in human macrophages. Furthermore the 
released virus has proteins commonly found on exosomes. These findings formed the 
background for the “Trojan virus hypothesis”, which suggested that viruses such as HIV 
could hijack and hide in exosomes secreted from an infected cell, and because the 
retroviruses are released in the form of exosomes, they could then escape the host 
defence (Figure 1.1). It has been demonstrated that the cellular prion protein (PrPc) and 
the transformed infectious PrPscrapie (PrPsc) are found in exosomes secreted into the 
culture medium and exosomes that express PrPsc were infectious, indicating the role of 
exosomes in the spread of prions (Fevrier et al., 2005) 
 
Exosomes have also been shown to play a role in allergy. B-cell derived exosomes can 
present allergen-derived peptides and stimulate allergen-specific T-cells to proliferate 
and to produce cytokines, indicating that exosomes could be an immuno-stimulatory 
factor in an allergic immune response (Admyre et al., 2008). Another study has shown 
intranasal administration of tolerogenic exosomes in mice one week before 
sensitization/exposure to olive pollen allergen inhibited the development of IgE 
response, Th2 cytokine production, and airway inflammation and maintained long-term 
specific protection in vivo (Prado et al., 2008). Another group reported that exosomes 
derived from bronchoalveolar lavage fluid (BALF) from asthmatic and healthy people 
39 
 
have significantly different phenotypes and functions.  BALF exosomes from people 
with allergic asthma may be involved in subclinical inflammation by promoting LTC4 
and IL-8 secretion in airway epithelium (Torregrosa Paredes et al., 2012).  
 
Isolation of exosomes 
 
Despite the increasing number of groups that are investigating the properties of 
exosomes and the sparked interest in this field, there is still not a standardised 
purification protocol for isolating exosomes. The most widely used technique to isolate 
exosomes is sequential centrifugation at 300 x g and 10,000 x g to get rid of cells, debris 
and large vesicles, and a final 100,000 x g ultracentrifugation for 2 hours to pellet 
exosomes. However, some vesicles bud from the plasma membrane and can be 
anywhere between 50 to 1,000 nm in diameter. As a result, the 100,000 x g pellet may 
be a mixture of exosomes and other vesicles. To further purify the exosomes, 
ultracentrifugation on a sucrose gradient can be used or filtration of the exosomes using 
a 0.2 µm filter.  
 
Recently, a new product with unknown composition called ‘Exoquick’ was released on 
the market. This product claims to precipitate exosomes by a single step from a small 
volume of body fluid or cell culture supernatant. It is not possible to comment on the 
efficiency of this product until full characterisation of these particles in terms of size, 
floatation on sucrose gradient and protein composition has been performed. Thus it is 
not possible to conclude on the types of these particles at this stage, i.e. exosomes or 
other types of vesicles. A very recent study by Thery’s group has found that CD9 could 
also be present on microvesicles larger than 100 nm and particles smaller than 50 nm 
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and thus concluded that CD9 was not a specific marker for exosomes. Since the 
particles recovered by using ‘Exoquick’ bear large amount of CD9 and low amounts of 
CD63, it was suggested that this procedure was not specific for exosomes derived from 
the endosomes (Bobrie et al., 2012a).  
 
These techniques do not separate exosomes from viruses or other nano-sized vesicles 
that could exist in cell culture supernatants and have a similar density to the exosomes. 
To solve this problem, a modified protocol used ‘Optiprep’ (a density gradient medium). 
The exosomes were collected around 10% and HIV virions were collected around 15%. 
Unfortunately, the vesicles purified this way were not fully characterised as exosomes 
(Cantin et al., 2008).  
 
Exosomes can also be purified by using immnoaffinity techniques, which use beads or 
other solid substrates coated with an antibody that recognise a marker on exosomes. 
CD63 could supposedly be used for exosomes from all cell types. Immunoaffinity 
techniques are very useful to isolate exosomes for further analysis of their composition, 
but cannot produce clinical grade exosomes or be applied for functional studies, because 
there may be possible alternations of the surface of the exosomes during the acid elution 
of exosomes from the beads and antibody. Thus, there is a need to develop better 
purification techniques to produce clinical grade exosomes. One good procedure has 
been reported. They used ultrafiltration of the medium through a 500-kDa NMWCO 
hollow fibre cartridge and ultracentrifugation into a 30% sucrose/ deuterium oxide 
(D2O) (98%) cushion (density 1.210 g/cm3), whereby exosomes from monocyte-
derived dendritic cells were purified based on their unique size and density (Lamparski 
et al., 2002).  
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Flotation of vesicles on sucrose gradients can allow some separation but this separation 
is not absolute. Thus, completely satisfactory means for distinguishing different types of 
vesicles secreted by the same cell are still lacking. It should be taken into consideration 
that other possible contaminating vesicles should be minimised when culturing for the 
collection of exosomes. It was suggested that 3 things should be noted; first, cells 
should be cultured in either serum-free medium or medium with serum which has been 
depleted of small vesicles by ultracentrifugation at 100,000 x g. Second, apoptotic 
vesicles and other membrane vesicles of non-endocytic origin will contaminate the 
exosomes if there are more than 5% dead cells. Third, if large membrane vesicles have 
not been depleted from the cell supernatant or biological fluid before freezing, the large 
membrane vesicles will break into small exosomes-sized vesicles and will contaminate 
the pellet as well (Chaput and Thery, 2011).   
 
Clinical implications 
 
Use of exosomes as a potential immunotherapy vaccine and diagnostic biomarker.  
 
Tumour cell-derived exosomes containing tumour antigens plus MHC class I molecules 
can transfer tumour antigens to DCs to induce a CD8
+
 T cell dependent anti-tumour 
immune response. Exosomes released from DCs pulsed with tumour antigens were also 
shown to elicit strong anti-tumour responses. One study compared exosomes derived 
from tumour cells and exosomes derived from dendritic cells in aspects of the 
stimulatory efficiency of the antitumor immune responses induced by these two 
commonly used exosome vaccine (Hao et al., 2006). 
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As I have mentioned before, exosomes can induce tolerance and help protect against 
sensitization to allergen in mice. Thus, it is possible exosome-based vaccine could be 
developed and could be used as an alternative therapy to conventional therapies for 
diseases associated with allergies (Prado et al., 2008).   
 
Clinical Trials 
 
Two phase I clinical trials have been carried out on patients with advanced stage 
melanomas or non-small cell lung carcinomas expressing melanoma-associated antigen 
(MAGE). These trials required the establishment of good manufacturing procedures to 
obtain clinical-grade exosomes from patients’ DC loaded with tumour antigen derived 
peptides. These studies proved that it is feasible and safe to give exosomes to human 
subjects and that the exosomes are efficient in inducing antigen-specific T-cell 
responses. The only side effects were mild localized reactions at the site of injection and 
mild fever in a few patients. The clinical outcomes were encouraging, showing transient 
stabilization of the disease in half of the patients in the melanoma trial and a third of the 
patients in the lung carcinoma trial (Escudier et al., 2005; Morse et al., 2005).  
 
Another report that studied the use of ascites-derived exosomes (Aex) in combination 
with the granulocyte-macrophages colony-stimulating factor (GM-CSF) in the 
immunotherapy of colorectal cancer was also published. 40 patients with advanced 
colorectal cancer were involved in this study and they were randomly allocated to 
treatments with Aex alone or Aex with GM-CSF. Both treatments were safe and the 
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Aex plus GM-CSF can induce tumour-specific anti-tumour cytotoxic T lymphocyte 
(CTL) response (Dai et al., 2008) 
 
The first clinical trials used exosomes released from immature dendritic cells. These 
exosomes could preferentially induce tolerance. The maturation stages of dendritic cells 
could also affect the immune properties of exosomes (Chaput and Thery, 2011).   Based 
on these results, a phase II clinical trial is on-going in France in patients with non-small 
cell lung cancer that have been stabilized by chemotherapy. This study will use the 
second generation exosomes from IFN-treated DCs. IFN is a cytokine that induces the 
expression of CD40, CD80, CD86, and CD54 on dendritic cell-derived exosomes. 
These molecules are important for T cell priming and/or the DC/T cell interactions. The 
new generation of exosomes have enhanced immunostimulatory properties and could 
directly activate a Mart-1 specific CD8+ T cell clone and of NK cells in vitro, and the 
priming of CD8+ T cells in vivo (Viaud et al., 2011). The major goal of this clinical trial 
is to improve progression-free survival 4 months after chemotherapy. Other objectives 
include the clinical efficacy of these exosomes (overall survival, objective response 
rates and safety of these exosomes, etc (Chaput and Thery, 2011).  
  
Depletion of tumour exosomes from blood as a possible treatment for cancer? 
 
There are contradictory views on tumour exosomes. They carry antigens from the 
tumours and can present them to dendritic cells. They could also be immunosuppressive 
and inhibit the functions of T lymphocytes or natural killer cells The actual results of 
the effects of tumour exosomes in vivo are still not very clear, nevertheless, it was still 
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suggested that depletion of membrane vesicles from the blood circulation of patients is a 
possible anticancer treatment (Ichim et al., 2008). There were even products already 
developed called Hemopurifier and Her2osome produced by Aethlon medical. Both 
products belonged to the Aethlon ADAPT™ (adaptive dialysis-like affinity platform 
technology) system, an innovative device strategy involving extracorporeal 
hemofiltration and capture of target exosomes from the entire circulatory system of the 
patient using an affinity plasmapheresis platform (Marleau et al., 2012). It was claimed 
that both products can reduce circulating tumour secreted exosomes and Her2osome can 
also reduce circulating Her2 protein in patients with Her2
+
 breast cancer.  
 
Hemopurifier was claimed to have broad capabilities against viral pathogens such as 
Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV), etc. Studies 
demonstrated that Hemopurifier was safe for human and reduced more than 50% of 
viral load after 4-hour treatments in both HIV patients and HCV patients without the 
need of any antiviral drugs (Tullis et al., 2009). Hemopurifier is now being evaluated in 
a clinical study in India to test its efficiency to deplete viral load when it is combined 
with the use of HCV standard of care drug therapy. The company is also trying to 
initiate clinical studies in the United States. (www.aethlonmedical.com) 
 
The other member of the Aethlon ADAPT™ system is HER2osome.  Her2 stands for 
‘Human Epidermal Growth Factor Receptor 2’ and is a protein giving higher 
aggressiveness in breast cancer.  Approximately 25-30% of breast cancers have HER2 
overexpression. The goal of HER2osome is to reduce circulatory HER2 protein and 
breast cancer exosomes, which has been identified as playing an important role in the 
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progression of breast cancer. The immobilization of a HER2 antibody and an exosome 
targeted affinity agent provides a mechanism to clear both targets from the circulatory 
system of HER2
+
 breast cancer patients.  It can be utilised on Dialysis machines already 
located in hospitals worldwide.   (www.aethlonmedical.com) 
 
An alternative explanation of tumour exosomes in the circulation of cancer patients 
suggested that they are not necessarily signs of tumour progression, but could simply be 
the result of tumour expansion (Thery, 2011). It is still unclear whether depletion of 
tumour-derived exosomes from cancer patients would be harmful or beneficial for the 
patient since the function of tumour-derived exosomes in vivo is still unclear. Thus, 
caution needs to be taken in using such approaches without proper understanding of 
what exosomes secreted by tumour cells do in vivo. 
 
Breast cancer 
 
The female breast is made up mainly of milk-producing glands called lobules, tiny tubes 
that carry the milk from the lobules to the nipple called ducts, and stroma that include 
fatty tissue, connective tissue surrounding the ducts and lobules, blood vessels, and 
lymphatic vessels. Most breast cancers begin in the cells that line the ducts (ductal 
cancers). Some begin in the cells that line the lobules (lobular cancers), while a small 
number start in other tissues (Figure 1.6). Breast cancer is the leading type of 
malignancy in women, with devastating properties such as invasiveness and abilities to 
metastasize. Prognosis and appropriate treatment depend on patient age, tumour size, 
hormone receptor status, and HER2 status, etc. Gene expression profiling has been used 
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to identify several major breast cancer subtypes including luminal A, luminal B, HER2-
enriched, basal-like and normal like subtypes. Most breast cancers are luminal tumours. 
They are hormone receptor positive.  Hormone receptor negative breast cancers include 
two major subtypes, HER2 and basal-like. Details of the gene expression, response to 
treatment, and prognosis are listed in Figure 1.6.  
 
Breast cancer can also be categorized based on its histologic type. The two most 
common histologic types of invasive breast cancer include ductal and lobular 
carcinomas, which account for most cases of breast cancer. Less common invasive 
breast cancer includes inflammatory breast cancer and Paget’s disease of the nipple. 
Other less common forms of invasive breast cancer are medullary, mucinous, papillary 
and tubular carcinoma, which together account for about 10% of all cases (Li et al., 
2005).  
Non-invasive breast cancer is an abnormal growth of cells still within the areas of cells 
where it started. They have not invaded and this is referred to as stage 0. Non-invasive 
breast cancer includes ductal carcinoma in situ and lobular carcinoma in situ.  
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Figure 1.5: Structure of the normal breast. The female breast is made up mainly of 
lobules, ducts and stoma. Most breast cancer starts in cells that line the ducts. Some 
breast cancer starts in cells that line the lobules. A small number of breast cancers start 
in other tissues. Image was adapted from www.cancer.org/ 
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Figure 1.6: Major molecular subtypes of breast cancer determined by gene 
expression profiling. Adapted from Schnitt, et al, 2010 (Schnitt, 2010).  
 
Causes of breast cancer 
 
The causes of breast cancer are unknown. Certain risk factors can affect a person’s 
chances of getting breast cancer. There are several risk factors. First, it is rare in women 
under the age of 35, and most breast cancers occur in women over 50. Second, previous 
cancers and other breast conditions could also increase the risk. These include previous 
breast cancer, ductal and lobular carcinoma in situ, over-production of slightly abnormal 
cells, and dense breast tissue.  Third is hormonal factors including delayed age at first 
full term birth, use of combined hormone replacement therapy (HRT), not breastfeeding 
or breastfeeding for less than a year, early onset of period (before 12) or a late 
menopause  (after 55) and taking the contraceptive pill. These factors could allow 
MDA-MB_231 
(Basal 
phenotype) 
MCF7 
(Luminal A 
phenotype) 
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exposure to the hormones oestrogen and progesterone for continuous long periods and 
thus increase the risk. The fourth one is lifestyle factors including smoking tobacco, 
excess body weight, lack of exercise and alcohol consumption. The final factor is 
genetic factor (family history). Breast cancer risk is higher in women who have close 
family relatives with this disease.  A small percent of breast cancers are linked to 
inherited mutations in certain genes. The most commonly mutated genes are BRCA1 
and BRCA2 genes, women with mutations in those genes have about 80% chance of 
developing breast cancer throughout their lives.  
 
Prevention of breast cancer 
 
Cancers are caused by multiple factors acting simultaneously and hence could be 
prevented by intervening on single or multiple risk factors. A healthy, balanced diet and 
regular exercise reduce lifetime weight gain and avoid or limit alcohol intake may help 
reduce the risk of breast cancer. For women at an increased risk, genetic testing for 
BRCA genes, chemoprevention using drugs such as Tamoxifen that lower breast cancer 
risk may help reduce the risk. For women with very high breast cancer risk, 
prophylactic surgical removal of the breasts or ovaries may be an option.  
 
Treatment of breast cancer 
  
The main treatments for breast cancer are surgery, radiotherapy, chemotherapy, 
hormone therapy and biological therapy (targeted therapy). 
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Rab27a 
 
The RAB27A gene is a member of the RAS oncogene family. The protein encoded by 
Rab27a is a member of the GTPase Rab family and may be involved in protein transport. 
It was shown that overexpression of Rab27a could be related to the invasive and 
metastatic potential of cancer cells, and Rab27a expression increased in human breast 
cancer as invasive and metastatic potential increased (Wang et al., 2008).  They have 
also shown that Rab27a overexpression could redistribute the cell cycle and the 
percentage of cells in S phase which were dramatically increased and cells in G0 and G1 
phase were decreased, demonstrating that Rab27a overexpression in breast cancer cells 
could cause the tumour cells to divide faster. Consistent with these results, another very 
recent study has shown that inhibiting the expression of RAB27A decreased exosome 
production and the release of proangiogenic factors from tumour cells, and also 
inhibited tumour growth and metastasis. These data suggest that RAB27A should be 
considered as a potential therapeutic target in cancer (Peinado et al., 2012). 
It was shown that Rab27a silencing can inhibit MVE docking with the plasma 
membrane and inhibit exosome release (Ostrowski et al., 2010). It has also been shown 
that knocking down Rab27a in Hela cells increases the size of MVE multivesicular 
bodies. It was reported that either Rab27a is required for docking and when it is absent, 
the vesicles fuse with each other instead of fusing with the plasma membrane; or 
Rab27a prevents the fusion of CD-63 positive compartments with each other and its 
absence causes the CD-63 positive compartments to fuse together, and the enlarged 
MVEs fails to fuse with the plasma membrane because of the size (Ostrowski et al., 
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2010). Because of its identification in the secretion of exosomes, we have also used 
Rab27a as a target for disruption of the exosome pathway in this study.  
 
Aims of the project 
 
As there are contradictory views of tumour-derived exosomes, further characterising 
tumour-derived exosomes will contribute significantly to this emerging field, and 
contribute towards the possible future use of exosomes as biomarkers, vaccines, or gene 
delivery vehicles. The main aim of this project is to characterise exosomes and 
microvesicles secreted from breast cancer cells. Another major aim of the study is to 
investigate whether the Rab27a associated exosomes pathway can be monitored by 
Nanoparticle analysis (NTA), which will be introduced in a later chapter.  
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Chapter II Materials and Methods 
 
Cell culture of human breast cancer cell lines. 
 
 MDA-MB-231 cells were cultured in RPMI 1640 (Lonza, UK) with 10% FCS 
(Globepharm, Cork, Ireland) and 10,000 units/ml penicillin, 10 mg/ml streptomycin and 
2mM glutamine (PSG) (Sigma Aldrich, Poole, UK). MCF 7 cells were cultured in 
DMEM with 10% FCS, PSG and 10 μg/ml insulin Confluent cultures were routinely 
passaged by removing the culture medium and washing with approximately 1 ml of 0.5 % 
trypsin EDTA (ethylenediamine tetraacetic acid), and then a further 1 ml of trypsin was 
added to the cells and the flasks were incubated for approximately 2 minutes in the 
incubator. Trypsin was then neutralised with approximately 10 ml of complete culture 
medium.  All tissue culture procedures were performed in a class 2 containment cabinet. 
Cells were grown in T75 cm
2
 or T175 cm
2
 tissue culture flasks (Thermo Fischer 
Scientific, Surrey, UK) in an incubator at 37 °C in a humidified atmosphere of 5 % CO2 
in air. The cells were tested for mycoplasma contamination and were negative.  
 
In vitro cell culture of Jurkat T cells   
 
Jurkat cells were grown in RPMI 1640 with 10% FCS and PSG and were routinely 
passaged by 1:1 dilution with fresh RPMI medium.  Cells were inspected daily using an 
inverted phase microscope to ensure that they were healthy. 
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In vitro cell culture of HeLa cells   
 
HeLa cells were grown in RPMI 1640 with 10% FCS and PSG and were routinely 
passaged with fresh RPMI medium using the trypsin technique described above. 
 
Cell counting 
 
Cell counting was facilitated by using a Z1 Coulter® Particle Counter (Coulter Particle 
Characterization, Hialeah, USA). Isoton was used as a blank count and the average was 
deducted from the reading when counting cells. Approximately 200 μl of cell 
suspension in medium was added to 20 ml of Isoton in a beaker. At least 3 readings 
were recorded on the coulter.  
 
Freezing and thawing of cells 
 
Cells were trypsinised and centrifuged at 300 x g for 10 minutes. The supernatant was 
then discarded and the cell pellet was re-suspended in freezing medium (90% FCS and 
10% DMSO (dimethyl sulfoxide)). Approximately 1 ml of cells was added to each 1.5 
ml cryo vials (Corning Incorporated, New York, USA). The vials were then transferred 
into an isopropanol-filled freezing container and were left at -80 °C for approximately 
24 hours before being transferred to the liquid nitrogen storage tanks.  
 
Before cells were taken out from the liquid nitrogen, appropriate medium was warmed 
in a 37 °C water bath. Cells were then taken out of liquid nitrogen and warmed in the 
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water bath. Cells were then pipetted into the flask and the warm culture medium was 
added slowly. Cells were returned to the incubator and the medium was changed after 
24 hours.  
 
Flow Cytometry 
 
A Beckton Dickinson FACScan (Becton-Dickinson BioSciences, Oxford, UK) was used 
for all the flow cytometry studies. Data acquisition was performed using CellQuest 
software (San Jose, CA, USA), and analysis was performed by using Summit software 
(Dakocytomation, Glostrup, Denmark). 
 
Annexin V staining 
 
Approximately 500,000 Jurkat cells were seeded into each of the 4 wells of a 6 well 
plate. MDA-MB-231 and MCF 7-derived exosomes were added into 2 of the wells and 
PBS was added to another well as a control. Final concentration of the exosomes was 60 
ug/ml. After 24 hours, Jurkat cells (250 μl) were harvested and pelleted on a desktop 
microfuge, Pellets were resuspended in 500 μl of binding buffer, Annexin V-FITC  (5 μl) 
(Sigma-Aldrich, Poole, UK) was added and incubated for 5 minutes. Samples were then 
analysed by using flow cytometry 
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PI staining to study Jurkat cell apoptosis caused by MDA-MB-231/MCF7 
conditioned medium or exosomes  
 
Apoptosis induced by conditioned medium 
Approximately 10 ml of RPMI, MDA supernatant, DMEM and MCF 7 supernatant was 
spun at 300 x g for 10 minutes and then 10,000 xg for 30 minutes. The pellet was then 
discarded and supernatant was added to Jurkat cells in a 6 well plate. After 48 hours, 
cells were centrifuged again on a desktop microfuge (VWR International, Leicestershire, 
UK), washed twice with ice-cold PBS, fixed with 70% ethanol in the cold room for at 
least 30 minutes, washed twice with ice-cold PBS and then stained with PI in the dark 
for 30 minutes. Data acquisition was achieved by using CellQuest software. FLH-1 
channel was chosen for green fluorescence. Analysis was performed by using Summit 
software. 
 
Apoptosis induced by exosomes 
 
Approximately 300, 000 Jurkat T cells (250 μl) were seeded into each well of a 24 well 
plate. Approximately 250 μl of MDA exosomes (52 μg) was added to 250 μl of Jurkat 
cells (final exosome concentration 104 μg/ml). Jurkat cells with 250 μl PBS added was 
used as control. MCF7-derived exosomes was added to one well of Jurkat cells (final 
exosomes concentration 400 μg/ml). After 24 hours, cells were pelleted and washed 
twice with ice-cold PBS, fixed with 70% ethanol in the cold room for at least 30 
minutes, washed twice again with ice-cold PBS and then stained with PI in the dark for 
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30 minutes. Data acquisition was achieved by using CellQuest software. FLH-1 channel 
was chosen for green fluorescence. Analysis was performed by using Summit software. 
 
E. coli Transformation 
 
Competent JM109 cells were thawed on ice, and 20 μl of cells and 0.5 μl of each DNA 
plasmid were added into each eppendorf, which was then incubated on ice for 20 
minutes. Cells were heat shocked for 50 seconds at 42 °C and were then immediately 
put on ice for approximately 2 minutes. Luria Broth (LB) medium (100 μl) was added to 
each eppendorf. And all eppendorfs were incubated at 37 °C in a shaking incubator for 
1 hour. Approximately 100 μl of each sample was taken and pipetted onto a LB agar 
plate containing Ampicillin (100 μg/ml). All plates were incubated overnight at 37 °C. 
One single colony from clone 1-4 and all 4 clones mixed together was taken and put 
into 5 ml LB medium with ampicillin (100 μg/ml) in a 50 ml tube. After approximately 
8 hours, they were put into a shaking incubator overnight. Approximately 200 μl was 
then taken out from each tube and was added to 100 ml LB containing ampicillin, which 
was then subject to plasmid purification by using plasmid midi prep kit from Qiagen 
according to manufacturer’s instructions, or aliquoted and stored at -80 °C to create 
stocks.  
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ScaI Digestion and Agarose Gel Electropheresis 
 
All 5 Plasmid DNA’s (Negative scrambled, shRNA 1, shRNA 2, shRNA 3 and shRNA 
4) were checked by restriction digestion with the restriction enzyme ScaI (Roche 
Applied Science, Roche Diagnostics Ltd, West Sussex, UK). 
Reaction solutions (10 μl) were made as follow: DNA (2 μl), 10x Buffer (1 μl), ScaI 
enzyme (0.5 μl), dH2O (6.5 μl). Samples were analysed on either 1% or 2% agarose gels. 
To make the gel, 0.5 g (for 1%) or 1 g of Iberose (Webscientific, Crewe, UK) was 
added to 50 ml of 1x TAE buffer in a culture flask. The 1x TAE buffer was diluted from 
a 50x TAE buffer stock (242 g Tris, 18.6 g EDTA, 57.1 ml Glacial acetic acid, pH 8). It 
was covered with cling film, which was pierced a few times and heated in a microwave. 
It was mixed at regular intervals by swirling the flask. Approximately 2 μl of ethidium 
bromide (Sigma) was added after the mixture had cooled down. It was then allowed to 
set for about 20 minutes. Samples and Lambda HindIII marker (Promega Corporation, 
Southampton, UK) were mixed with loading dye (Bioline, London, UK) and loaded 
onto the gel. It was run at 100V for approximately one hour. DNA was visualised on a 
Molecular Imager ChemiDoc
TM
 XRS Imaging system. (Bio-Rad Laboratories Ltd, 
Hertfordshire, UK.)  
 
Cell Transfection 
 
Cells were grown in a six-well plate prior to transfection.  The cells were transfected by 
either using a shRNA plasmid from Santa Cruz (Santa Cruz Biotechnology Inc, 
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Heidleberg, Germany) or using the SureSilencing shRNA plasmids for human Rab27a 
from Qiagen (Qiagen, Crawley, UK). Briefly, approximately 1 μg of each shRNA was 
added to 50 μl of serum free RPMI. Lipofectamine 2000 (2 μl) (Invitrogen, Paisley, UK) 
was added to another 50 μl of serum free RPMI and was incubated at room temperature 
for 5 minutes. The contents of the two tubes were then mixed together gently and 
incubated at room temperature for 20 minutes. The total 100 μl of the mixture was 
added to 1 ml of MDA cells and incubated overnight in a tissue culture incubator. The 
next morning, medium was replaced with RPMI containing 3 μg/ml puromycin to select 
for stable transfectants.  
 
Soft agar assay 
 
Agar (5%) was melted and diluted 1 in 10 in RPMI with additives to give 0.5 % agar.  
Approximately 2 ml of the mixture was added to each well of all the 6-well plates. 
Plates were allowed to set for approximately 1 hour. Stock of cells (10,000 cells/ml) 
were prepared for each cell line used. For the top layer, 1 ml 3% agar was added to 8 ml 
RPMI and was mixed gently. Approximately 1 ml of cells was added to the mixture and 
mixed gently. Approximately 2 ml of the mixture (2,000 cells) was added to each of the 
3 wells. (Experiment was performed in triplicates). For soft agar assay with the addition 
of exosomes,  exosomes (15 μg) was added into each well. Colonies was counted after 
21 days. 
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Immunostaining of MDA-MB-231 cells. 
 
Approximately 1 million MDA-MB-231 cells were collected and centrifugation at 300 x 
g was performed. Approximately 300 µl PFN buffer (PBS containing 2% FCS and 0.1 % 
sodium azide) was added to the cell pellet and 100 µl of the sample was added to each 
of 3 wells of a 96-well plate. Supernatant was discarded after centrifugation at 300 x g. 
For the negative control, PFN buffer (50 µl) was added to the well, 45 µl PFN buffer 
with either 5 µl anti-CD9 antibody or 45 µl PFN buffer with 5 µl anti-CD63 antibody 
was added accordingly. The plate was then left rotating for 30 minutes at 4 °C. The cells 
were then pelleted by centrifugation at 300 x g at 4 °C. The supernatant was discarded 
and the cell pellets washed in 200 µl PFN buffer again. Approximately 50 µl FITC-anti-
mouse antibody (Sigma) was added into each well and the plate was left at 4 °C for 30 
minutes with agitation. Cell were then pelleted again at 300 x g and washed in 200 µl 
PFN buffer. Each cell pellet was re-suspended in 100 µl PBS. Samples were transferred 
into flow cytometry tubes and 300 µl PBS was added to each sample. The samples were 
then analysed by flow cytometry.  
 
CFSE and PE/RPE double staining 
 
RPE-conjugated mouse anti-human CD9 antibody (AbD Serotec, Oxford UK) and PE-
conjugated mouse anti-human CD63 antibody (Invitrogen) were pre-cleared by 
ultracentrifugation at 10,000 xg for 10 minutes.  The same number of MDA-MB-231 
cells was seeded into two 6-well plates and allowed to attach. A 2 mM stock was made 
by adding 11 mg CFSE powder to 10 ml PBS, 50 μl of which was added to 10 ml PBS 
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to further dilute it to 10 μM. Supernatant from cells were discarded and 2 ml of the 10 
μM CFSE was added to each well. The plates were then incubated in dark in the 
incubator at 37 °C for 15 minutes. CFSE was then discarded and the wells were washed 
3 times with serum-containing RPMI.  Serum free RPMI (2 ml) was then added to each 
well. The plates were returned to the incubator for 48 hours. Supernatant was then 
collected and ultracentrifuged at 300 x g for 10 minutes and 10,000 x g for 30 minutes. 
The pellet was discarded and 5 μl either CD9 or CD63 antibody was added to 0.5 ml 
supernatant and left rotating for 3 hours at 4 °C.  Supernatant was then analysed by flow 
cytometry. 
 
Scratch assay 
 
Cells were trypsinised and 250,000 cells were plated onto each well of a 24 well plate. 
The plate was then incubated at 37 °C in an incubator of 5 % CO2 for approximately 24 
hours to allow cells to adhere and become confluent.  The cell monolayer was scraped 
in a straight line to create a scratch with a P200 pipette tip. Cells were washed once with 
1 ml of growth medium to get rid of cell debris and then 1 ml of fresh growth medium 
was added. A reference point was made at the bottom of each well with an ultrafine tip 
marker to allow the same field to be captured every time. The scratch made was 
immediately to the right of the reference point. The plate was then placed under a 
microscope and the first image of the scratch was taken. The plate was returned to the 
tissue culture incubator and incubated for further 12 hours, and then the second set of 
images was taken.  Images were then taken every hour until all the gaps were closed. 
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Images were then imported to Image J and the results of scratch assays were plotted as 
percentage of wound closure relative to hour 0. 
 
Bradford assay 
 
Protein concentrations of samples were determined by using the Bradford assay. 
Bradford reagent was purchased from Sigma. Normally, for measuring exosomal 
protein concentration, 6 controls of known concentrations of BSA (Bovine serum 
albumin) were prepared using a stock concentration of 10 μg /ml: 0 μg/ml, 0.2 μg/ml, 
0.4 μg/ml, 0.6 μg/ml, 0.8 μg/ml and 1 μg/ml. For measuring the protein concentration of 
cell lysates, 6 control samples of known concentration were prepared: 0 μg/ml, 2 μg/ml, 
4 μg/ml, 6 μg/ml, 8 μg/ml and 10 μg/ml.  A standard curve was then prepared using 
Microsoft excel. All samples’ measurements were taken at wavelength 595 nm on a 
spectrophotometer. The concentrations of the samples were then calculated using the 
measurements and the equation from the standard curve. 
 
Invasion assay 
 
Inserts (Becton Dickinson UK, Biocoat
TM
 Gowth Factor Reduced Matrigel
TM
 Invasion 
Chamber 24 well plate 8.0 micron, Catalogue number 354483) were taken out from the 
freezer and were allowed to come to room temperature. Inserts were rehydrated by 
adding 0.5 ml of warm RPMI to the interior of each of the inserts. The plate was left for 
2 hours in the incubator 37 °C 5% CO2. After 2 hours this medium was carefully 
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removed and discarded. The same numbers of control inserts were prepared by using 
sterile forceps to transfer them onto another companion plate.  
 
MDA-MB-231 and Rab27a-inhibited MDA-MB-231 cells were trypsinised and 
resuspended in RPMI with 10% FCS and centrifuged at 1,000 rpm for 10 minutes at 
room temperature. The supernatant was removed and the cells were resuspended in 
serum-free RPMI with 0.1 % Bovine serum albumin (BSA). Cell suspensions (5 x 10
4
 
cells/ml) in serum-free RPMI containing 0.1 % BSA were prepared. 
 
RPMI medium containing the additives (10% FCS and PSG) was used as a 
chemoattractant. The RPMI medium (0.75 ml) was added to the bottom wells of both of 
the companion plates. Sterile forceps were used to transfer the chambers and control 
inserts to the wells containing the chemoattractant. Air bubbles were avoided by slightly 
tipping the inserts or chambers at a slight angle when putting in. Approximately 0.5 ml 
of cells (2.5 x 10
4
 cells) was then added to each of the chambers and the inserts and the 
plates were incubated for 22 hours in the incubator.  
After 22 hours the non-invading cells were removed from the upper surface of the 
membrane by scrubbing the membrane surface gently with a cotton swab. The 
scrubbing was repeated with a second cotton swab moistened with RPMI medium 
subsequently.  
 
The cells on the lower surface of the membrane were stained with RAPI-DIFF II stain 
pack (Raymond A. Lamb, London, UK). This kit contains 3 different solutions. Solution 
A is the fixing solution which contains methanol. Solution B is an acid dye that contains 
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Eosin Y. Solution C is a basic dye which contains Methylene Blue. Each solution was 
added to three rows of two 24-well plate. Two beakers of distilled water were also 
prepared. The chambers and inserts were transferred sequentially through each solution 
and the two beakers of water for rinses. Inserts were immersed into each solution for 
approximately 30 seconds. The inserts were then taken out using forceps and were 
placed on a piece of paper towel to air dry for 60 minutes. The cells that had migrated 
through the control insert and invasion insert were counted using an inverted 
microscope under the 40X objective. Cell counting was facilitated by photographing the 
membrane through the microscope. Three fields of each insert were taken. For ‘true’ 
representation of the cell number throughout the membrane, fields were chosen in the 
centre as well as the peripheral of the membrane. Cells were then counted and average 
calculated.  
 
Data was expressed as the percent invasion through the Matrigel matrix and membrane 
relative to the migration through the control inserts. Percent invasion was determined as 
follows: 
                       Mean # of cells invading through Matrigel insert membrane  
% invasion =                                                                                                              X 100 
                       Mean # of cells migrating through control insert membrane 
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SDS-PAGE and Western Blot 
The glass plates were assembled and the resolving gel was made as follows.  
A
  8% Resolving gel 12% Resolving gel 15% Resolving gel 
H2O 4.6 ml  3.3 ml  2.3 ml  
Acrylamide 2.7 ml  4.0 ml  5.0 Ml  
1.5 M Tris pH 8.8 2.5 ml  2.5 ml   2.5 ml  
10 % SDS 100 μl  100 μl  100 μl  
10% APS 100 μl  100 μl  100 μl  
 TEMED 6 μl  4 μl  4 μl  
B 
  Stacking gel 
H2O 5 ml  
Acrylamide 1 ml  
0.5 M Tris pH 6.8 2.5 ml  
10 % SDS 100 μl  
10% APS 100 μl  
TEMED 10 μl  
 
Table 2.1: Contents of resolving gels (A) and the stacking gel (B). Samples were 
resuspended in SDS sample buffer with or without the reducing agent Dithiothreitol) 
and denatured by heating at 70 °C for 1 minute. Electrophoresis was carried out in a 
Biorad mini-Protean II electrophoresis equipment in SDS-PAGE running buffer for 
approximately 1 hour at 150 V or until the dye reached the bottom of the gel. 
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Electrophoresis was carried out in SDS-PAGE running buffer for approximately 1 hour 
at 150 V. Protein samples were then transferred onto a nitrocellulose membrane (in 
blotting buffer (25 mM Tris, 192 mM Glycine) at 100 V for approximately 30 minutes). 
Ponceau S was used to check the protein transfer. The nitrocellulose membrane was 
washed in water and then with PBS containing 0.1% Tween 20. Blocking buffer (PBS 
containing 0.1% Tween and 5% Skimmed milk powder) was then added and the 
membrane was left on a shaker for approximately 15 minutes. Primary antibodies were 
diluted into PBS containing 0.1% Tween and incubated with the membrane and were 
left on a shaker in a cold room overnight unless specified.  Membranes were washed 3 
times with PBS containing 0.1% Tween at 10 minutes intervals. Appropriate secondary 
antibody was diluted in PBS containing 0.1% Tween and incubated with the membrane 
for approximately 20 minutes. Membranes were then washed 3 times with PBS 
containing 0.1% Tween at 10 minutes intervals. Approximately 1ml of PBS, 300 l of 
Peroxide and 300 l of enhancer (Super signal West Femto) (Pierce, Perbio Science UK 
Ltd, Northumberland, UK) was mixed together and incubated with the membrane for 
approximately 1 minute. Excess fluid was then absorbed with tissue. Antibody binding 
was then visualised with Fujifilm Intelligent Dark Box LAS-3000 (Fujifilm UK Ltd, 
Bedford, UK). 
 
Cell Lysis 
 
Cells were trypsinised and centrifuged at 1,000 rpm for 5 minutes and then washed in 
100 l of PBS. Cells were centrifuged again at 1,000 rpm for 5 minutes and then lysed 
in 100 μl of lysis buffer (10 mM Tris pH 7.6, 130 mM NaCl, 1 % Nonidet P-40 (NP40), 
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10 mM N-ethylmaleimide (NEM) and 1 mM phenylmethylsulfonyl fluoride (PMSF)) 
and incubated on ice for 10 minutes. Debris was then removed by centrifugation at 
20,000 x g for 5 minutes at 4 °C. The pellet was then discarded and the supernatant 
contained all the nuclear material. Protein concentration was measured using the 
Bradford method as described before.  
 
Isolation of exosomes 
 
After cell culture reached 90% confluency, culture medium was discarded and then 
replaced with serum free culture medium. After 24-48 hours, cell culture supernatant 
was collected. Exosomes were isolated using centrifugation at 300 x g for 10 minutes to 
get rid of dead cells and debris, at 10,000 x g for 30 minutes to get rid of large particles, 
followed by ultracentrifugation at 100,000 x g for 2 hours to pellet the exosomes using 
either the SW55Ti rotor or the SW32Ti rotor in a Beckman Optima L-100 
ultracentrifuge (Beckman Coulter, London, UK). The supernatent was then discarded 
and exosome pellets were resuspended in various volumes of PBS or lysis buffer. 
Concentrations were measured using Bradford method.  
 
Electron Microscopy 
 
Electron microscopy was performed in collaboration with Dr John Lucocq, School of 
Medicine.  Briefly, 100,000 x g pellet resuspended in PBS was adsorbed to 
pioloform/carbon coated 150 mesh EM grids and embedded in uranyl acetate methyl 
cellulose films. Micrographs were taken in a systematic uniform random method (SUR; 
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Lucocq, 2012, in press) and in the horizontal direction on the micrograph, caliper 
diameters of all structures displaying clear membrane profiles over at least half of the 
particle profile were measured using photoshop CS5 (Adobe). Qualitative micrographs 
were selected to reflect the mean caliper diameter as determined by in the SUR sample. 
 
Nanoparticle tracking analysis (NTA) 
 
Approximately 300 μl of tissue culture samples were taken by a 1 ml syringe and 
introduced into the sample chamber through the luer fittings on the top plate of the 
Nanosight LM10 unit (Nanosight Ltd, Amesbury, UK) fitted with a 635 nm laser. The 
unit was held vertically and very gentle pressure was applied on the syringe to push the 
sample in. Sample was left to equilibrate to unit temperature for a moment and then was 
connected to the microscope and visualised by using the Nanosight’s Nanoparticle 
Tracking Analysis (NTA) 2.2 Analytical software. Three videos of 30-60 seconds were 
recorded for each sample, with a shutter speed of 30 milliseconds and camera gain of 
680. Other software settings vary for different experiments. If the sample concentration 
was too high and exceeds the analysis limit, a dilution was then made so the software 
gave a more accurate reading. Backward calculation was then used to get the 
concentration of the neat sample. In between samples, the chamber was cleaned 
thoroughly. First of all the sample was extracted via the Luer port, then the sealing nuts 
securing the top plate was screwed off and the inside of the window was cleaned with 
lens tissue dampened with 70% ethanol. 
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Estimation of the size of control beads 
 
Polystyrene latex beads of known sizes were supplied by NanoSight. Approximately 10 
μl of 100 nm or 200 nm beads, and 20 μl of 400 nm beads were diluted in 1 ml of PBS. 
The samples were loaded onto the NanoSight LM10 system and three 30 seconds videos 
for each sample were captured with camera level 12. The videos were then analysed 
using the NTA 2.2 software. Software settings for analysis were: Detection threshold: 6. 
blur: auto, minimum expected particle size: 50 nm. 
 
Estimation of concentration of control beads 
 
The 100 nm control beads (10 μl) were added to 1 ml of PBS in an Eppendorf.  
Approximately 0.5 ml of the solution was mixed with 0.5 ml PBS to generate a 1 in 2 
dilution. 0.5 ml of the newly made solution was mixed with another 0.5 ml PBS to make 
a 1 in 4 dilution. This was performed once again to make the 1 in 8 dilution. The 
samples were then loaded onto the NanoSight system and three videos for each sample 
were captured with camera level 12. The videos were analysed using the NTA 2.2 
software with the settings: detection threshold: 6, blur: auto and minimum expected 
Particle Size: 50nm. 
 
Detection of Taxol and Curcumin induced apoptosis by NTA 
 
The same number of MDA-MB-231 cells was seeded in each well of two 6-well plates. 
After cells attached to the surface, medium was replaced with serum free medium and 5 
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μM or 10 μM Curcumin (Sigma) was added accordingly. Two hours after addition of 
Curcumin, 5 μM or 10 μM paclitaxel/Taxol (Sigma) was added. After 24 and 48 hours, 
supernatant was collected and centrifuged at 300 x g. The pellets were discarded and 
supernatant was analysed on Nanosight to detect apoptotic vesicles. The extended 
dynamic range mode (EDR) was chosen as this mode allows the recording of a set of 
two videos at the same time with different shutter and gain settings, enabling the 
simultaneous analysis of large and small particles when highly polydisperse sample are 
expected. Three videos of 30 seconds were recorded for each sample. Software settings 
for analysis were: detection threshold: 6 and 10, camera level 12 and 16, blur: auto, 
minimum expected particle size: 50 nm. 
 
Immunodepletion using Anti-CD9 and anti-CD63 coupled-beads 
 
Approximately 25 μl Dynabeads (sheap anti-mouse IgG from Invitrogen) were washed 
with 1 ml PBS containing 1% BSA. Eppendorfs were placed in magnetic separator for 1 
minute and supernatant was discarded. This was repeated twice and 25 μl of PBS 
containing 1% BSA was added to resuspend beads. Antibody (15 μl) was added to 
beads and left at 4 °C rotating for 1 hour. Eppendorfs were then taken out and placed on 
magnetic separator for 1 minute. Antibody-coupled beads were washed with 1 ml PBS 
containing 1% BSA twice as described before, and then resuspended in 25 μl of PBS 
containing 1% BSA. MDA-MB-231 cells were grown in tissue culture flasks to 90% 
confluency and the medium was replaced with serum free RPMI. Supernatant was 
collected after 48 hours and ultracentrifuged at 300 x g for 10 minutes and then 10,000 
x g for 30 minutes. Different amounts of antibody-coupled beads (0 μl, 0.5 μl, 1 μl, 2 μl, 
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5 μl and 10 μl) were added to each 400 μl of supernatant accordingly. They were 
incubated together for 3 hours at 4 °C. Eppendorfs were then taken out and placed on 
magnetic separator for 1 minute. The beads were discarded and the supernatant was 
analysed on Nanosight. Three 30 seconds videos were recorded for each sample using 
camera level 15. The videos were analysed using the NTA 2.2 software with the settings: 
detection threshold: 6, blur: auto, and minimum expected particle size: 50nm. 
 
Exosome pull down by antibody-coupled magnetic beads 
 
Dynabeads were prepared as described before. MDA cells were grown to 90% 
confluency and the supernatant was collected and was spun at 300 x g for 10 minutes, 
10,000 x g for 30 minutes and 100, 000 x g for 2 hours. The pellet was then resuspended 
in 1 ml serum free RPMI and was split into 2 eppendorfs. Either CD9 or CD63-coupled 
beads (25 μl) was added into each eppendorf.  Samples were left on a rotator at 4 °C 
overnight. Samples were then placed on magnetic separator for 5 minutes, supernatant 
was then discarded and 200 μl of 0.2 M glycine, pH 2.8 was added into each sample. 
The samples were then incubated at 37 °C for 5 minutes. Samples were taken out and 
the process was neutralised by adding 5 μl of 2 M Tris, pH 8. Samples were then placed 
on magnetic separator for approximately 2 minutes. Supernatant was then collected and 
the beads were discarded. Debris or beads were cleared from the samples by 
ultracentrifugation at 10,000 x g. The top supernatant from each sample was collected 
and 500 μl serum free RPMI was added to each sample. Both samples were then 
analysed on Nanosight. Three 30 seconds videos were recorded for each sample using 
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camera level 16. The videos were analysed using the NTA 2.2 software with the settings: 
detection threshold: 6, blur: auto, and minimum expected particle size: 50 nm. 
 
Multiple freezing-thawing of exosomes 
 
CEM cells were grown to 90% confluency and the cell culture medium was replaced 
with serum free RPMI. Supernatant was collected after 48 hours and was analysed on 
Nanosight. Multiple freeze-thawing of the exosomes was accomplished by freezing of 
the sample contacting exosomes in dry ice for approximately 1 minute. Thawing was 
done by gentle shaking at room temperature for 3 minutes.  Approximately 500 μl was 
taken out after each thawing step before the sample was returned to dry ice. Samples 
were analysed by NTA. Three 30 seconds videos were recorded for each sample using 
camera level 16. The videos were analysed using the NTA 2.2 software with the settings: 
detection threshold: 6, blur: auto, and minimum expected particle size: 50 nm. 
 
Immunofluorescence Microscopy 
 
A few drops of MDA-MB-231 cells, negative scrambled shRNA targeted MDA cells 
and Rab27a-targetted MDA cells (shRNA 2 and shRNA 3) were seeded on tissue 
culture dish with cover glass bottom called ‘FluroDishTM’. (World Precision 
Instruments, Hitchin, UK). This was done in duplicates so a total of 8 dishes were 
prepared. After approximately 20 hours, cells were fixed with 1.5 ml of 4% 
paraformaldehyde for 15 minutes at room temperature. Cells were then washed 3 times 
at 5 minutes intervals with PBS containing 0.1 M Glycine. Cells were then 
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permeabilized with PBS conatining 0.2% BSA and 0.05% Saponin for 5 minutes at 
room temperature. Cells were then rinsed with PBS. Primary anti-CD63 mouse 
monoclonal antibody (1 μg/ml) (Santa Cruz) was added and incubated for 1 hour at 
room temperature. Cells were then washed 3 times with PBS at 5 minutes intervals. 
Secondary Donkey-Anti-Mouse FITC antibody was added and incubated for 
approximately 1 hour. Cells were then washed with PBS for 3 times at 5 minutes 
intervals. PBS was then removed and 1 drop of Vectashield with DAPI (Vector 
Laboratories, Peterborough, UK) was added to each dish. Then immediately a 
siliconized circle coverslide (Hampton Research, Aliso Viejo, USA) was put onto the 
dish and edges were sealed with nail vanish. Slides were viewed under 100 x 
magnification under a fluorescence microscope. 
 
RNA Purification and quantification 
 
RNA was purified using RNeasy® Mini kit (Qiagen) following manufacturer’s 
instructions and the concentration was measured on Nanovue (Nanovue 4282 V1.7.3, 
GE Healthcare, Little Chalfont, UK). Briefly, cells were pelleted and 350 μl of RLT 
buffer was added to each cell pellet. Cells were then homogenised to reduce lysate 
viscosity by shearing high molecular weight genomic DNA and cellular components 
with a 21-gauge needle for 10 times. Approximately 350 μl of 70% ethanol was then 
added.  All 700 μl of each sample was transferred to a silica column in a 2 ml collecting 
tube and spun for about 3000 x g for 15-30 seconds on a desktop centrifuge to allow the 
RNA to bind to the columns.  Liquid was then discarded and the column was washed 
with 700 μl RW1 buffer. Samples were centrifuged again the columns were washed 
73 
 
again in RW1 buffer. They were then spun and washed twice with 500 μl RPE buffer. 
After the last wash, the columns were spun for 2 minutes instead of 30 seconds. The 
column was then transferred to new 1.5 ml tubes with the lids cut off. Sterile water (30 
μl ) was added to each column and after centrifugation for 1 minute, the RNA was 
eluted. Samples were then stored at -80 °C straight away.  
 
cDNA conversion 
 
Total RNA (0.5 μg) was used to reverse-transcribe into cDNA. Each sample was made 
up to a final volume of 8 μl with DNAse-free water. Approximately 1.5 μl of buffer and 
5 μl of DNase 1 enzyme were added (All from Roche). Samples were left in the PCR 
machine for 30 minutes. After 30 minutes, samples were taken out and 1 μl of RQ1 
DNAse stop solution (Promega) was added. Samples were then heated at 65°C in the 
PCR machine for 10 minutes. Approximately 4 μl of RNA was taken out and mixed 
with 20 μl distilled water and 2 μl Hexanucleotide Mix (Roche). Samples were heated 
on the PCR machine for 10 minutes at 65°C. Samples were taken out and put on ice. 
Approximately 1 μl RNase inhibitor, 8 μl 5x RT buffer, 4 μl deoxynucleoside 
triphosphates (DNTPs) and 1 μl reverse transcriptase enzyme (all from Roche) was 
added to all samples, which were then heated at 25 °C for 10 minutes, 55 °C for 30 
minutes and 95 °C for 2 minutes on the PCR machine.  
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RT-PCR 
 
PCR was performed using ReadyMix
TM
 Taq PCR Reaction Mix (Sigma). The table 
below show the amount of reagent added. 
  Samples Negative control 
Master mix 12.5 μl 12.5 μl 
dH2O 9.5 μl 10.5 μl 
Primer (forward) 1 μl of 10 μM stock 1 μl of 10 μM stock 
Primer (Reverse) 1 μl of 10 μM stock 1 μl of 10 μM stock 
cDNA 1 μl    / 
 
Table 2.2: Components of the reaction mix used for RT-PCR. 
 
The Rab27a and β-actin primers used were as follows: Rab27A forward primer: 5'-
GCCACTGGCAGAGGCCAG-3'; Rab27A Reverse primer: 5'-
GAGTGCTATGGCTTCCTCCT-3'; β-actin forward primer: 5'-
AATATGGCACCACACCTTCTACA-3’; β-actin reverse primer: 5'-
CGACGTAGCACAGCTTCTCCTTA-3'.  
 
Primer sequences were based on Herrero-Turrión, et al (Herrero-Turrion et al., 2008). 
PCR amplification was as follows: 1 cycle as initial denaturation at 95 °C for 3 minutes, 
denaturation at 95 °C for 30 seconds, annealing at 62 °C for 30 seconds, extension at 
72 °C for 1 minute (35 cycles of denaturation, annealing and extension in total), and 
final extension at 72 °C for 10 minutes. For PCR using Rab27b primers (Santa Cruz), 
annealing was performed at 59 °C for 30 seconds and all other steps were the same as 
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Rab27a. 5 μl loading buffer (Bioline) was added to each of the 25 μl PCR products and 
10 μl of which was loaded onto a 2% agarose gel in 1X TAE buffer and visualised by 
ethidium bromide staining on an ultraviolet (UV) transilluminator. 
 
Loading of Fluorescent siRNA onto exosomes 
 
Exosomes (7 µg) derived from MDA-MB-231 cells and 500 nM ‘AllStars Negative 
Control siRNA, Alexa Fluor 488’ (Qiagen) were mixed with various volume of 
electroporation buffer to make final volume of 200 µl. The composition of the 
electroporation buffer is listed below: 1.15 mM potassium phosphate pH 7.2 (To make 
up 10 ml of a stock of 1 M potassium phosphate buffer with pH 7.2, mix 7.17 ml 1 M 
K2HPO4 and 2.83 ml  1 M KH2PO4), 25 mM potassium chloride (KCL) (Sigma), and 21% 
Optiprep (Sigma). For all experiments, the samples were electroporated in a 4 mm 
cuvette at 125 µF, 400 Volts or 500 µF, 400 volts. For loading of the ‘AllStars Negative 
control siRNA’ onto exosomes, a sample of exosomes with siRNA added but was not 
electroporated was also prepared as a negative control. And each sample was then 
separated into two parts, 300 µl filtered PBS was added to one part of each sample and 
was analysed by flow cytometry. Filtered PBS (4 ml) was added to the other part of 
each sample and ultracentrifugation at 100, 000 x g was performed. The resulting pellet 
from each sample was then resuspended in 400 µl filtered PBS and was analysed using 
flow cytometry.  
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Loading of Rab27a or Erap1 siRNA onto exosomes  
 
Exosomes (7 µg) from MDA-MB-231 cells or Jurkat T cells was added to 
electroporation buffer to make up final volume of 200 µl in 4 mm cuvettes. Different 
volume of Rab27a siRNA (Santa Cruz), or Erap1 (Santa Cruz) siRNA, or ‘AllStars 
negative control’ siRNA was also added.  Samples were then electroporated at 500 µF, 
400 volts. Samples were then washed in 4 ml filtered PBS. Ultracentrifugation at 
100,000 x g was then performed for 2 hours to pellet the exosomes with encapsulated 
siRNA. The supernatant was discarded and the pellet was re-suspended in 30 µl filtered 
PBS. All samples were then added to either MDA-MB-231 cells or HeLa cells in a 6-
well plate (90% confluency). Cells were also transfected with different volume of 
Lipofectamine 2000 as a positive control. Supernatant was removed after 24 hours and 
the cells were lysed directly in lysis buffer by using the wide end of a yellow tip to 
gently scrape the cells off. Samples were incubated for 20 minutes on ice. 
ultracentrifugation at 20,000 x g was then performed for 5 minutes to get rid of debris. 
Supernatant was kept and the pellet was discarded. The concentration of samples was 
measured by using the Bradford method. Protein (20 µg) was loaded either onto a 12% 
gel (for checking Rab27a knock down) or an 8% gel (for checking erap1 knock down), 
the gel was ran at 150 V for approximately 1 hour and transferred to a nitrocellulose 
membrane at 100V for 30 minutes. Blocking buffer was added to the membrane and 
incubated for 20 minutes on a shaker. Rab27a mouse monoclonal antibody (Sigma) or 
6H9 anti-Erap1 mouse monoclonal antibody (R&D Systems, Abingdon, UK) was added 
to the membrane and left shaking overnight at 4 °C. The membrane was then washed 
with PBS-tween for 1 hour at 20 minutes intervals. Secondary antibody was added and 
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incubated at room temperature for 20 minutes. The membrane was then washed again 
for 1 hour at 20 minutes intervals. Antibody binding was then visualised with Fujifilm 
Intelligent Dark Box LAS-3000. 
 
Treatment of cells with 5-(N,N-Dimethyl) amiloride hydrochloride  (DMA) 
 
Approximately 50,000 MDA-MB-231 cells were seeded into each well of a six-well 
plate. After the cells were approximately 50 % confluent, the medium was replaced with 
serum free medium and different concentrations of DMA (Sigma, UK) was added to 
cells. Cells with no DMA added were used as a control. After 24 hours, the supernatant 
was collected and centrifugation was performed at 300 x g for 10 minutes then 10, 000 
x g for 30 minutes. The resulting supernatant was then analysed by using NTA.  
 
Lipidomics analysis of exosomes derived from MDA-MB-231 cells and the parental 
cells 
 
Lipidomics was performed by Dr Terrence Smith in the Biomedical Sciences Research 
Complex (BSRC), University of St. Andrews. Briefly, MDA-MB-231 cells were 
detached by incubating with 5mM EDTA for approximately 4 minutes. Cells were then 
pelleted after centrifugation at 300 xg. Cells were washed in PBS and re-suspended in 
100 µl PBS. Exosomes were collected by using sequential centrifugation and 
ultracentrifugation described earlier. The 100, 000 x g pellets were re-suspended in 100 
µl PBS. Lipids from cells and exosomes were extracted by the Bligh-Dyer method, i.e. 
78 
 
with chloroform/methanol (1:2), and the lipids were analysed using an Absceix 4000 
QTrap, a triple quadrupole mass spectrometer equipped with a nanoelectrospray source. 
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Chapter III: Studying Exosomes and Microvesicles using Flow 
Cytometry, Western Blot and Lipidomics. 
 
Introduction 
 
The two tumour cells lines used in this chapter were MDA-MB-231 and MCF7. The 
MDA-MB-231 breast cancer cell line was obtained from the pleural effusions of a 
Caucasian breast cancer patient in 1973 at the M. D. Anderson Cancer Centre.  The 
MDA-MB-231 cell line is estrogen receptor (ER), progesterone receptor (PR) and 
Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) triple negative. The 
tumour type is a metastatic adenocarcinoma and it is a basal B subtype. MCF7 is a 
breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman. The 
MCF7 cell line is ER and PR positive and has HER2 overexpression. The tumour type 
is a metastatic adenocarcinoma and it is luminal subtype (Kao et al., 2009). 
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  MDA-MB-231 MCF7 
Origin 
Isolated from pleural effusions 
of a 51 year old Caucasian 
female 
Isolated from pleural effusions of a 69 
year old Caucasian female 
Cell type Epithelial (Adenocarcinoma) Epithelial (Adenocarcinoma) 
Hormone 
receptor status 
ER, PR and HER2/ERBB2 
triple negative 
ER and PR positive with HER2 over-
expression 
Invasiveness Highly invasive Weakly invasive 
 
Figure 3.1: Examples of images and summary of the two breast cancer cell lines 
used in this study. 
Jurkat cell line is an immortalized line of T lymphocyte cells; it was isolated from the 
peripheral blood of a 14 year old boy with T cell leukemia in the late 1970s. The human 
lymphoid CEM T-cell line has also been used in this study. 
 
The aim of this chapter was to confirm the presence of exosomes in our conditioned cell 
cultures preparations by western blotting, electron microscopy and flow cytometry.  
MDA-MB-231 MCF7 
Scale bar: 100 µM Scale bar: 100 µM 
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It has been reported that tumour-secreted exosomes have immunosuppressive functions. 
Exosomes derived from tumour cell lines bear Fas ligand (FASL) that can induce T cell 
apoptosis leading to suppression of T-cell responses in vitro (Abusamra et al., 2005). 
Tumour derived exosomes have also been shown to express NKG2D ligands such as 
MICA and possibly MICB, which down regulates NKG2D and supresses the function 
of CD8
+
 T cell or NK cell (Clayton et al., 2008). 
 
To determine whether MDA-MB-231 and MCF7 secreted exosomes affect the growth 
of T cells and investigate whether they are consistent with Abusamra et al and Clayton 
et al’s findings, exosomes derived from both tumour cell lines were added to Jurkat 
cells.  
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Results 
 
Exosomes exist in our 100,000 x g preparation 
 
Cell supernatants were collected and centrifuged at 300 x g for 10 minutes, 10,000 x g 
for 30 minutes and 100,000 x g for 2 hours. The pellet was then resuspended in PBS. To 
confirm the presence of exosomes in our preparation, the resuspended pellet was 
analysed by immunoblotting to check for the characteristic exosomal markers Alix and 
Tsg 101. MHC class I has also been detected in both cell lines, although the MCF 7 cell 
line express low levels of MHC class I, and even lower levels were detected on MCF 7 
exosomes (Figure 3.2).  
MDA-MB-231         MCF7 
CL         Exo       CL       Exo 
 
 
 
 
Figure 3.2: Western Blot of MDA and MCF7 Exosomes. Cells were lysed and 
protein concentration was measured using the Bradford method. Equal amount of 
protein of cell lysates (CL) and exosomes (Exo) were loaded onto a 12% gel. 
Membranes were probed with the indicated antibodies and then Fujifilm Intelligent 
Dark Box LAS-3000. 
ALIX  
TSG101 
MHC Class   
90 KDa 
50 KDa 
50 KDa 
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An analysis of a sample of the MDA exosome preparation with electron microscopy 
also revealed typical cup-shaped exosomes (Figure 3.3). This indicates that exosomes 
are present in our preparations.  
 
Figure 3.3: Electron Microscopy of MDA Exosomes. Typical cup-shaped exosomes 
are present in our preparation. Electron microscopy was performed by Dr John Lucocq. 
 
To illustrate the inherent problems (limitivity to detect particles lower than 200 nm) 
associated with analysing exosomes and microvesicles by flow cytometry, MDA-MB-
231 cells were grown to 90% confluence and the medium was replaced with serum free 
medium. After 48 hours, the supernatant was collected and centrifuged at 300 x g for 10 
minutes, 10,000 x g for 30 minutes and 100,000 x g for 2 hours. The supernatant after 
each centrifugation was kept and analysed on a FACScan flow cytometer. PBS, 48 nm, 
100 nm, 410 nm beads and serum free medium were used as controls.  
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B  
 
Figure 3.4: Flow Cytometry Analysis of beads, controls and MDA supernatant. (A). 
48 nm, 100 nm and 410 nm beads were measured using flow cytometry. PBS and serum 
free RPMI was used as background control. (B). Medium was replaced with serum free 
medium when MDA cells reached 90% confluence, supernatant was collected after 48 
hours and centrifuged at 300 x g, 10,000 x g and 100,000 x g. Supernatant was collected 
after each centrifugation and analysed by flow cytometry.  
48nm 100nm  410nm 
PBS Serum free RPMI 
MDA Supn after 
300 x g 
MDA Supn after 
10,000 x g 
MDA Supn after 
100,000 x g 
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48 nm and, to a lesser extent, 100 nm beads display signals that overlap with the control 
PBS sample and the control serum free medium sample (Figure 3.4A).  There was a 
reduction in the signal after 10,000 x g and 100,000 x g ultracentrifugation of cell 
supernantants. Comparing the supernatant after 10,000 x g and the supernatant after 
100,000 x g, we can see some material was depleted after the 100,000 x g 
ultracentrifugation and the material was within the correct size range of exosomes when 
compared with the control beads (Figure 3.4B). Although all the samples do overlap 
with the background noise, the data did reveal that exosome-sized particles existed in 
the tissue culture supernatant preparations.  
 
Adding antibiotics to MDA-MB-231 cells.  
 
We wanted to study antibiotic-induced exosome/microvesicle release. Antibiotics 
including G418 and Hygromycin were used in this experiment. 
 
Figure 3.5: Adding antibiotics to MDA-MB-231 cells. 60 μl of G418 and 60 μl of 
Hygromycin were added to 3 mls of MDA cells in a 6 well plate. Supernatant was then 
collected after 72 hours and centrifuged at 300 x g and then analysed on the Facs 
machine to study antibiotics induced microvesicle release.  
Untreated 
MDA 
MDA+20 μg/ml 
G418 
MDA+20 μg/ml 
Hygromycin 
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The increase in side scatter observed in Figure 3.4A when using synthetic polystyrene 
beads does not always reflect the data seen in real exosome and microvesicle samples. 
Primarily this is because the synthetic beads do not allow laser light to pass through 
them, so disperse light mostly in side scatter. An example of the more complex signals 
seen in both forward and side scatter profiles in ‘real’ vesicles can be detected when 
antibiotics are added to cell cultures.  For example, we added antibiotics to MDA cells, 
and observed the population of microvesicles shifted to the right (FSC) (Figire 3.5). 
Interestingly, if the side scatter is a better indicator of size when analysing small 
nanoparticles, then it is tempting to assume that G418 and Hygromycin does not 
necessarily affect the size of the microvesicles released, but has increased the 
complexity of the microvesicles.  
 
Exosomes derived from MDA-MB-231 and MCF 7 cells induce apoptosis of 
Leukaemic Jurkat T cell line as identified by Annexin V staining.  
 
The induction of apoptosis of immune cells by tumour-derived exosomes has been 
previously reported. To investigate whether our tumour-cell derived exosomes can 
affect the growth of T lymphocytes, exosomes derived from MDA-MB-231 cells and 
MCF 7 cells were added to the Jurkat T cell line.  Annexin V staining shows an increase 
in apoptosis in Jurkat cells following treatment with exosomes derived from MDA-MB-
231 and MCF 7 cells, with MDA-derived exosomes being more potent than MCF7 
exosomes. 
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Untreated 
Jurkat 24h 
Jurkat+PBS 
24h 
Jurkat+MDA 
exosomes 24h 
(55.2 μg/ml) 
Jurkat+MCF7 
exosomes 24h 
(60 μg/ml) 
17.73% 
23.15% 
36.59% 
26.87% 
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Figure 3.6: Annexin-v staining of untreated Jurkat cells and Jurkat cells treated 
with MDA and MCF7 exosomes. Approximately 500,000 Jurkat cells were seeded 
into each of the 4 wells of a 6 well plate. MDA and MCF 7 exosomes were added into 2 
of the wells and PBS added to another. After 24 hours, 250 μl of Jurkat cells were 
harvested and spun down on desktop microfuge, Pellets were resuspended in 500 μl of 
binding buffer, 5 μl of Annexin V-FITC were added and incubated for 5 minutes. 
Samples were then analysed by using flow cytometry. Experiment was performed three 
times. (A). One representative experiment result was shown. (B). Bar chart of 
comparison of percentage of apoptotic cells between samples from three experiments. 
Error bars indicate standard deviation. ** P<0.01 
 
After 24 hours, 36.59 % of the Jurkat cells were apoptotic after addition of exosomes 
derived from MDA-MB-231 and 26.87 % of the Jurkat cells were apoptotic after the 
addition of exosomes derived from MCF 7, whereas the apoptotic cells were 17.73 % 
and 23.15 % accordingly in the control untreated Jurkat cell and Jurkat cells with PBS 
added (Figure 3.6A). The differences are statistically significant (Figure 3.6B). Thus our 
purified preparations of exosomes display previously reported characteristic behaviour, 
further confirming their identity. 
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MDA-MB-231 and MCF 7 cells-conditioned medium (supernatant) induces 
apoptosis of Jutkat T cells 
 
To further investigate the effect of tumour cell-derived exosomes on cell cycle and 
apoptosis, cell conditioned medium, rather then purified exosomes, from MDA-MB-231 
and MCF7 cells were added to Jurkat cells, which were then subsequently stained with 
propidium iodide. Apoptosis in Jurkat cells was detected as a sub-G0 population in flow 
cytometric analysis and the percentage of apoptotic cells were gated and calculated by 
using Summit software.  
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Figure 3.7: Comparison of adding unconditioned MDA/MCF7 medium and 
conditioned MDA-MB-231/MCF7 medium to Jurkat cells. Approximately 10 mls of 
medium and supernatant was spun at 300 x g for 10 minutes, then 10,000 xg for 30 
minutes. The supernatant was then added to Jurkat cells. After 48 hours, cells were 
washed withice-cold PBS, fixed with 70% ethanol, washed twice with ice-cold PBS and 
then stained with PI for 30 minutes. Data are representative of two experiments.  
Jurkat+RPMI 48h 
Apoptotic cells: 12.33% 
G0/G1: 35.9% 
S: 12.07% 
G2/M: 18.23% 
 
Jurkat+MDA 
supernatant 48h 
Apoptotic cells: 10.56% 
G0/G1: 68.01% 
S: 12.85% 
G2/M: 5.79% 
 
Jurkat+DMEM 48h 
Apoptotic cells: 21.87% 
G0/G1: 38.53% 
S: 10.2% 
G2/M: 10.23% 
 
Jurkat+MCF7 
supernatant 48h 
Apoptotic cells: 31.1% 
G0/G1: 32.9% 
S: 4.1% 
G2/M: 2.3% 
 
Sub G0    G0/G1   S       G2/M 
Sub G0    G0/G1   S       G2/M 
Sub G0    G0/G1   S       G2/M 
Sub G0    G0/G1   S       G2/M 
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Adding 48 hour MDA-MB-231 supernatant/conditioned medium to Jurkat cells did not 
induce more apoptosis (10.56%) compare to the Jurkat cells with unconditioned serum 
free RPMI medium added (12.33%), whereas adding 48 hour MCF 7 supernatant to 
Jurkat cells has increased the number of apoptotic cells to 31.1% from 21.87% with the 
unconditioned serum free DMEM medium added (Figure 3.7). The G0/G1 peak was 
dramatically increased after addition of MDA-MB-231 cells-conditioned medium to 
68.01% compared to 35.9% after addition of RPMI medium (Figure 3.7, first and 
second panel), whereas adding MCF7-conditioned medium did not increase the G0/G1 
peak compared to the addition of DMEM medium (Figure 3.7, third and fourth panel). 
G2/M phase fraction was 18.23% and 10.23% in the control groups (with addition of 
RPMI and DMEM), respectively, but decreased significantly to 5.79% and 2.3% after 
the addition of conditioned medium derived from MDA-MB-231 cells and MCF7 cells.  
 
MDA-MB-231 and MCF 7 cells-derived exosomes induces apoptosis of Jurkat T 
cells identified by PI staining. 
 
To confirm the exosomes-induced Jurkat cell apoptosis, MDA-MB-231 and MCF 7-
derived exosomes were added to Jurkat cells. Because our exosomes were resuspended 
in PBS, PBS was added to Jurkat cells as a control. Apoptosis in Jurkat cells was 
detected by PI staining and appeared as a sub-G0 population in flow cytometric analysis 
and the percentage of apoptotic cells were gated and calculated by using Summit 
software. 
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Untreated Jurkat 48h Sub G0         G0/G1    S           G2/M 
Apoptotic cells: 13.13% 
G0/G1: 51.25% 
S: 14.15% 
G2/M: 16.93% 
 
Jurkat + PBS 48h 
Apoptotic cells: 22.34% 
G0/G1: 53.86% 
S: 12.07% 
G2/M: 9.62% 
 
Sub G0        G0/G1        S         G2/M 
Jurkat + 104 μg/ml 
MDA exosomes 48h 
Apoptotic cells: 34.95% 
G0/G1: 35.42% 
S: 11.11% 
G2/M: 12.68% 
 
Sub G0     G0/G1       S         G2/M 
93 
 
B 
 
 
 
 
 
 
Apoptotic cells: 10.23% 
G0/G1: 59.13% 
S: 16.35% 
G2/M: 16.15% 
 
Sub G0  G0/G1 S   G2/M 
Untreated 
Jurkat 24h 
Apoptotic cells: 41.21% 
G0/G1: 30.49% 
S: 12.12% 
G2/M: 14.19% 
 
Jurkat +PBS 24h 
Jurkat +MCF7 
exosomes 24h 
(400μg/ml) 
Apoptotic cells: 17.82% 
G0/G1: 47.10% 
S: 19.35% 
G2/M: 15.65% 
 
Sub G0    G0/G1 S     G2/M 
Sub G0  G0/G1 S   G2/M 
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Figure 3.8: PI staining of MDA-MB-231 and MCF 7 derived exosomes induced 
Jurkat cell Apoptosis. (A) 250 μl of MDA exosomes (52 μg) was added to 250 μl of 
Jurkat cells. Jurkat cells with PBS added was used as control. After 48 hours, Jurkat 
cells were fixed then stained with PI. (B) MCF7-derived exosomes were added to Jurkat 
cells (final exosomes concentration 400 μg/ml. Jurkat cells were fixed and stained with 
PI after 24 hours. Data are representative of three independent experiments. (C). 
Percentage of apoptotic cells calculated from three experiments. Error bars indicate 
standard deviation. * P<0.05 ** P<0.01. (D). Images of untreated Jurkat cells and Jurkat 
cells treated with exosomes derived from MDA-MB-231 and MCF 7 cells.  
 
After 48 hours, 13.13% of untreated Jurkat cells and 22.34% of Jurkat cells treated with 
PBS were apoptotic as measured by the sub-G0 phase fraction. Incubation of 104 μg/ml 
MDA-MB-231 exosomes with Jurkat cells for 48 hours has increased the number of 
   Jurkat 48 h                                      Jurkat+PBS 48 h         Jurkat+MDA-MB-231 exosomes  48h 
   Jurkat 24 h                                         Jurkat+PBS 24 h                      Jurkat+MCF7 exosomes 24h 
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apoptotic cells to 34.95 % (Figure 3.8A). Microscopic images show changed 
morphology of apoptotic cells (Figure 3.8C, first panel). After 24 hours, 10.23% of 
untreated Jurkat cells and 17.82% of Jurkat cells treated with PBS were apoptotic. 
Incubation of 400 μg/ml MCF7 exosomes with Jurkat cells for 24 hours has 
dramatically increased the number of apoptotic cells to 41.21 % (Figure 3.8B). The 
percentage of apoptotic cells after tumour exosomes treatments were significantly 
different from that from untreated controls or cells treated with PBS. (Figure 3.8C) 
Images show increased number of apoptotic cells compare to untreated cells (Figure 
3.8D, second panel). 
 
Detection of CD9 and CD63 positive vesicles in our preparation by CFSE and PE 
double staining.  
 
CD9 and CD63 are both members of the tetraspanin family. They are typically found on 
the surface of exosomes. We wanted to confirm the presence of CD63 and CD9 on 
MDA-MB-231 cells and find out the percentage of CD9 and CD63 positive particles. 
The cells were incubated with mouse monoclonal CD9 or CD63 antibodies and a 
fluorescent FITC-anti-mouse secondary antibody and then analysed by flow cytometry.  
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Figure 3.9:  Confirmation that CD9 and CD63 are present on MDA-MB-231 cells 
and are more enriched in exosomes (A). Expression of CD9 and CD63 on MDA-MB-
231 cells were analysed by flow cytometry. MDA-MB-231 cells were pelleted, stained 
and analysed by flow cytometry.  (B). Expression of CD9 and CD63 on MDA-MB-231 
cells and on exosomes were analysed by western blot. (C). CD9 is mainly expressed at 
the cell surface and some intracellular compartments. (D). CD 63 accumulates at 
intracellular compartments only (multivesicular bodies).  
 
CD63 
MDA-MB-231                       
CL    Exosomes 
CD63 CD9 
CD9 Unstained Unstained      CD63 
Unstained CD9 CD63 
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The flow cytometry results indicate that MDA-MB-231 cells do express CD9 and CD63 
as a very significant shift has been observed for both antibodies (Figure 3.9A). 
Nevertheless, when analysing 5 µg of cell lysate protein by western blotting, the bands 
for both CD9 and CD63 were very faint, or even invisible, whereas the signal for both 
protein in exosomes was very strong (Figure 3.9 B). These results indicate that CD9 and 
CD63 are present on MDA-MB-231 cells and are highly enriched on MDA-MB-231 
cell-derived exosomes. Unexpectedly, the cellular distribution of CD9 and CD63 as 
determined by fluorescence microscopy was significantly different. CD9 was mainly 
expressed in patches on the plasma membrane and also in some intracellular 
compartments (possibly MVB) (Figure 3.9C left panel). CD63 accumulates at 
intracellular compartments only (MVBs) and is not found at the plasma membrane 
(Figure 3.9C right panel).  
 
Our preparation is likely to be a mixed population of exosomes and other types of 
microvesicles or subtypes of exosomes. We wanted to compare the percentage of CD9 
and CD63 containing vesicles in our preparation. In order to do this, MDA cells were 
stained with CFSE first and then stained with either RPE-conjugated mouse anti-human 
CD9 antibody (AbD Serotec) or PE-conjugated mouse anti-human CD63 antibody. 
Antibodies were also added to serum free RPMI to act as controls.  
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Figure 3.10: CFSE and PE double staining of MDA-MB-231 supernatant. (A) Data 
were plotted as FL2 channel versus FL1 channel. (B) Overlays of control MDA-MB-
231 supernatant and stained supernatant were produced by using summit software. Red: 
MDA-MB-231, Green: MDA-MB-231+CFSE, Blue: MDA-MB-231+CD9, Yellow: 
MDA-MB-231+CD63.  Results are representative of at least three experiments. 
 
Serum fee RPMI+CD9      MDA-MB-231 + CFSE      MDA-MB-231 + CFSE + CD9 
                                           R4: 9.97%                            R4: 26.26% 
     Serum fee RPMI+CD63        MDA-MB-231 + CFSE         MDA-MB-231 + CFSE + CD63 
                                                    R4: 0.02%                              R4:23.92% 
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Serum free RPMI with CD9 antibody added was excluded by applying gates using the 
Summit software. We want particles that were stained positive for both CFSE (green) 
and PE (red), so Gate R4 is what we are interested in (Figure 3.10A). The data indicated 
that MDA-MB-231 supernatant treated with both CFSE and PE-conjugated CD9 
showed that approximately 26.26% particles were stained both green and red (Figure 
3.10A, first row, last image). However, MDA-MB-231 cells that were stained with 
CFSE alone had also shown 9.97% red fluorescence (Figure 3.10A, first row, second 
image), because CFSE green staining leaked into the red channel, so the proper 
percentage of CD9 containing particles secreted by the cells should be calculated as  
26.26%-9.97%=16.29%. The same applied for anti-CD63 antibody, with 23.92%-
0.02%=23.9% CD63 containing particles.   
 
The overlay of the data showed that unstained MDA-MB-231 was negative for green 
fluorescence. MDA-MB-231 cells stained with CFSE alone or with either antibody 
showed the peak has shifted to the right in FL1 and the peaks overlapped nicely. In FL2 
channel, unstained MDA-MB-231 cells were negative, cells that were stained with 
CFSE alone shifted to the right slightly (indicating the leak over into FL2 channel). 
Cells stained with CD9 antibody shifted further to the right and cells stained with CD63 
antibody showed a more dramatic shift (Figure 3.10 B).  
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Insertion of foreign genetic material into exosomes and into cells by using 
exosomes as delivery vehicles 
 
Exosomes are perfect candidates for drug or siRNA delivery because they could be self-
derived and thus should not provoke any immune responses. Thus, we wanted to 
investigate whether we could load siRNA onto exosomes derived from MDA-MB-231 
cells and jurkat cells and whether those exosomes could deliver the siRNA into targt 
cells. 
 First, we wanted to investigate whether we could load siRNA into exosomes by using 
electroporation. Exosomes from MDA-MB-231 cells were collected as described before. 
First, AllStars Negative Control siRNA, ‘Alexa Fluor 488’ (Qiagen) was used to test 
whether this technique works. This siRNA has green fluorescence so it is detectable by 
flow cytometry. The siRNA was added to 7 µg MDA-MB-231-derived exosomes and 
were either electroporated or un-electroporated as a control.   
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Figure 3.11: Loading of Alexa Fluor 488-tagged siRNA into exosomes. 7 µg MDA-
MB-231 derived exosomes were mixed with 500 nM Alexa Fluor 488-tagged siRNA, 
and were subsequently exposed to an electric field pulse. A sample of exosomes with 
siRNA without electroporation was also prepared as a negative control. After 
electroporation, Exosomes were washed in PBS and ultracentrifugation at 100, 000 x g 
was used to pellet the exosomes. The pellets were then re-suspended in PBS and 
analysed by flow cytometry.  
 
Exosomes + SiRNA un-electroporated and spin at 100, 000 x g 
Exosomes + SiRNA electroporated (125 µF, 400 volts) and spin at 100, 000 x g 
Exosomes + SiRNA electroporated (500 µF, 400 volts) and spin at 100, 000 x g 
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As expected, no fluorescence could be detected if the sample was not electroporated 
(Figure 3.11A). The sample that was electroporated with the settings of 125 µF and 400 
volts showed fluorescence (Figure 3.11B), and the sample that was electroporated with 
the settings of 500 µF and 400 volts showed more significant fluorescence (Figure 
3.11C). These data indicate that the siRNA was transferred, or associated with the 
exosomes by using electroporation.  
 
Next, we investigated whether MDA-MB-231 derived exosomes were able to transfer 
the encapsulated siRNA to the parental cells and whether the siRNA can knock down 
the targeted gene. Rab27a siRNA was transfected into the exosomes using the described 
electroporation method. A non-targeting siRNA (Allstars negative control siRNA) was 
used as a negative control. The exosomes were co-cultured with MDA-MB-231 cells 
and the effect of the siRNA was examined by using western blot to check the Rab27a 
protein expression level. The cells were also transfected by using the siRNA in 
conjunction with lipofectamine 2000 as a positive control.  
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                                              Different transfection methods 
MDA-         exosomes                         Lipofectamine 2000      Exosomes 
MB-231      Non-targeting siRNA          Rab27a siRNA          Rab27a siRNA 
CL               1 µl           2.5 µl                 1 µl         2.5 µl             1 µl          2.5 µl 
   
  
B 
 
Figure 3.12: Transfecting MDA-MB-231 cells by various methods. A. Western blot 
analysis of MDA-MB-231 cells transfected with Rab27a and Allstars negative control 
siRNA using self-derived exosomes by electroporation to load siRNA into exosomes 
and incubating the exosomes with the cells. MDA-MB-231 cells were also transfected 
with Rab27a siRNA using the well-established reagent lipofectamine 2000 as a positive 
control. The western blot result was representative of three experiments. B. Analysis 
through densitometry of western blot data probed against Rab27a and normalised 
against β-actin levels. Data was obtained by using ImageJ to analyse results from three 
experiments. Error bars indicate standard deviation. * P<0.05 
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Transfecting the cells with different volume of the non-targeting ‘Allstars negative 
control’ siRNA did not affect Rab27a expression level when compared with the 
untreated control. Transfecting 1 µl Rab27a siRNA using either Lipofectamine 2000 or 
exosomes did not appear to influence Rab27a expression, whereas using 2.5 µl Rab27a 
siRNA knocked down Rab27a successfully, with Lipofectamine slightly more effective 
compared to exosomes (Figure 3.12 A and B). Thus, this preliminary experiment 
suggests that exosomes containing siRNA can be used to target specific proteins of 
interest. 
 
To further confirm the ability of exosomes to transfer siRNA, we have decided to use 
Jurkat T cells to transfer siRNA in HeLa cells to knock down  the Erap1 gene, which 
has recently been shown to be associated with the arthritic condition ankylosing 
spondylitis, an area of research our laboratory is interested in. Erap1 targeting siRNA 
was transfected into the exosomes using the above described electroporation method. 
As before, non-targeting siRNA (Allstars negative control siRNA) was used as a 
negative control. The exosomes were co-cultured with HeLa cells and the effect of the 
siRNA was examined by using western blot to check the Erap1 protein expression level. 
 
 
 
 
 
106 
 
A 
       Non-targeting siRNA   Erap1 siRNA            
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Figure 3.13: Transfecting HeLa cells with Erap1 siRNA. A. Western blot analysis of 
HeLa transfected with Erap1 and Allstars negative control siRNA using self-derived 
exosomes by electroporation to load siRNA into Jurkat T cells-derived exosomes and 
incubating the exosomes with the cells. B. Analysis through densitometry of western 
blot data probed against Erap1 and normalised against β-actin levels that represent 
protein loading. Data are representative of two experiments.  
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Transfecting the cells with different volume of the non-targeting ‘Allstars negative 
control’ siRNA appeared to inhibit Erap1 expression level slightly when compared with 
the untreated control, but was not different between the two concentrations. In contrast 
transfecting 2.5 µl Erap1 siRNA using exosomes did not knock down the gene, whereas 
using 5 µl Erap1 siRNA appeared to inhibit Erap1 successfully (Figure 3.13 A and B). 
 
Lipidomics analysis of MDA-MB-231 cells and exosomes 
 
The biogenesis of exosomes undoubtedly requires appropriate lipid mediators, such as 
LBPA and Ceramide. Lipidomics appeared as an emerging field in the early 2000s and 
lipid and protein composition of exosomes would be a starting point to characterise 
these fascinating particles.  Lipid composition of exosomes have been analysed on 
exosomes derived from reticulocytes (Vidal et al., 1989), a B lymphocyte cell line 
(Wubbolts et al., 2003), a rat mast cell line and a human dendritic cell line (Laulagnier 
et al., 2004). The phospholipid composition of reticulocyte-derived exosomes were 
shown to be very similar to that of the plasma membrane (Vidal et al., 1989). Whereas 
the cholesterol/phospholipid ratio in B cell-derived exosomes was increased three times 
compared to the composition of the parental cells, and the class of sphingomyelin (SM) 
was also increased. (although only MHC- II enriched exosomes were considered in this 
experiment) (Wubbolts et al., 2003). Exosomes from a rat mast cell line or human 
dendritic cell line also showed specific phospholipid composition different from that of 
the parent cells, with no change in cholesterol/phospholipid ratio, but showed a 2-fold 
increase in the class of SM compared to the cell membrane (Laulagnier et al., 2004). 
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This increase in SM is consistent with the results from the B cell-derived exosomes. 
Therefore a high SM content could be a general feature of exosomes.  
 
Thus, it will be intriguing to investigate whether MDA-MD-231 cells and the exosomes 
derived from these cells show any differences in lipid composition. Lipid analysis of 
both components was then performed.  
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 -EMS: 42 MCA scans from Sample 5 (20120710 SIMO0NP MDA -VE SURVEY ) of 20120710 SIMO0NP MDA.wiff (Nanospray) Max. 3.5e8 cps.
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Figure 3.14: Lipid composition analysis. Lipid extracts from MDA-MB-231 cells 
were analysed by electrospray-mass spectrometry by positive survey scans (600-1000 
m/z) (A), and negative survey scans (600-1000 m/z) (B). Exosomes derived from 
MDA-MB-231 cells were analysed by positive scans (C) and negative scans (D) the 
same way.  Lipid species identified are annotated as lipid class with total number of 
lipid carbons: number of double bonds, (C:DB). (E). Summary of the Lipidomics study. 
 
 
The lipid analysis of MDA cells by electrospray mass spectrometry  (Figure 3.14) 
revealed the expected classes of phospholipids such as phosphatidylcholine (PC), as 
observed in the positive ion mode survey scans (Figure 3.14A), while the negative ion 
mode survey scan (Figure 3.14B) showed phosphatidylinositol (PI), phosphatidylserine 
(PS), phosphatidylethanolamine (PE) and phosphatidylglycerol (PG). Other lipids that 
were observed include cardilipin and the signaling molecules phosphorylated PIs (data 
not shown). 
 
The extracted exosomes show the same classes of phospholipid species (Figure 
3.14C&D), but the distribution is significantly different. For example the major PI in 
the MDA-MB-231 cells is PI 38:3, however in the extracted exosomes, this is only a 
minor PI species and the PI 36:2 is the major PI species. The exosomes also showed 
some evidence of PIPs, however due to limiting amounts of material, their 
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characterisation was not possible. The classes of lipids identified from our prelimary 
study are shown in table 3.14E (Figure 3.14E). 
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Discussion 
 
Determining the presence of exosomes secreted by breast cancer cell lines. 
 
We have isolated exosomes from MDA-MB-231 cells and MCF7 cell cultures. 
Confirmation of the presence of exosomes in our preparation was confirmed by a 
combination of several different techniques, including western blotting (Figure 3.2), 
electron microscopy (Figure 3.3), and flow cytometry (Figure 3.4). Overall, the 
exosomes exhibited typical ‘cup’ shaped morphology, expressed typical protein markers, 
and were within the expected size range (50-150nm).  
 
Tumour cell-conditioned medium and tumour cell-derived exosomes induced 
Jurkat T cell apoptosis 
 
Immune escape by tumours is a critical factor in avoiding destruction by the host 
immune system. It has been reported that tumour-derived exosomes can have 
immunosuppressive functions. Exosomes derived from tumour cells can bear Fas ligand 
that can induce T cell apoptosis leading to suppression of T-cell responses in vitro 
(Abusamra et al., 2005; Andreola et al., 2002). Tumour derived exosomes may also bear 
NKG2D ligands such as MICA and MICB that can down-regulate MKG2D present on 
CD8
+
 T cell or NK cell subsets (Clayton et al., 2008).  
 
Our data show that MDA-MB-231 supernatant/conditioned medium did not induce 
more apoptosis (10.56%) compared to the Jurkat cells with unconditioned serum free 
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RPMI medium added (12.33%), but has dramatically increased the G0/G1 phase from 
35.9% to 68.01% and decrease the G2/M phase significantly from 18.23% to 5.79%, 
whereas adding 48 hour MCF 7 supernatant to Jurkat cells has increased the number of 
apoptotic cells to 31.1% from 21.87%) and decreased the G2/M phase from 10.23% to 
2.3%. In contrast with the MDA-MB-231 cell-conditioned medium, MCF7-conditioned 
medium did not increase the G0/G1 phase. These data suggest that MDA-MB-231 
conditioned medium have induced cell arrest in the G0/G1 phase, delayed the 
progression of cell cycle, and inhibited cell proliferation, whereas MCF7-conditioned 
medium was more potent in inducing apotosis, but did not arrest the cells in the G0/G1 
phase. These data also indicate that conditioned medium from different tumour lines 
have different behaviours.  
Our data show that treatment of Jurkat cells with MDA-MB-231 or MCF7 derived 
exosomes induced apoptosis as determined by Annexin-V staining. Treatment of Jurkat 
cells with MDA-MB-231 cell and MCF7 cell-conditioned medium also induced 
apoptosis as determined by PI staining. PI staining also revealed that treatment of Jurkat 
cells with 104 µg/ml MDA-MB-231 derived exosomes or 400 µ/ml MCF 7 derived 
exosomes drove 35.21 % and 41.21 % cells toward apoptosis. One could argue that 400 
µg/ml seems like a very high concentration and this is unlikely to be the case in vivo. 
However, such high concentrations are not uncommon in the literature. Furthermore 
exosomes are likely to be short-range messengers, meaning that the concentration of 
exosomes near the originating cells will be high and will decrease as the distance 
increases. Thus the physiological concentration of relevance in any system remains an 
open question, and is a significant problem in the field currently. 
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CFSE and PE double staining 
 
Next, we confirmed the presence of CD9 and CD63 on MDA-MB-231 cells by 
immuno-staining and both CD9 and CD63 were present on the cells. The presence of 
CD9 and CD63 on the MDA-MB-231 cells and exosomes were confirmed by western 
blotting. CD9 and especially CD63 were more enriched in exosomes compared to 
parental cells. The enrichment of CD9 and CD63 in exosomes was a reason they were 
selected as exosome markers. However, a very recent study by Thery’s group suggested 
that CD9 is not a specific marker for exosomes as it is also present in larger, possibly 
plasma membrane-derived, microvesicles pelleted at 10,000 x g and also particles 
smaller than 50 nm that co-pelleted with exosomes (Bobrie et al., 2012a). We 
investigated the intracellular distribution of CD9 and CD63 in MDA-MB-231 cells by 
using immunofluorescence methods and they do not localise in the same intracellular 
departments. CD9 was found mainly in patches on the plasma membrane and rarely in 
intracellular compartments but CD63 was only found in intracellular compartments 
(most likely MVBs). This is consistent with the recent study by Thery’s group (Bobrie 
et al., 2012a).  In most cells, CD63 is present in intracellular compartments of 
endosome/lysosome origin (Pols and Klumperman, 2009); this is also the case for 
MDA-MB-231 cells used in this study.  In comparison, CD9 was observed mainly at the 
cell surface in MDA-MB-231 cells (Figure 3.7). CD9 has been described both at the cell 
surface and at intracellular multivesicular bodies/endosomes (Buschow et al., 2009; 
Cramer et al., 1994) 
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The percentage of CD9 and CD63 containing vesicles were analysed in this study by 
using CFSE and PE double staining. 23.9% of vesicles were stained positive for CD63 
and 16.29% vesicles were stained positive for CD9. Overlay of the FL2 channels also 
showed that more vesicles stained positive for CD63 compare to the number of vesicles 
that stained positive for CD9. It is hard to conclude from these data the percentage of 
exosomes in our preparation. As CD9 is expressed in patches on the plasma membrane, 
it is possible that CD9 are only present in some multivesicular bodies and not all of 
them, and thus are not present on all exosomes. This will explain why CD63 antibody 
stained more vesicles compare to CD9 antibody. On the other hand, if CD9 was not 
only present on exosomes, but also present in larger microvesicles (over 100 nm) and 
smaller vesicles (smaller than 50 nm) (Bobrie et al., 2012a), with the latter co-pelleting 
with exosomes at 100, 000 x g, the CD9 antibody should have labelled more vesicles 
compare to CD63 antibody. It is possible that the antibodies did not work effectively 
and did not bind to all the CD9/CD63 positive vesicles. Nevertheless, CD63 is a more 
reliable exosomes marker compare to CD9.  
 
Insertion of foreign genetic material into exosomes and into cells by using 
exosomes as delivery vehicles 
 
Viruses, polyethylenimine (PEI)-based nanoparticles and liposomes are the three main 
classes of delivery vehicles that have been the centre of research on therapeutic RNAi.  
A study that successfully engineered exosomes to specifically target brain tissue and 
successfully transited the blood brain barrier to knock down a therapeutic target gene of 
Alzheimer’s disease has sparked interest to use exosomes as new generation of delivery 
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vehicle (Alvarez-Erviti et al., 2011).  A more recent study has successfully 
demonstrated that  exosomes from peripheral blood delivered the administered siRNA 
into monocytes and lymphocytes, causing selective gene silencing (Wahlgren et al., 
2012).  
 
We have successfully introduced non-targeting fluorescent siRNA and Rab27a siRNA 
into MDA-MB-231 cells-derived exosomes using electroporation, and these exosomes 
effectively delivered the siRNA into the MDA-MB-231 cells causing knock down of 
Rab27a gene expression. Since exosomes can be produced by the recipients’ own cells 
make them an ideal non-immunogenic vector to transfer heterologous nucleic acids such 
as therapeutic siRNAs.  siRNAs were chosen as the genetic material because they were 
small in size (21-23 nt) and can lead to gene-silencing (Wahlgren et al., 2012).  To use 
the exosomes as gene delivery vehicles, the siRNAs were required to be transferred into 
the exsomes. Electroporation was the chosen method. The settings were adopted from 
Alvarez-Erviti et al (Alvarez-Erviti et al., 2011). Next, two different methods were used 
to transfer the siRNA into cells. Lipofectamine 2000 was a well-known transfection 
reagent and was used to transfer Rab27a siRNA into cells. Exosomes encapsulating the 
siRNA were also tested for the ability to transfer the siRNA into cells. Although the 
effect of gene knock down was more visible when lipofectamine 2000 was used 
compared to exosomes (Figure 3.12), it is undeniable that the data does suggest that the 
exosomes transferred Rab27a siRNA into the cells successfully and caused Rab27a 
knock down.  
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We have also used Jurkat T cells-derived exosomes to transfer encapsulated siRNA into 
HeLa cells and knocked down the Erap1 gene, which is associated with ankylosing 
spondylitis. The knock down was not as efficient as using MDA-MB-231-derived 
exosomes to transfer siRNA into MDA-MB-231 cells. This could be due to various 
factors, such as exosomes may interact differently with parental cells compared to other 
cells, and exosomes derived from different cells will have different properties, or that an 
improved siRNA target sequence is required. Nevertheless, both experiments showed in 
principle that exosomes are capable of delivery siRNA into cells and knocking down a 
target gene.  
Current vectors pose a unique problem and they have not been proven successful in 
clinical trials because they have issues such as toxicity, immunogenic concerns and 
targeting problems. It is very important to discover a safe gene delivery vector. 
Exosomes maybe a perfect candidate because they can be derived from the patients’ 
bodies and should not provoke any immune responses. Our data complement the 
findings of the other two groups (Alvarez-Erviti et al., 2011; Wahlgren et al., 2012) and 
suggested that exosomes can be used as gene delivery vectors.  
 
Lipidomics analysis of MDA-MB-231 cells and exosomes 
 
The mechanisms for sorting lipids onto exosomes and the lipid composition of 
exosomes are still unclear. Thus any lipid composition study will significantly 
contribute towards the characterisation of exosomes. Our prelimary data showed that the 
lipid composition of exosomes derived from MDA-MB-231 cells were different from 
that of the parental cells.   
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It has been reported that the secretion of the PLP in association with exosomes was 
independent of the ESCRT machinery, but required the sphingolipid ceramide. 
(Trajkovic et al., 2008), suggesting that by using different intracellular machinery, 
subpopulations of MVBs can be formed which may also lead to different types of 
exosomes. Bobrie et al has suggested that sub-populations of exosomes exist in the 
100,000 x g preparation and these particles could be derived from other organelles, or 
even formed out of the secretory pathway (Bobrie et al., 2012a) (Bobrie et al., 2012b). 
Thus it is possible that our preparation of exosomes contain these ‘sub-types’ of 
exosomes derived from a source other than endosomes, or the sorting of lipids into 
exosomes is uniquely regulated. The different results obtained from other studies may 
indicate that different cells use different mechanisms for lipid sorting into exosomes.  
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Chapter IV: Nanoparticle tracking analysis with Nanosight. 
 
Introduction 
 
Why Nanosight? 
 
Due to the small sizes of exosomes and microvesicles, their analysis has been quite 
problematic. Commonly used techniques include isolation by centrifugation, 
immunoisolation by using antibodies, western blotting, coupling onto latex beads 
followed by flow cytometry, and electron microscopy. Flow cytometry analysis of 
exosomes/microvescles has also been reported (Abusamra et al, 2005), but most flow 
cytometers have a lower detection limit of 200-300 nm, and thus are  not very accurate 
in detecting exosomes, and as indicated in the previous chapter, and it may be hard to 
distinguish exosomes from other microvesicles and the background.  
The Technology 
Nanoparticle tracking analysis (NTA) was developed in 2006 and allows direct and real-
time visualisation and analysis of nanoparticles in liquids (Carr et al, 2009).  Nanosight 
visualises and measures many types of nanoparticles with the size range of 30 nm to 
1000 nm.   
The Nanosight model we used in this study is the LM 10 (Figure 4.1 A). The unit is 
made of a metal housing containing a single mode laser diode which aims a focussed 
laser beam through the sample chamber. On top of the metal housing is an optical 
window mounted in a detachable stainless steel top plate. Samples (Approximately 300 
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μl) are introduced into the chamber by using a 1 ml disposable syringe through Luer 
fittings (Figure 4.1B).  Particles move in the liquid sample under Brownian motion and 
are seen as small point scatterers of light when they pass through the laser beam (Figure 
4.1C). This can then be visualised by looking down the microscope, with videos 
recorded and analysed, or saved and analysed at a later time.  
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A                                              B 
 
             C 
                                                               
 
 
Figure 4.1: Nanosight and the technology. (A). Nanosight model LM-10. (B). A 635 
nm laser beam is fired through the sample chamber. (C). Particles resuspended in liquid 
are seen as little point of light moving rapidly, which can be visualised by using the 
microscope or NTA on the computer screen.   Diagram adapted from 
www.Nanosight.com 
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Nanoparticle Tracking Analysis software (NTA) 
 
The video captured can be analysed by a dedicated single nanoparticle tracking 
programme (NTA). Videos are captured directly and analysed straight away or imported 
for analysis at a later time. The first frame of the video is normally used to adjust the 
settings of the software such as detection threshold, background subtraction, blurring, 
etc. Detection threshold should be set at a level where a small red cross is placed on the 
centre of each individual particle. It then tracks the movement of the particle per frame, 
all the particles are tracked simultaneously until at least two hundred tracks are 
completed (Figure 4.2). The NTA then analyses the distance each particle travelled and 
converts it to size, based on the Stokes-Einstein equation (Figure 4.2). The differential 
size distribution is shown on NTA in real time and a graph constructed at the end of the 
analysis. Cumulative undersize and cumulative oversize data can also be shown on the 
graph. 
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Figure 4.2.  NTA analysis of nanoparticles. (A) Red tracks are the distance that each 
particle travelled. (B). The Stokes-Einstein equation used by NTA. X and y are average 
distance each particle moved as tracked by the software, Dt is particle diffusion 
coefficient, T is temperature, η is solvent viscosity, d is the particle hydrodynamic 
diameter and KB is Boltzmann’s constant. Diagram adapted www.Nanosight.com 
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Results 
 
The accuracy of Nanosight in measuring size and concentration. 
 
To be able to use the Nanosight for analysing samples, we need to first test its accuracy 
in measuring size and concentration. By analysing particles of a known size and 
comparing it with the detected size, we were able to evaluate the accuracy of Nanosight 
on measuring size. 
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            100 nm                                  200 nm                                       400 nm 
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Figure 4.3: Measurement of size and concentration by using Nanosight. (A). The 
100 nm, 200 nm and 400 nm beads supplied by Nanosight were diluted in PBS and 
analysed on the Nanosight. Black writing shows the actual size of the beads and red 
writing shows the sizes detected by Nanosight. (B).Screen shots of the 100 nm, 200 nm 
and 400 nm beads from NTA. (C). 5 μl of the 100 nm beads was diluted into 1 ml PBS. 
And a 1 in 2, 1 in 4 and 1 in 8 dilution was made. Samples were then analysed on the 
Nanosight and three 30 seconds videos were taken. Error bars indicate standard 
deviation. Data are representative of four experiments.  
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Approximately 5 μl 100 nm, 200 nm and 400 nm Nanosight beads were suspended in 1 
ml PBS and 300 μl of each sample was taken and run on the Nanosight. The differential 
size distribution of 3 samples is shown in Figure 4.3 A. The detected peak size was 100 
nm, 199 nm and 403 nm accordingly.  This shows that the Nanosight is very accurate at 
determining particle size. Figure 4.3 B shows screen shots of the videos of the 
Nanosight beads that NTA has recorded.  
 
We next determined the ability of NTA to determine concentration. Approximately 5 μl 
of 100 nm beads was diluted into 1 ml PBS and 500 μl of the mixture was added into 
500 μl PBS to make a 1 in 2 dilution. The same was repeated to make 1 in 4 dilutions 
and then 1 in 8 dilutions.  All 4 samples were then run on the nanosight. Results show 
an almost straight line, indicating that the Nanosight is acceptably accurate, although 
not perfect, in determining concentration differences (Figure 4.3 C).  
 
 Supernatant from MDA-MB-231 and MCF 7 after 300 x g and then 10, 000 x g 
 
To investigate the sizes of the exosomes/microvesicles secreted from MDA-MB-231 
cells and MCF 7 cells. Medium from both cell lines was replaced with serum free 
medium when cells were 90% confluent and supernatant was collected after 48 hours. 
Cell and supernatant were spun at 300 x g and then 10, 000 x g to remove debris. The 
resulting supernatant was then analysed on Nanosight. The peak size of MDA-MB-231 
cell-derived exosomes was 129 nm and the peak size of MCF7 cell-derived exosomes 
was larger at 153 nm.  
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Figure 4.4: Comparison of the size of exosomes from MDA-MB-231 and MCF 7 as 
detected by the Nanosight. MDA-MB-231 cells and MCF 7 cells were grown to 90 % 
confluency and supernatant was collected. Cells and debris were depleted by 
centrifugation at 300 x g and large microvesicles were depleted by ultracentrifugation at 
10,000 x g. The remaining supernatant was analysed on the Nanosight. Data are 
representative of at least three experiments. 
 
 
Immunodepletion of exosomes/microvesicles using antibody-coupled magnetic 
beads. 
 
As with many other published preparations of exosomes, ours is likely to contain a 
mixture of microvesicles including exosomes. I have described the labelling of CD9 or 
CD63 positive vesicles using CFSE and PE double staining method in the last chapter. 
129 nm    153nm 
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To further investigate the percentage of CD9 or CD63 positive vesicles, an 
immunodepletion experiment was performed.  
 
The percentage of CD9 and CD63-containing microvesicles was analysed by coupling 
primary antibody to secondary antibody-coated dynabeads and then incubating the 
beads with cell supernatant after centrifugation at 300 x g and ultracentrifugation at 10, 
000 x g. The technique is shown in schematic drawing in Figure 4.5.  
Dynabeads coated with 
secondary and  primary 
antibody
Mouse monoclonal IgG to CD63 
(primary antibody)
Exosome
Sheep-anti mouse IgG 
(secondary antibody)
 
Figure 4.5: Schematic drawing of the technical approach used to selectively 
capture exosomes present in cell culture supernatants by coupling of anti-CD63 
mouse monoclonal antibody to sheep-anti-mouse antibody coated dynabeads. 
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Supernatant was collected and spun at 300 x g for 10 minutes then 10,000 x g for 30 
minutes. The resulting supernatant was pre-cleared with dynabeads without specific 
antibody to allow for non-specific binding of microvesicles to the beads. Different 
amounts of antibody-coupled dynabeads were then added and incubated with 
supernatant overnight. The beads were then separated out with a magnetic separator and 
the supernatant was analysed on NTA to check for depletion. Figure 4.6 shows the 
binding of antibody-coated dynabeads to CD63 on exosomes.  Depletion using anti-
CD9 antibody was performed the same way. 
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Figure 4.6: Immuno depletion of the supernatant post 10,000 x g spin using anti-
CD9 and anti-CD63 antibody coupled magnetic dynabeads. 24 h culture supernatant 
was centrifuged at 300 x g and 10, 000 x g and the resulting supernatant was pre-cleared 
with beads for 30 minutes. Antibody-coupled beads werethen added to 400 μl pre-
cleared supernatant. After 3 hours, the samples were placed on a magnetic separator. 
The beads were discarded and supernatant were analysed on the Nanosight.  This 
experiment was performed three times. Error bars indicate standard deviation.  
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The data shows that pre-clearing the supernatant with magnetic beads leads to a 
decrease in microvesicles in the supernatant as analysed by NTA (Figure 4.6), and this 
applies for both antibodies. Adding a small amount of anti CD9 antibody (0.5 μl) seems 
to have achieved the optimum depletion efficacy, with 52.1% particles depleted when 
compare to supernatant and 31.7% when compare to pre-cleared supernatant. Increased 
antibody concentration did not seem to affect the depletion. Nevertheless, at higher 
concentrations of CD9, there was a decrease in the depletion of CD9-positive particles. 
It is possible that higher concentration of the CD9 antibody contaminated the result with 
debris. For CD63, 5 μl of the antibody achieved the best depletion result, with 49.9 % of 
particles depleted when compare to the supernatant and 28.5% depleted when compare 
with the per-cleared supernatant.  
 
Nanosight analysis of exosomes pulled down by CD9 and CD63 coupled-magnetic 
beads 
 
Sequential centrifugation and ultracentrifugation are the most common way used to 
isolate exosomes. It is unknown whether the size of our exosomes prepared by 
sequential centrifugation and ultracentrifugation would differ from the size of exosomes 
purified by bead-based purification. In order to find out about the size of such purified 
exosomes, an exosomes pull down assay was performed. The technique used was 
similar to the immune-depletion experiment illustrated in Figure 4.5.  
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Figure 4.7: The size of exosomes purified by immunoaffinity capture method. CD9 
or CD63 antibody was coupled onto the beads.  25 μl of antibody-coupled beads were 
added into 0.5 ml exosomes in serum free RPMI. Samples were left rotating at 4 °C 
overnight. Exosomes were eluted from the beads by adding 200 μl 0.2M Glycine, PH 
2.8 at 37 °C for 5 minutes and then neutralised by adding 5 μl of 2M Tris PH 8. 
Supernatant was spun at 300 xg for 10 minutes and 10, 000 x g for 30 minutes, 0.5 nm 
serum free RPMI was added to each sample and then analysed on the Nanosight.  
Results are representative of three experiments.  
 
Exosomes pulled down by both CD9 and CD63 showed a peak size of 131 nm. The 
orange line indicates exosomes pulled down by CD9-coupled magnetic dynabeads and 
yellow line shows exosomes pulled down by CD63-coupled dynabeads. The red line is 
the control with beads added to serum free RPMI (Figure 4.7).  
 
131 nm 
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Comparing the exosomes purified by immunoaffinity binding (Figure 4.7) and our 
‘usual’ preparation of exosomes (Figure 4.4) together, our results show that the peak 
size of the ‘usual’ preparation of exosomes was 129 nm (Figure 4.4) and the peak size 
of the purified exosomes was 131 nm (Figure 4.7).  
 
These data suggest that the size of the population of exosomes purified by 
immunoaffinity binding does not significantly differ from the exosomes prepared by 
ultracentrifugation.  
 
NTA detection of apoptosis induced by Paclitaxel and Curcumin.  
 
Paclitaxel was isolated from the bark of the Pacific yew tree, Taxus brevifolia. It is sold 
under the trade name Taxol. It is the best anti-cancer drug isolated from plants (Bava et 
al., 2005). It interferes mechanistically with the dynamic instability of microtubules, 
protecting them from disassembly and thereby arrests the cell cycle at the G2/M phase, 
finally leading to apoptotic cell death or reversion to the G0-phase of the cell cycle 
without cell division (Horwitz, 1994). The major disadvantage is the drug’s dose 
limiting toxicity. It was reported that a combination of Taxol and Curcumin achieved 
better anticancer effects compare to Taxol alone (Bava et al., 2005). Therefore it would 
be intriguing to be able to detect apoptotic vesicles induced by adding Taxol and 
Curcumin to MDA-MB-231 cells, which could potentially be of use in a clinical setting 
to monitor chemotherapeutic efficacy. Apoptotic vesicles can have a size range between 
50-500 nm (Thery et al., 2009), thus placing many of them above the normal size of 
exosomes observed here by NTA. 
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Briefly, MDA-MB-231 cells were grown to approximately 50% confluence. This was to 
avoid significant apoptotic vesicles in our controls. The growth medium was replaced 
with serum free RPMI and the appropriate concentration of Curcumin was added to 
sensitize the cells. After 2 hours, Taxol was added to appropriate wells. Samples were 
collected after 48 hours and spun at 300 x g to remove dead cells and debris, and were 
then analysed by NTA to investigate whether apoptotic vesicles can be detected by 
using the ‘extended dynamic range’ (EDR) function of NTA.  
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Figure 4.8: Detection of apoptotic vesicles induced by adding Taxol and Curcumin 
to MDA-MB-231 cells. (A). Untreated MDA-MB-231 control and MDA-MB-231 
treated with DMSO. (B). MDA-MB-231 cells treated with Taxol alone or Taxol and 
Curcumin. (C). Images show the morphology of treated versus untreated cells. Cells 
treated with 10 nM Taxol&10 μM Curcumin show vesicle formation in cytoplasm. (D). 
Taxol and Curcumin treated MDA-MB-231 cell supernatant was centrifuged at 300 x g 
and analysed by flow cytometry after 48 hours. Serum free RPMI was used as a control. 
These data are representative of four experiments.  
Untreated MDA-MB-231      +4.5 μl DMSO           + 9 μl DMSO 
 
 
+5 nM Taxol       +5nM Taxol&5μM Curcumin    +10nM Taxol       +10nM Taxol&10μM Curcumin     
 
 
Serum free RPMI         Serum free RPMI+5nM Taxol        Serum free RPMI+5 nM Taxol +5μM Curcumin 
MDA-MB-231 supernatant     MDA-MB-231+5nM Taxol          MDA-MB-231+5 nM Taxol+5 μM Curcumin 
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The results indicated that our controls (MDA-MB-231 alone and MDA-MB-231 with 
different volumes of DMSO) show a major peak of approximately 139nm, 122 nm and 
147 nm (Figure 4.8 A) and very low amount of large/apoptotic vesicles, thus DMSO did 
not significantly influence the cell culture distribution of particles.  In marked contrast, 
NTA detected a very identifiable second peak after drug treatment, and adding 
Curcumin had boosted the peak (Figure 4.8 B). This second peak was within the size 
range of 180-300 nm and is likely to be apoptotic vesicles induced by treatment with 
Taxol and Curcumin. It needs to be highlighted that previously sensitization of the cells 
with Curcumin prior to treatment with Taxol has boosted apoptosis, and increase the 
concentration of Taxol and Curcumin has induced more apoptosis. It should also be 
noted that 24 hours after adding 10 nM Taxol and 10 μM Curcumin, cells appeared to 
be enlarged and there was visible vesicle formation in the cytoplasm (Figure 4.8 C). 
There was no vesicle formation in the cytoplasm when cells were treated with a 
combination with both drugs at a lower concentration, or with Taxol alone at a higher 
concentration.  
 
Samples were also analysed by flow cytometry (Figure 4.8 D), which detected extra 
material after addition of Taxol alone or Taxol with Curcumin. It seems to have shifted 
to the right and slightly upwards after adding 5 nM Taxol and shifted upwards more 
significantly after adding both drugs with no visible shift to the right. This further 
proved that treatment with drugs has induced particle release. As expected, it is hard to 
use the flow cytometry data alone to interpret the size and complexity of the extra 
particles secreted by adding drugs because of the insensitivity of flow cytometer with 
small nanoparticles.  
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Multiple freeze/thaw does not affect exosome size. 
 
Since exosomes are being recognised more and more as mediators of intercellular 
communications and could be used within clinical settings, it is very important to know 
how stable exosomes are during storage. Thus, we have measured the size and integrity 
of exosomes after multiple freezing and thawing over 6 sequential cycles using dry ice.  
 
 
Figure 4.9: Multiple freezing/thawing of CEM supernatant. CEM cells were grown 
to 90% confluency. Medium was replace with serum free RPMI. Supernatant was 
collected after 48 hours. Freezing and thawing was accomplished by freezing the 
sample on dry ice, followed by thawing at room temperature for 3 minutes. Error bars 
indicate standard deviation. 
 
The data show that multiple freezing and thawing does not cause changes in exosome 
size and no significant fragmentation was observed (Figure 4.9). These data suggest that 
this storage method is well-suited for storing exosomes.  
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Comparison of MDA-MB-231 supernatant after 300 x g and then 10, 000 x g and 
MDA-MB-231 exosomes purified by centrifugation and suspension in PBS.  
 
Commonly used purification steps of exosomes include centrifugation and 
ultracentrifugation and suspension of exosomes in PBS. It is unknown whether pelleting 
exosomes and re-suspension in PBS would cause the formation of any exosome 
aggregates. Large aggregates could have different behaviour in many biological assay 
systems in comparison to disperse particle solutions. To investigate whether some 
exosomes could be clumped together after pelleting, a sample of MDA-MB-231 
supernatant after 300 x g and then 10, 000 x g ultracentrifugation and a sample of 
exosomes purified after 100,000 x g and resuspended in PBS were compared on the 
Nanosight.  
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Figure 4.10: NTA comparison of supernatant after 10, 000 x g ultracentrifugation 
and pellet after 100,000 x g ultracentrifugation re-suspended in PBS. 48 hour 
MDA-MB-231 supernatant was collected and centrifuged at 300 x g then 10,000 x g. 
The resulting supernatant was split into 2 parts, one part was analysed directly on the 
Nanosight (Red line) and the other part was spun at 100, 000 x g and the pellet was re-
suspended in PBS (yellow line). Data were representative of two experiments.  
 
Analysis of both samples by the Nanosight shows no obvious difference between the 
two samples (Figure 4.10). Both samples have a peak size of approximately 130 nm. 
Although a small amount of large particles/aggregates with sizes between 400-700 nm 
were detected in the 100,000 x g pellet, no significant aggregates were detected by the 
Nanosight.  
 
 
 
10,000 x g supernatant          100,000 x g pellet re-suspended in PBS 
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NTA can detect increases in microvesicle release 
 
To test the ability of NTA to detect increases in microvesicle release, we treated the 
MDA-MB-231 cells with Tamoxifen and Thimerosal. Tamoxifen is an antagonist of the 
estrogen receptor. The binding of Tamoxifen to the estrogen receptor does not activate 
the receptor but this stops the hormone from binding to the receptor. It is widely used 
for the treatment of both early and advanced estrogen receptor positive breast cancers. 
Thimerosal is a drug known to induce apoptosis. 
 
 
Figure 4.11: Microvesicles released from MCF7 cells were increased after addition  
of Thimerosal or Tamoxifen. 200,000 MCF7 cells were seeded into each well of a six-
well plate. Medium were replaced with serum free medium and drugs were added after 
cells attached. After 48 hours, cell supernatant was collected and spun at 300 x g then 
10,000 x g.  The samples were then analysed by NTA and 3 videos were recorded. ** 
P<0.01.  Error bars indicate standard deviation. These results were representative of 
three experiments. 
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Results show that cells treated with 5 µM Thimerosal and 20 µM Tamoxifen increased 
exosomes/microvesicles release compared to untreated cells and cells treated with 
DMSO. Increase in exosomes/microvesicles release was highly significant when cells 
were treated with 20 µM Tamoxifen. 
 
Treatment with MDA-MB-231 with DMA 
 
In order to investigate whether NTA is a suitable tool for rapid screening of drug 
inhibition of exosome secretion, we treated the MDA-MB-231 cells with 25 µg/ml 5-
(N,N-dimethyl)-hydrochloride (DMA), inhibitor of the H
+
/Na
+
 and Na
+
/Ca2
+
 channels,  
which has previously been shown to reduce the secretion of exosomes (Chalmin et al., 
2010; Sreekumar et al., 2010) 
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Figure 4.12: Treatment of MDA-MB-231 cells with DMA.  Approximately 50,000 
cells were seeded into each well of a six well plate. After cells reached approximately 
50% confluency, different concentrations of DMA was added. Supernatant was collect 
after 24 hours, centrifuged at 300 x g and 10, 000 x g, then analysed by NTA. Error bars 
indicate standard deviation. ** P<0.01. Data are representative of three experiments. 
Results show that addition of 10 µg/ml DMA reduced exosome release, but this 
reduction was not statistically significant. Addition of 25 µg/ml and 40 µg/ml DMA 
significantly reduced exosome release as estimated by NTA.  
Results show that treatment with 25 µg/ml and 40 µg/ml DMA significantly reduced 
exosomes release as measured by NTA (Figure 4.12).  
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Discussion 
Since the emergence of NTA in 2006, it has been increasingly used in different fields of 
study such as nanoparticle synthesis and aggregation, toxicity and environment, drug 
delivery and micelles, exosomes and Pharma and vaccines, etc . For example, for 
nanoparticles synthesis and aggregation, some groups that used pulsed laser ablation to 
produce nanoparticles also used NTA to examine the particles size distribution (Suh et 
al., 2007). A recent paper has critically evaluated the ability of NTA to measure 
nanoparticles and protein aggregates. They have shown that NTA is very accurate in 
measuring both monodispersed and polydispersed samples and has better peak 
resolution when compared to DLS (dynamic light scattering) (Filipe et al., 2010).    
 
The accuracy of Nanosight in measuring size and concentration. 
 
First, the ability of NTA to measure size and concentration was determined by using 
polystyrene beads of known sizes supplied by Nanosight. The data suggested that 
although the detected sizes vary very slightly from the true sizes of the 200 nm and 400 
nm beads, the results were still acceptably accurate. For measuring concentration, our 
data showed an almost straight line of the bead concentration at different dilutions. The 
Nanosight claims that the machine can measure concentration range from 10
8
 to 10
9
 
particles/ml. It was found in this study that the most accurate sample concentration 
range is 2 x 10
8 
to 1 x 10
9
.  
 
 
 
147 
 
Supernatant from MDA-MB-231 and MCF7 after 300 x g and then 10, 000 x g 
 
Supernatant collected from MDA-MB-231 cells were collected, centrifuged at 300 x g 
and 10, 000 x g, the supernatant was then analysed on NTA. The peak value of the 
MDA-MB-231 supernatant was 129 nm and the peak value for MCF7 supernatant was 
159 nm.   
 
Immunodepletion of exosomes/microvesicles using antibody-coupled magnetic 
beads. 
 
CFSE and PE double staining described in the last chapter only labelled a relatively 
small percentage of the vesicles, so we further investigated the percentage of CD9 and 
CD63 positive vesicles by using secondary antibody-coated dynabeads coupled with 
either CD9 or CD63 primary antibody to pull down vesicles that were positive for either 
CD9 or CD63. Different amounts of antibodies were used and the supernatant that was 
depleted of either CD9 or CD63 positive vesicles were analysed on NTA. For CD9, 0.5 
µl- 2 µl achieved better depletion compared to lower or higher concentrations of the 
antibody. It is possible using high concentrations of antibody may contaminate the 
supernatant with debris. For CD63, 5 µl seemed to have achieved the best depletion 
result.  
 
Because non-specific binding of microvesicles to the beads exists, and it is hard to 
predict whether any exosomes would bind to the beads non-specifically and be excluded 
from the pre-cleared supernatant, it is hard to give a definite answer of the percentage of 
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CD9 or CD63 positive vesicles in our preparation by using this method. We could only 
conclude that at least 31.7 % of these vesicles were CD9 positive and at least 28.5% of 
these vesicles were CD63 positive (Figure 4.6).  These data do vary from the result we 
obtained from the CFSE and PE double labelling experiment, which showed even 
weaker labelling (Figure 3.10). The discrepancy was not surprising as binding efficacy 
of different antibodies could vary. 
 
Each protein is uniquely packed and loaded onto exosomes and also it has been reported 
that there might be different types of MVEs and exosomes. It is possible that not all thus 
necessarily contain CD9 or CD63 and exosomes should not be identified by a single 
molecular marker. CD9 has also been identified as present on other types of vesicles 
other than exosomes (Bobrie et al., 2012a)   It is also possible the antibody to exosome 
ratio was not ideal and did not achieve the best binding efficacy. 
 
Nanosight analysis of exosomes pulled down by CD9 and CD63 coupled-magnetic 
beads 
 
An immunoaffinity method was used to pull down particles positive for either CD63 or 
CD9. NTA analysis of both populations of vesicles showed peak sizes of 131 nm, 
indicating that the sizes of exosomes purified by this method does not differ from the 
sizes of exosomes sedimented by sequential centrifugation. Of some note, however, 
purifying exosomes by immunoaffinity does not generate clinical grade exosomes as the 
acid elution of the exosomes from the beads and antibody may cause possible 
alterations of the surface of the exosomes. 
149 
 
NTA detection of apoptosis induced by Paclitaxel and Curcumin 
 
Chemotherapeutic drugs exhibit their cytotoxic effect by inducing apoptosis in tumour 
cells. Chemotherapy may fail because the cancer cells become resistant to the 
therapeutic drugs. In the presence of toxic drugs, cancer cells can mutate and develop 
resistance to the drug, they can then divide and multiply and produce a tumour that is 
resistant to the drug. To overcome this problem, sometimes combinations of 
chemotherapeutic drugs are given at the same time, but multiple resistances can still 
occur. Thus, it is very important to know whether chemotherapeutic drugs being used 
can induce apoptosis in the tumour cells and the ability to detect apoptotic vesicles will 
be of great clinical significance.  
 
It has been reported that Curcumin can sensitize tumour cells and make the therapeutic 
effect of Taxol more efficient in HeLa cells (Bava et al., 2005). We tested the ability of 
Taxol alone and Taxol in combination with Curcumin to induce apoptosis in MDA-MB-
231 cells and tested whether NTA could detect apoptotic vesicles. For the supernatant 
from untreated cells or the supernatant from cells treated with DMSO, no large vesicles 
or very small amount of large vesicles were detected (possibly aggregates or 
microbubbles), and the peak sizes are between 120 nm to 150 nm, within the correct 
range of exosomes. In contrast, for supernatant from cells treated with either Taxol 
alone or Taxol with Curcumin, multiple peaks were detected.  Apart from the main 
‘exosome’ peak, another very noticeable peak with size between 180 nm to 250 nm 
constantly showed up with multiple experiments, indicating a different population of 
vesicles being secreted after the addition of these drugs. The percentage of apoptotic 
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vesicles were higher when treated with both drugs compared to the percentage of 
apoptotic vesicles induced by Taxol alone. This is consistent with the study by Bava et 
al, who illustrated that combining 5 nM Taxol with 5 μM curcumin enhances anticancer 
effects more efficiently than Taxol alone as demonstrated by increased cytotoxicity and 
reduced DNA synthesis in HeLa cells (Bava et al., 2005).  
 
The vesicle formation in the cytoplasm of the apoptotic cells and enlargement of the 
cells was only observed when the cells were treated with a combination of 10 nM Taxol 
and 10 μM curcumin, indicating that a different mechanism may exist when high 
concentrations of Taxol and Curcumin was added. This will require further 
investigation. Flow cytometry also detected extra material after the addition of drugs, 
although the difference is not very significant. This could be due to the limitations of 
flow cytometry and insensitivity for detecting nanoparticles.  
 
Multiple freeze/thaw does not affect exosome size. 
 
It is very important to know whether multiple freezing and thawing would affect the 
stability of exosomes. Multiple freezing and thawing was achieved by snap freezing in 
dry ice and thawing in 37 °C water bath. Exosomes sizes did not change significantly 
after 6 times of freezing/thawing, indicating there is no obvious structural change or 
degradation. This is consistent with the study published by Sokolova et al, who 
examined the stability of exosomes during storage at -4 °C, -20 °C and 37 °C. They 
have found that exosomes sizes decreased at 4 °C and 37 °C, indicating a structural 
change or degradation (Sokolova et al., 2011).  In contrast, another study demonstrated 
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that exosomes derived from IL-10-treated dendritic cells can supress inflammation and 
collagen-induced arthritis, and this suppressive effect is not just due to the delivery of 
the suppressive cytokine IL-10, but also requires the integrity of the exosome membrane. 
They have also shown by electron microscopy that multiple freeze/thawing using dry 
ice and water bath disrupted the exosomal membrane. Four freeze/thawing cycles 
disrupted the exosomes membrane and abrogate the suppressive effect (Kim et al., 
2005). It has also been reported that the miRNAs present in exosomes from breast milk 
are very stable and are resistant to harsh conditions including multiple freeze/thawing 
(Zhou et al., 2012). Thus, it is unclear how exactly multiple freeze/thawing would affect 
the structure, function and contents of exosomes. Such information is, however, of 
critical importance if exosomes are to be used in clinical practice. 
 
Comparison of MDA-MB-231 supernatant after 300 x g and then 10,000 x g and 
MDA-MB-231 exosomes purified by centrifugation and suspension in PBS.  
 
Ultracentrifugation is the most widely used method for collecting exosomes, but it is 
unknown whether the 100, 000 x g ultracentrifugation and resuspending the 100, 000 x 
g pellet would cause the exosomes to form aggregates. The supernatants after 300 x g 
and then 10,000 x g and the 100, 000 x g pellet re-suspended in PBS were compared by 
using NTA. Very small amounts of large particles or aggregates were detected in the 
100, 000 x g pellet re-suspended in PBS. We can conclude that the ultracentrifugation 
steps and re-suspension in PBS does not cause the significant formation of large number 
of aggregates.  
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NTA can detect increases in microvesicle release 
 
 Finding a rapid screening tool for increases in exosomes release will have significant 
clinical significance. NTA successfully detected increase in exosomes/microvesicles 
release from MCF7 cells induced by treatment with Tamoxifen and Thimerosal (Figure 
4.11), indicating the possibility of using NTA as a cost effective, fast and reliable 
candidate.  
 
Treatment of MDA-MB-231 cells with DMA 
 
The ability to rapidly screen for drugs and agents that interfere specifically with 
exosome secretion may be of direct clinical importance. Decreasing exosome 
production using dimethyl amiloride has been reported to enhance the in vivo antitumor 
efficacy of the chemotherapeutic drug cyclophosphamide in 3 different mouse tumour 
models (Chalmin et al., 2010). It was also reported that treatment with 25 µg/ml  DMA 
caused a significant 80% decrease in exosome release as evidenced by a decrease in 
CD63 expression in exosomal fractions examined by western blot (Sreekumar et al., 
2010). Other groups have also reported that DMA reduced exosome release from 
cardiomyocytes by measuring the Acetylcholine esterase activity (Gupta and Knowlton, 
2007; Zhang et al., 2012).  Inhibition of exosomes released from tumour cells by using 
DMA has also been reported (Merendino et al., 2010).  
 
We tested the ability of NTA to detect decreases in exosomes released from MDA-MB-
231 cells after treatment with DMA. Adding 10 µg/ml has reduced 
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exosomes/microvesicles released by 25.4%, adding 25 µg/ml and 40 µg/ml decreased 
exosomes/microvesicles production by 31.8% and 34.5 %. Although the percentage of 
decrease is not consistent with Sreekumar et al’ s group, who detected an 80% decrease, 
this could be due to different cell lines being used and different techniques being used to 
measure the decrease. 
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Chapter V: Rab27a and its effects on exosome release  
 
Introduction 
 
Rab27a belongs to the small GTPase Rab superfamily. It may be involved in protein 
transport and small GTPase mediated signal transduction. Rab27a has been shown to be 
involved in the exocytosis of secretory granules in melanocytes and cytotoxic T-cells. 
Rab27a is the only protein in the family whose loss of function is known to lead to 
disease, with Griscelli syndrome type 2 being an immunodeficiency genetic disorder 
that causes partial albinism. Patients with this disease have defects in cytotoxic T 
lymphocytes whose lytic granules fail to fuse with the plasma membrane and release 
their contents.  
 
Rab27a regulates the transport of lysosome-related organelles, such as melanosome 
transport in melanocytes and lytic granule release in cytotoxic T cells. Rab27a has been 
shown to regulate the docking of vesicles with plasma membrane and the release of 
exosomes in HeLa cells. They have also noticed that multivesicular endosomes in the 
Rab27a knock down cells appear to be enlarged. Rab27a could be required for docking 
and vesicle fusion with each other instead of fusing with the plasma membrane when 
Rab27a has been knocked down. Alternatively, Rab27a could prevent fusion of the 
vesicles with each other and knocking it down caused formation of enlarged 
compartments whose physical sizes prevent them from fusing with the plasma 
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membrane (Ostrowski et al, 2010).  Rab27a and Rab3a also regulate the docking step of 
dense-core vesicle exocytosis in neuroendocrine PC12 cells (Tsuboi a et al, 2006).  
Overexpression of RAB27A gene has also been shown to promote breast cancer cell 
invasiveness and the metastasis potential of the cancer by promoting the secretion of 
insulin-like growth factor-II (IGF- II) (Wang et al, 2008). 
 
Ashen mice, which contain a splicing mutation in RAB27A, have been studied by a lot 
of groups. Ashen mice exhibit reduced intensity in coat colour, reduced number of 
platelet dense granules (Wilson et al., 2000) and defects in cytotoxic T cells which 
prevent them from killing the target cell.  
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Results 
 
Rab27a shRNA treatment of MDA-MB-231 cells inhibits exosome release from 
MDA-MB-231 cells.  
 
It has been reported that knocking down Rab27a in HeLa cells reduces exosome 
secretion (Ostrowski et al, 2010). Therefore we wanted to determine whether inhibiting 
Rab27a in MDA-MB-231 cells also resulted in a lowering of exosome secretion as 
analysed by NTA. Cells were stably transfected individually and with a RAB27A-
targetting shRNA plasmid. Control and transfected cells were then lysed and analysed 
by immunoblotting (Figure 5.1 A), which revealed inhibition of Rab27a protein 
expression. Normalisation against actin with imageJ indicated that the knock down was 
approximately 50% (Figure 5.1 B). 
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Figure 5.1: Transfecting MDA-MB-231 cells with Rab27a shRNA reduces the 
protein expression level. Cells were transfected with 1 μg of plasmid DNA and stable 
transfected cells were maintained in RPMI + 3 μg/ml Puromycin. (A). Cells were lysed 
and protein concentration was measured using the Bradford method. Equal amount of 
protein was loaded onto a 12% gel. Membranes were probed with the indicated 
antibodies. β-actin was also used to show equal loading.  Results are representative of at 
three experiments. (B). Quantification of the band normalized with the corresponding β-
actin band. Quantification was perfomed by using ImageJ from three experiments. Error 
bars indicate standard deviation. ** P< 0.01 
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To investigate whether inhibiting Rab27a also inhibits exosomes secretion in MDA-
MB-231 cells and whether the decrease in exosome secretion was detectable by using 
NTA, the same number of control MDA–MB-231 cells and Rab27a KD cells were 
grown in a 6-well plate.  
  
 
Figure 5.2: Exosome secretion comparison between untreated MDA-MB-231 cells 
and Rab27a knock down cells. Normal growth medium was replaced with serum free 
medium when both cell lines reached 90% confluency. Supernatant was then collected 
after 48 hours and was then ultracentrifuged at 300 x g for 10 minutes and 10,000 xg for 
30 minutes. Pellet was diacarded and supernatant was compared on the Nanosight. Error 
bars indicate standard deviation. ** P<0.01 
 
To confirm these findings, we decided to extend our observations and use more shRNA 
targetting Rab27a. ‘SureSilencing shRNA plasmid for human Rab27a’ (QIAGEN) was 
purchased which included 4 shRNA constructs which target the human RAB27A gene. 
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A negative scrambled shRNA construct was also supplied as a control. To confirm the 
plasmids supplied were the right size, plasmids were digested by ScaI (Figure 5.3). 
 
 
Figure 5.3: Sca 1 restriction digestion of the plasmid DNA. Purified plasmid DNA 
was checked by restriction digestion with ScaI which linearises the plasmid. Samples 
were analysed on 1 % agarose gels, at a constant voltage of 100 V for 45 minutes. DNA 
was visualised on an ultraviolet (UV) transilluminator. 
 
The plasmids were confirmed to be the right size. MDA-MB-231 cells were then 
transfected using these shRNA plasmids. Cells were lysed and western blot was used to 
check the efficiency of inhibition of expression.  
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Figure 5.4: Transfecting MDA-MB-231 cells with Rab27a shRNA. Cells were 
transfected with 1 μg of 4 different types of shRNAs, a mixture of 4 shRNAs and a 
scrambled control. (A) Cells were lysed and protein concentration was measured using 
the Bradford method. Equal amount of protein was loaded onto a 12% gel. Membranes 
were probed with the indicated antibodies. β-actin was also used to show equal loading. 
Western blot result was representative of three experiments. (B) Quantification of the 
band normalized with the corresponding β-actin band. Quantification was performed by 
using ImageJ from three experiments.  Error bars indicate standard deviation. ** P< 
0.01 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
MDA
Untreated
shRNA 1 shRNA 2 shRNA 3 shRNA 4 Neg
Scram
All 4
shRNAs
** 
** 
** 
** 
** 
β-Actin  
 
Rab27a  
 
50 kDa 
34 kDa 
161 
 
Immunoblotting again revealed efficient inhibition of Rab27a expression by all the 
ShRNA plasmids (Figure 5.4 A & B). Normalisation against actin analysed by using 
imageJ revealed that No.2 and No. 3 were more efficient compared to others, with No. 3 
being the most efficient, when compared to control untransfected MDA-MB-231 cells 
and the negative scrambled construct (Figure 5. 4 B).  
 
To further confirm the knock down of the Rab27a gene at the miRNA level, RNA was 
isolated from control MDA-MB-231 cells and Rab27a KD cells, RNA was then reverse-
transcribed into cDNA and RT-PCR was performed. The expression level of the other 
Rab27 isoform, Rab27b, was also checked by PCR, based on a recent publication that 
indicated the possible inhibition of Rab27b in a similar system (Bobrie et al, 2012).  
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Figure 5.5: RT-PCR to check the knock down at the miRNA level.  RNA was 
purified from untreated MDA-MB-231 cells and Rab27A shRNA transfected cells using 
RNeasy® Mini kit. 0.5 μg total RNA was used reverse-transcribed into cDNA. PCR 
was done using ReadyMix
TM
 Taq PCR Reaction Mix from Sigma. The RT-PCR 
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Rab27A 
β-actin 
Rab27B 
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products were analysed by 2 % agarose gels, at a constant voltage of 100 V for 45 
minutes. DNA was visualised on an ultraviolet (UV) transilluminator. (A). PCR for 
Rab27A. (B). PCR for Rab27B. Results are representative of at least three experiments.  
 
RT-PCR results show that all shRNAs except No.4 gave knocked down Rab27A 
efficiently, these results are similar with the western blot data and have further 
confirmed the knock down at the mRNA level (Figure 5.5 A). Surprisingly, shRNA1, 
shRNA2 and shRNA3 also knocked down Rab27B completely, whereas shRNA4 and 
all 4 shRNA mixed together did not affect the Rab27B expression level (Figure 5.5B). 
 
 
Figure 5.6: Exosome secretion comparison between untreated MDA-MB-231 cells 
and Rab27 knock down cells. Equal number of untreated and Rab27 KO MDA cells 
were seeded in a 6 well plate. After 24 hours, cell medium was replaced with serum free 
medium.  After 24 hours, cell culture supernatant was collected and ultracentrifuged at 
300 x g and then 10,000 xg for 30 minutes and analysed on the Nanosight. The 
concentration of microvesicles was compared. Results are representative of at least three 
experiments. Error bars indicate standard deviation. * P<0.05, ** P<0.01  
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The cell supernatant from both control and transfected cells were ultracentrifuged at 300 
x g  and then 10, 000 x g and analysed by NTA. Lower number of exosomes were 
secreted from the Rab27 KD cells, with the exception of No.1, when compared to 
control cells. This could be because of loss of expression in the cells (Figure 5.6). 
Comparing exosome release from shRNA2, shRNA3 and mix to the scrambled control 
shRNA, all 3 were statistically different. 
 
We further investigated that the decrease in the particle numbers were due to a reduction 
in exosome secretion. The total amount of secreted exosomes, was determined by 
measuring the total amount of protein in the 100,000 x g pellet.  
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Figure 5.7: Total amounts of protein in the exosome pellets purified using our 
standard ultracentrifugation method. Cells were seeded in either two T150 cm
2
 
flasks with 10 million cells in each flask (for 20 million cells) or one T75 cm
2 
flask (for 
3.5 million cells). Medium were replaced with serum free medium as soon as cells 
attached. Supernatant was collected after 48 hours and spun to collect exosomes. 
Exosomal protein concentration was measured using Bradford method. Data are 
representative of two experiments.  
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Consistent with the Nanosight results, the total amount of protein in the exosome pellet 
from Rab27 KD cells were significantly reduced compared to the total amount of 
protein in the exosome pellet from untreated MDA-MB-232 cells (Figure 5.7). Typical 
exosome markers were also further analysed by immunoblotting. Briefly, 
exosomes/microvesicles were collected from the supernatant of the same number of 
control MDA-MB-231 and Rab27a KD secreting cells. 
 
 
 
         
         
         
 
Figure 5.8: Characterisation of exosomal proteins by immunoblotting.  20 million 
control MDA-MB-231 cells and Rab27 KD cells were seeded and the medium was 
replaced with serum free medium after cells were attached. Exosomes were then 
analysed by immunoblotting for the comparison of typical exosomal markers Alix, 
Tsg101 and CD63. One representative experiment out of three is shown here.  
 
Consistent with the NTA data, a reduction in the signals of typical exosomal markers 
(CD63, Alix and Tsg101) was observed from the immunoblotting results, indicating that 
exosome release was indeed reduced from Rab27 KD cells when compared with control 
cells (Figure 5.8).   
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It has been reported that knocking down Rab27a or Rab27b changes the morphology of 
MVBs in HeLa cells (Ostrowski et al., 2010). To investigate whether knocking down 
Rab27 in MDA-MB-231 cells have the same effect, MVBs were stained with a typical 
MVB marker CD63.  
 
 
 
Figure 5.9: Immunofluorescence microscopy of control MDA cells and Rab27 
knock down cells. A few drops of cells were seeded onto fluorodishes. After 24 hours, 
Cells were fixed with 4% paraformadehyde for 15 minutes at RT, washed 3 times with 
PBS containing 0.1M Glycine, and permeabilized with PBS containing 0.2% BSA and 
0.05% Saponin. Cells were then incubated with anti-CD63 primary antibody and FITC 
anti-mouse secondary antibody, stained and visualized under a fluorescent microscope.  
This experiment was performed four times. 
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Immunofluorescenct microcopy images show that the MVBs in Rab27 KD cells appear 
enlarged when compared to the MVBs in the control MDA-MB-231 cells and the 
scrambled control cells (Figure 5.9). It is possible that Rab27a is required for the fusion 
of MVBs with plasma membrane and MVBs fuse with each other which lead to 
enlarged MVBs, or Rab27a prevents MVBs from fusing with each other and the lack of 
it cause MVBs to fuse together and the enlarged size impair their abilities to fuse with 
the plasma membrane (Ostrowski et al., 2010).  
 
Knocking down Rab27 has reduced migration rate and invasiveness of MDA-MB-
231.  
 
It has been reported that tumour cells secrete exosomes which inhibit immune responses 
and promote their growth, or promote angiogenesis or migration to form metastases. We 
hypothesized that tumour secreted exosomes promotes changes in tumour behaviour, 
and that reduced secretion of exosomes should mean less growth and migration. We 
have shown that knocking down of Rab27 reduces the number of exosomes secreted by 
MDA-MB-231 cells. To test whether knocking down of Rab27 attenuates the cell’s 
ability to grow and migrate, MDA-MB-231 cells were subject to a scratch assay.  
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Figure 5.10: Scratch assay of MDA cells and Rab27 knock down cells. The same 
number of cells from each cell line was seeded into a 6 well plate. When the cells 
reached confluency after approximately 24 hours, the cell monolayer was scraped in a 
straight line to create a scratch with a P200 pipette tip. Cells were washed with media 
and fresh media was added. (A). Photos were taken at 0 hours and 14 hours and were 
compared. (B). Results of scratch assays were plotted as percentage of wound closure 
relative to hour 0. Error bars indicate standard deviation. Results are representative of 
four experiments. ** P<0.01 
 
As expected, after 14 hours of scratching the plate, the gaps from MDA cells and 
control scrambled cells have almost closed completely (Figure 5.10A, first row and 
fourth row), whereas the gaps from the Rab27 knock down cells were still visible 
(Figure 5.10A, second and third row), with shRNA3 transfected cells showing the 
slowest closure (Figure 5.10A, third row).  Results from three replicate experiments 
were plotted as percentage of wound closure relative to hour 0. The data revealed that 
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control Rab27 KD cells showed a deficit in growth and/or migration in comparison to 
control MDA-MB-231 cells and MDA-MB-231 cells containing scrambled shRNA, 
which had a percentage of closure of over 90%, whereas the percentage of wound 
healing for shRNA2 and shRNA3 were only approximately 60% and 30 % accordingly.  
 
It has been reported that overexpression of Rab27A may be related to the invasiveness 
of breast cancer. To determine whether knocking down of Rab27 would impact on cell’s 
growth and invasive potential and whether this reduction is due to the reduction of 
exosome secretion, untreated MDA cells, two of the transfected lines and the scrambled 
control were tested in the matrigel invasion assay.  
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Figure 5.11:  Matrigel Invasion assay results for untreated MDA cells and Rab27 
knock down cells. Matrigel coated inserts was pre-treated according to manufacturer’s 
instructions. 0.75 ml RPMI with 10% FCS and PSG were added to the bottom of the 
wells as chemoattractant. 2.5 x 10
4
 cells in serum-free RPMI + 0.1% BSA were seeded 
into the control inserts and Matrigel-coated inserts. After 22 hours of incubation, cells 
on top of the inserts were scrubbed off and cells that migrated/invaded through the 
inserts were stained and counted. (A). These are the cells that invaded through the 
Matrigel coated inserts. (B). These are the cells that migrated through the control inserts. 
(C). Percentage of invasion was calculated according to the equation stated in the 
materials and methods section. Result was representative for three experiments. Error 
bars indicate standard deviation.  ** P<0.01 
 
The number of cells that migrated through the control inserts and invaded through the 
Matrigel coated inserts vary between untreated MDA cells and Rab27 KD cells. Slightly 
less RAB27 knock down cells migrated through the normal control inserts (Figure 
5.11B), but dramatically less RAb27 knock down cells invaded through the matrigel 
inserts compared to untreated MDA cells and control scrambled cells (Figure 5.11 A).  
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Percentage of invasion was calculated as number of invaded cells divided by number of 
migrated cells.  
 
ShRNA 3 shows the lowest number of invaded cells (Figure 5.11A). Thus, the knocking 
down of RAB27 has dramatically reduced the cell’s ability to invade. Knocking down 
of RAB27 also affected the cell’s ability to migrate (Figure 5.11B), but the affect is not 
as dramatic. In order to investigate whether the cloning efficiency of tumour cells 
changed as well as the reduced ability of the cells to migrate and invade and whether 
this was due to a reduced number of exosomes released in the knock down cells, we 
performed an anchorage independent colony assay.  
 
Figure 5.12: Soft agar assay of control MDA cells and Rab27 knock down cells. 5% 
agar was melted and mixed with RPMI to make 0.5% agar. 2 ml was added to each well 
of all the 6 well plates as the bottom layer. It was left to set for about 1 hour. Stock 
concentration of 10,000 cells/ml was prepared. 3% agar was mixed with RPMI and 1 ml 
of cell. 2 ml of the mixture was added to each well to make the top layer. 15 μg of 
exosomes were added to each of the wells of shRNA2 and shRNA 3 cells. Experiment 
was done in triplicates.   * P<0.05, ** P<0.01 
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ShRNA2 and shRNA3 targeted cells formed fewer colonies compared to control MDA-
MB-231 cells, however supplementation with 15 μg MDA-MB-231 derived exosomes 
increased the number of colonies formed (Figure 5.12). 
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Discussion 
 
Rab27a shRNAs treatment of MDA-MB-231 cells inhibits exosome release from 
MDA-MB-231 cells.  
 
We used a single shRNA construct from Santa Cruz and SureSilencing shRNA 
plasmids for human Rab27a from Qiagen, which included 4 shRNA constructs which 
target the human RAB27a gene. A negative scrambled shRNA construct was also 
supplied as a control. Plasmids were digested by ScaI and were confirmed to be the 
right size. Western blot was used to check the knock down of Rab27a and normalisation 
against β-actin showed confirmed knocking down of Rab27a. RT-PCR was used to 
check the knock down at the mRNA level and surprisingly, although Rab27a was 
knocked down at the mRNA level, shRNA No.1, No.2 and No.3 also knocked down 
Rab27b completely. A recent study from Thery’s group also reported that only 2 out of 
5 shRNAs they used that were designed to target Rab27a, inhibited this gene without 
affecting Rab27b (Bobrie et al., 2012a). Thus our data is in accordance with this 
observation. 
 
We then examined whether knocking down Rab27a affects exosome release from 
MDA-MB-231 cells and whether this decrease in exosome release could be detected by 
NTA. NTA analysis of the cell conditioned supernatants, post 10,000 x g spin, revealed 
lower numbers of exosomes in all the shRNA constructs expressing cells, with the 
exception of no.1 (shRNA 1 treated cells were looking very unhealthy and apoptotic). 
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Comparing exosome release from shRNA2, shRNA3 and mix to the scrambled control 
shRNA, all 3 were statistically different.  
 
We needed to confirm that the decrease in particle production was due to decreases in 
exosomes released and not decreases in other populations of microvesicles, so the 
Bradford method was then used to confirm that the amount of exosomal protein was 
decreased when comparing the exosomes secreted from the same number of untreated 
cells and shRNA3 treated cells. Western blot was also used to confirm that the intensity 
of the bands of typical exosome markers was decreased. These data suggest that 
inhibiting the expression of Rab27a (and Rab27b) inhibited the release of exosomes 
from MDA-MB-231 cells and shRNA2 and shRNA3 seem to be the most efficient, 
possibly because shRNA2 and shRNA3 not only targeted Rab27a, but also inhibited 
Rab27b, thus enhancing the effect, as Rab27b was also reported to inhibit exosomes 
release from HeLa cells (Ostrowski et al., 2010). A very recent study by the same group 
demonstrated that inhibition of Rab27b did not affect the secretion of exosomes by the 
two murine carcinomas used in the study as it did in HeLa cells, suggesting that Rab27 
proteins are not universal regulators of exosomes secretion (Bobrie et al., 2012b). 
Nevertheless, our data showed that Rab27 proteins do play a role in the regulation of 
exosomes secretion from breast cancer MDA-MB-231 cell line.   
 
Immunofluorescence also revealed that multivesicular bodies were enlarged and the 
distribution was more ‘peri-nuclear’, rather than distributed more evenly in the 
cytoplasm in the control cells. This is consistent with the study published by Ostrowski 
et, al, who demonstrated that inhibition of Rab27a lead to enlarged multivesicular 
178 
 
bodies and inhibition of Rab27b causing the multivesicular bodies to distribute in the 
peri-nuclear regions  (Ostrowski et al., 2010). Because our shRNAs inhibited the 
expression of both Rab27a and Rab27b, so both effects were observed in this study.  
 
Knocking down The Rab27 family has reduced migration rate and invasiveness of 
MDA-MB-231.  
 
It is still unclear whether the constant production of tumour cell-derived exosomes is 
beneficial or harmful for their own survival in vivo. Pancreatic tumour cell-derived 
exosomes have been shown to decrease tumour cell proliferation and induce apoptosis 
(Ristorcelli et al., 2008). On the other hand, tumour cell-derived exosomes have also 
been shown by most studies to promote cancer cell growth.  It was shown that tumour-
derived exosomes contribute to the growth of tumours by blocking the activation of NK 
cells (Liu et al., 2006).  Gastric cancer exosomes have been shown to promote cancer 
cell proliferation through activation of the PI3K/Akt and MAPK/ERK pathway (Qu et 
al., 2009a). 
 
We checked whether knocking down the Rab27 family affected the cell’s ability to 
grow by performing a scratch assay. The result of the scratch assay indicates that when 
the Rab27 family genes were knocked down, cells migrated at a slower rate. To test 
whether the knock down cells have attenuated ability to invade, a matrigel invasion 
assay was performed. Consistent with the scratch assay, fewer knock down cells 
migrated through the control inserts towards chemoattractants, and dramatically lower 
number of knock down cells invaded through the matrigel coated inserts.  
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Since our data suggest that knocking down the Rab27 family was associated with a 
decrease in the release of exosomes, and also associated with the reduced ability of the 
MDA-MB-231 cells to migrate and invade, we hypothesized that the reduced ability of 
the cells to migrate and invade could be due to, or at least partly due to decreased 
number of exosomes secreted by the knock down cells. Behaviour of the untreated 
MDA-MB-231 cells and the Rab27 family knock down cells were investigated further 
by performing a soft agar assay. The knock down cells produced a smaller number of 
anchorage-independent colonies compared to the untreated cells and supplement of the 
medium with MDA-MB-231-derived exosomes restores the colony formation. Thus, it 
is possible that the ability of MDA-MB-231 to migrate, invade and form colonies could 
be driven by the release of exosomes and a decrease in exosomes released would 
attenuate the cell’s ability to migrate, invade and metastasize. This would need to be 
further investigated and we do not exclude the possibility of involvement of other 
factors. Thus, the exosome pathway is a valid target to attempt to disrupt the behaviour 
of tumour cells. 
 
Our results, together with the very recent study showing that reducing the expression of 
RAB27A decreased tumour growth and metastasis (Peinado et al., 2012), and the study 
by Wang et al showing that overexpression of RAB27A correlates with breast cancer 
invasiveness and metastasis (Wang et al., 2008), indicate that RAB27A should be 
considered as a potential therapeutic target in cancer. 
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Summary 
 
The results we obtained in this chapter demonstrated that knocking down the Rab27 
family genes reduced exosomes released by in MDA-MB-231 cells and NTA is capable 
of rapidly detecting this decrease. The fact that knocking down Rab27 family reduced 
the cell’s ability to migrate, invade and form anchorage independent colonies, and 
adding MDA-MB-231 cells-derived exosomes restored the knock down cells’ ability to 
form colonies leads to the conclusion that MDA-MB-231 cell derived exosomes may 
play a role in the migration, invasion and metastasize of the cells. However, further 
investigation is needed to define the mechanism by which exosomes influence these 
changes in tumour behaviour. 
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Chapter VII: conclusions and future work 
 
Although interest in exosomes has expanded greatly in recent years, the biogenesis, 
composition and functions of exosomes are still less than perfectly clear. 
Characterisation of these fascinating vesicles will contribute to the understanding of 
how they behave.  The aim of my project is to further characterise the 
exosomes/microvesicles secreted from MDA-MB-231 and MCF7 breast cancer cell 
lines. In this study, we have used flow cytometry, western blot and NTA to characterise 
exosomes. In the first chapter of results, we have shown that MDA-MB-231 and MCF7 
breast cancer cell-derived exosomes were capable of inducing apoptosis of Jurkat T 
cells, supporting the theory of immunosuppressive functions of tumour-derived 
exosomes. We have also successfully used electroporation to transfer Rab27a siRNA 
into MDA-MB-231 cell-derived exosomes, and these exosomes were capable of 
delivering the encapsulated siRNA into MDA-MB-231 cells and knocking down the 
Rab27A gene. 
 
Secondly, NTA was used to characterise the exosomes. NTA was shown be very 
accurate at rapidly measuring size and concentration of particles. The ability of NTA to 
detect apoptotic vesicles may be of great clinical significance. 
 
In the final chapter of results, Data show that knocking down the Rab27 family reduced 
the number of exosomes released from MDA-MB-231 cells, and reduced the cell’s 
ability to proliferate and invade. Adding exosomes back to Rab27a/b knock down cells 
restored the cell’s ability to form colonies, highlighting the role of exosomes and the 
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Rab27 family in metastasis and invasiveness of tumour cells. Thus, the exosome 
pathway is a valid target to attempt to disrupt the behaviour of tumour cells and Rab27 
family could be potential a therapeutic target. NTA was capable of rapidly detecting 
decreases in exosomes released following DMA treatment of MDA-MB-231 cells and 
Rab27 knock down cells. Thus, this technique is likely to be of significant use in the 
monitoring of any fluctuation of exosome release (eg, after drug treatment in patients) 
and further characterisation of exosomes. 
 
The data presented in this thesis will contribute to the continued research and 
characterisation of exosomes. 
 
Studying of Microvesicles using Flow Cytometry, Western Blot and 
Lipidomics. 
 
In this chapter, exosomes were shown to be present in our preparation by using flow 
cytometry (Figure 3.4), western blot (Figure 3.2) and electron microscopy (Figure 3.3). 
Annexin V staining revealed that MDA-MB-231 and MCF7-derived exosomes caused 
apoptosis of Jurkat T cells (Figure 3.6), PI staining confirmed that MDA-MB-231 and 
MCF7 conditioned medium and exosomes derived from both tumour lines induced 
Jurkat T cell apoptosis (Figure 3.7 and Figure 3.8). It has been reported that the Cbl 
family of ubiquitin ligases might pay a role in regulation of gastric cancer exosome-
induced apoptosis of Jurkat T cells by increasing PI3K proteasome degradation, 
inactivation of PI3K/Akt signalling, therefore mediating some effects of caspase 
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activation (Qu et al., 2009b). It will be very interesting to find out the underlying 
molecular mechanism of the Jurkat cell apoptosis induced by breast cancer tumour cells 
observed in my study.  
 
CFSE and PE double staining were used to investigate the percentage of CD9 and 
CD63-positive vesicles preparation. We have shown that CD9 and CD63 have a 
different subcellular distribution (Figure 3.9) and CD63 and CD9 did not label the same 
percentage of vesicles (Figure 3.10). This could be due to in-sufficient binding efficacy 
of the antibodies or indicating sub-population of exosomes. In fact, CD9, which was 
previously considered as a reliable exosome marker, has been reported to present on 
vesicles other than exosomes and subpopulations of exosomes have also been suggested. 
There is still not a standardised protocol for isolating exosomes. ‘Exoquick’, the new 
product that claimed to isolate exosomes rapidly, was reported to isolate vesicles rich in 
CD9 and not CD63, hence the vesicles were unlikely to be exosomes (Bobrie et al., 
2012a). It will be very interesting to further investigate whether any other of the typical 
exosome markers are just specific for exosomes and such findings would help develop a 
standardized protocol or new products for isolating exosomes.  
 
We have successfully transferred Rab27a and Erap1 siRNAs into exosomes, which then 
delivered the siRNAs into cells and knocked down the expression (Figure 3.12). 
Exosomes have more advantages over existing gene delivery vectors. Delivery of 
siRNA into the brain by using genetically engineered immature dendritic cells-derived 
exosomes (Alvarez-Erviti et al., 2011) and using plasma cell-derived exosomes into 
monocytes and lymphocytes have been reported (Wahlgren et al., 2012). In our study, it 
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was not known whether the siRNAs were encapsulated in exosomes or were ‘attached’ 
to the outside of the exosomes. RNase treatment should be used in the future to ensure 
that the exosomes were indeed encapsulated in the exosomes. In the future, it will also 
be very interesting to transfer siRNAs into cells to knock down a therapeutic target of a 
specific disease. It will also be fascinating to isolate exosomes from dendritic cells from 
blood and engineer the exosomes to target different tissues and test the delivery of 
siRNA in vivo. This will contribute to the development of exosomes as drug delivery 
vehicles. 
 
we have shown that exosomes derived from MDA-MB-231 cells and the parental cells 
have very different lipid composition (figure 6.1). These preliminary data compliment 
with other lipidomics studies of exosomes and will contribute to the characterisation of 
exosomes. Some lipids were not able to be identified due to limited amount of exosomal 
material, thus, it will be very interesting to collect larger amount of exosomes to be 
analysed in the future. It will also be intriguing to investigate whether the DMA-treated 
MDA-MB-231 cells and the Rab27a shRNA expressing cells show any differences in 
the lipid composition compared to untreated MDA-MB-231 cells.  It will also be very 
interesting to compare the lipid composition of exosomes and MVBs. 
 
Nanoparticle tracking analysis with Nanosight. 
 
We have analysed the accuracy of NTA in measuring size and concentration (Figure 4.3) 
and the data suggested that NTA is very accurate in measuring both size and 
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concentration. We then analysed supernatant from MDA-MB-231 cells and MCF7 cells 
and exosome size was estimated by NTA (Figure 4.4). 
 Immunodepletion method was then used to try to deplete either CD9 or CD63 positive 
vesicles. The results vary slightly compared to that from the CFSE and PE double 
staining described in the last chapter, which also stained CD9 or CD63 positive vesicles. 
Using the immunodepletion method with magnetic dynabeads depleted 31.7 % of 
vesicles using anti-CD9 antibody and 28.5 % vesicles using anti-CD63 antibody 
compared to pre-cleared supernatant. Vesicles pulled down by both antibodies had a 
peak size of 131 nm, which was consistent with the neat supernatant. These data could 
suggest that only a small percentage of our preparation was exosomes, the rest was 
microvesicles; or the antibodies did not bind to all exosomes due to a low concentration 
of antibodies, etc; or there maybe subpopulations of exosomes that do not express CD9 
or CD63. These data would contribute to the characterisation of exosomes and 
microvesicles and as suggested in the last chapter, it will be very interesting to 
investigate whether the typical exosomes markers are specific for exosomes. It will also 
be interesting to use fluorescent antibodies (CD9 or CD63) to label our preparation and 
to use NTA to detect the fluorescence.  
 
The NTA’s ability to detect apototic vesicles was then investigated. It has been reported 
that a combination of Taxol and Curcumin achieved better anticancer effects compare to 
Taxol alone (Bava et al., 2005). Therefore it would be intriguing if NTA is able to 
detect apoptotic vesicles induced by Taxol and Curcumin. By using the EDR mode, 
NTA was able to detect the very distinguishable extra population of vesicles which 
range from approximately 180 nm to 300 nm (Figure 4.8). This may contribute to the 
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monitor of the effect of therapeutic drugs on patients’ tumour cells, eg, whether the drug 
can cause apoptosis of the tumour cells. It will be fascinating if we could label the 
tumour cell-derived exosomes and apoptotic vesicles and distinguish them from normal 
cells-derived exosomes and microvesicles, this will enable us to monitor whether 
therapeutic drugs are specific and are efficient in causing tumour cell apoptosis without 
affecting normal cells excessively.  
 
Multiple freezing and thawing does not affect the exosomes size, indicating that this 
method is well-suited for storing exosomes (Figure 4.9). Because the snap freezing-
thawing method was used in this study, it will be interesting in the future to see whether 
freezing for a long period of time and then multiple freeze/thawing would affect the 
exosomes’ sizes. We have shown that resuspending the 100, 000 x g pellet in PBS does 
not cause the exosomes to clump together (Figure 4.10). We have also shown NTA is 
capable of detecting increases in exosomes released following treatment with 
Tamoxifen and Thimerosal to MCF 7 cells.  
 
Rab27A and its effects on exosome release and cell’s invasive potential, 
etc. 
 
In this chapter we have shown that by transfecting cells with Rab27a shRNA, cells 
showed reduced exosome release (Figure 5.6). Western blot confirmed the knock down 
of Rab27a (Figure 5.1 and Figure 5.4). RT-PCR data suggested that No.1, No.2 and No 
3 shRNA also inhibited Rab27b expression (Figure 5.5). The reduction in exosome 
released was confirmed by measuring the amount of protein present in exosomes 
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secreted from same number of control cells and Rab27a knock down cells using the 
Bradford method (Figure 5.7), and also by measuring the quantity of typical exosome 
markers CD63, Alix and tsg101 present in exosomes secreted from same number of 
control and knock down cells using western blot (Figure 5.8) and all the data suggested 
that inhibiting Rab27a/Rab27b expression reduced exosome release. 
 
The scratch assay, invasion assay and cloning in soft agar indicated that inhibition of 
Rab27 affected the cells’ ability to migrate, invade and form anchorage-independent 
colonies. The cells’ abilities to form colonies were restored after the addition of 
exosomes back to Rab27a knock down cells. It has only been reported previously that 
breast carcinoma cells’s ability to form colonies was dependent on exosomes derived 
from fetal bovine serum (Ochieng et al., 2009), so the data presented in this study will 
contribute to the understanding of the functions of breast cancer cell-derived exosomes.  
 
These data suggest that the exosome pathway is an important pathway in tumour cells’ 
migration and metastasis and thus a valid pathway to target to disrupt tumour cells’ 
properties. Our data also suggest that NTA is a rapid tool for screening of drug 
inhibition of exosome release. 
 
It will be very interesting in the future to compare therapeutic drug-induced vesicle 
release in tumour and normal cells.  
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